<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Introduction</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>Sponsors, Clinical Trial Sites, and the Investigator</td>
<td>2</td>
</tr>
<tr>
<td>2.1</td>
<td>The Sponsor</td>
<td>2</td>
</tr>
<tr>
<td>2.2</td>
<td>How NCI Funds Research</td>
<td>3</td>
</tr>
<tr>
<td>2.3</td>
<td>Preclinical Development of Investigational Agents</td>
<td>3</td>
</tr>
<tr>
<td>2.4</td>
<td>Collaboration between DCTD and the Pharmaceutical Collaborators</td>
<td>4</td>
</tr>
<tr>
<td>2.5</td>
<td>Private Support of Trials Supported by NCI Funding</td>
<td>4</td>
</tr>
<tr>
<td>2.6</td>
<td>Private Support of Trials Sponsored but Not Funded by NCI</td>
<td>5</td>
</tr>
<tr>
<td>2.7</td>
<td>The Investigational New Drug Application (IND)</td>
<td>5</td>
</tr>
<tr>
<td>2.8</td>
<td>The Marketing Application</td>
<td>6</td>
</tr>
<tr>
<td>3</td>
<td>The Clinical Trial Site and the Investigator</td>
<td>7</td>
</tr>
<tr>
<td>3.1</td>
<td>Definition and Purpose of a Participating Site for Clinical Trials</td>
<td>7</td>
</tr>
<tr>
<td>3.2</td>
<td>Activities of a Participating Site</td>
<td>7</td>
</tr>
<tr>
<td>3.2.1</td>
<td>Protocol Development-Scientific Review and Biostatistical Consultation</td>
<td>7</td>
</tr>
<tr>
<td>3.2.2</td>
<td>Protocol Administration</td>
<td>7</td>
</tr>
<tr>
<td>3.2.3</td>
<td>Establishment of an Affiliate Program</td>
<td>8</td>
</tr>
<tr>
<td>3.2.4</td>
<td>Agent Accountability and Storage</td>
<td>8</td>
</tr>
<tr>
<td>3.2.5</td>
<td>Reporting of Results to CTEP</td>
<td>8</td>
</tr>
<tr>
<td>3.2.6</td>
<td>Data Management and Statistics</td>
<td>8</td>
</tr>
<tr>
<td>3.2.7</td>
<td>Quality Assurance</td>
<td>9</td>
</tr>
<tr>
<td>3.2.8</td>
<td>Biomarker and Imaging Studies</td>
<td>9</td>
</tr>
<tr>
<td>4</td>
<td>Phase 1 Trials</td>
<td>11</td>
</tr>
<tr>
<td>4.1</td>
<td>Scientific Policies of CTEP</td>
<td>11</td>
</tr>
<tr>
<td>4.1.1</td>
<td>Planning of Phase 1 Trials</td>
<td>11</td>
</tr>
<tr>
<td>4.1.2</td>
<td>Objectives</td>
<td>11</td>
</tr>
<tr>
<td>4.1.3</td>
<td>Patient Selection</td>
<td>12</td>
</tr>
<tr>
<td>4.1.4</td>
<td>Schedule Selection</td>
<td>12</td>
</tr>
<tr>
<td>4.1.5</td>
<td>Starting Dose</td>
<td>13</td>
</tr>
<tr>
<td>4.1.6</td>
<td>Dose Escalation</td>
<td>13</td>
</tr>
<tr>
<td>4.1.7</td>
<td>Pharmacokinetics</td>
<td>13</td>
</tr>
<tr>
<td>4.1.8</td>
<td>Studies to Determine Pharmacodynamic Effects</td>
<td>14</td>
</tr>
<tr>
<td>4.1.9</td>
<td>Imaging Studies to Determine Pharmacodynamic Effects</td>
<td>14</td>
</tr>
<tr>
<td>4.1.10</td>
<td>Phase 1b Studies</td>
<td>14</td>
</tr>
<tr>
<td>4.1.11</td>
<td>Phase 1 Organ Dysfunction Trials</td>
<td>14</td>
</tr>
<tr>
<td>4.2</td>
<td>Who Is Eligible to Study Phase 1 Agents</td>
<td>15</td>
</tr>
</tbody>
</table>
# Investigator's Manual 2009

## Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.2.1 Cooperative Agreement Awardees or Contractors</td>
<td>15</td>
</tr>
<tr>
<td>4.2.2 Other Phase 1 Investigators</td>
<td>16</td>
</tr>
<tr>
<td>4.3 Which Organizations Can Conduct Phase 1 Studies</td>
<td>16</td>
</tr>
<tr>
<td>4.4 Who Is Eligible to Administer Phase 1 Agents</td>
<td>16</td>
</tr>
<tr>
<td>4.5 How to Obtain Information about Phase 1 Agents</td>
<td>16</td>
</tr>
<tr>
<td>4.5.1 Investigator's Brochure</td>
<td>16</td>
</tr>
<tr>
<td>4.5.2 Investigational Drug Branch (IDB) Physicians</td>
<td>16</td>
</tr>
<tr>
<td>4.5.3 Career Development LOI</td>
<td>17</td>
</tr>
<tr>
<td>4.5.4 Other Information</td>
<td>17</td>
</tr>
<tr>
<td>5 Phase 2 Trials</td>
<td>18</td>
</tr>
<tr>
<td>5.1 New Agent Development Considerations</td>
<td>18</td>
</tr>
<tr>
<td>5.1.1 Planning and Coordination of Phase 2 Trials by CTEP</td>
<td>18</td>
</tr>
<tr>
<td>5.1.2 Single Agent Phase 2 Studies</td>
<td>18</td>
</tr>
<tr>
<td>5.1.3 Combining Agents</td>
<td>20</td>
</tr>
<tr>
<td>5.1.4 Randomized Phase 2 Studies</td>
<td>21</td>
</tr>
<tr>
<td>5.2 Protocol Considerations</td>
<td>21</td>
</tr>
<tr>
<td>5.2.1 Single Disease Studies</td>
<td>21</td>
</tr>
<tr>
<td>5.2.2 Eligibility Requirements</td>
<td>21</td>
</tr>
<tr>
<td>5.2.3 Accrual and Statistical Considerations</td>
<td>22</td>
</tr>
<tr>
<td>5.3 Which Organizations can Conduct Phase 2 Studies?</td>
<td>22</td>
</tr>
<tr>
<td>5.3.1 Cooperative Groups</td>
<td>22</td>
</tr>
<tr>
<td>5.3.2 Cancer Centers</td>
<td>22</td>
</tr>
<tr>
<td>5.3.3 Affiliates</td>
<td>23</td>
</tr>
<tr>
<td>5.3.4 New Agent Development Contractors and Cooperative Agreement and</td>
<td>23</td>
</tr>
<tr>
<td>Grant Awardees</td>
<td></td>
</tr>
<tr>
<td>5.3.5 Multicenter Phase 2 Trials</td>
<td>23</td>
</tr>
<tr>
<td>5.4 Who is Eligible to Administer Phase 2 Agents</td>
<td>23</td>
</tr>
<tr>
<td>5.5 Restriction on Participation in Phase 2 Studies</td>
<td>23</td>
</tr>
<tr>
<td>5.6 How to Obtain Information about Phase 2 Agents</td>
<td>24</td>
</tr>
<tr>
<td>5.6.1 Investigator’s Brochure</td>
<td>24</td>
</tr>
<tr>
<td>5.6.2 IDB Physicians</td>
<td>24</td>
</tr>
<tr>
<td>5.6.3 Clinical Research Pharmacists</td>
<td>24</td>
</tr>
<tr>
<td>6 Phase 3 Trials</td>
<td>25</td>
</tr>
<tr>
<td>6.1 Scientific Policies of CTEP</td>
<td>25</td>
</tr>
<tr>
<td>6.2 Who Is Eligible to Conduct Phase 3 Trials</td>
<td>25</td>
</tr>
<tr>
<td>6.3 Eligibility Requirements</td>
<td>26</td>
</tr>
<tr>
<td>6.4 Coordination of Planning with the Clinical Investigations Branch (CIB), CTEP</td>
<td>28</td>
</tr>
<tr>
<td>6.5 Cancer Trials Support Unit (CTSU)</td>
<td>29</td>
</tr>
<tr>
<td>7 The Letter of Intent and Drafting of a Protocol</td>
<td>30</td>
</tr>
<tr>
<td>7.1 The Letter of Intent (LOI)</td>
<td>30</td>
</tr>
<tr>
<td>7.1.2 Definition</td>
<td>30</td>
</tr>
</tbody>
</table>

Table of Contents - Investigator's Manual 2009
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.1.3</td>
<td>Purpose</td>
<td>30</td>
</tr>
<tr>
<td>7.1.4</td>
<td>Ground Rules for the LOI System</td>
<td>30</td>
</tr>
<tr>
<td>7.1.5</td>
<td>Submission of LOIs</td>
<td>31</td>
</tr>
<tr>
<td>7.1.6</td>
<td>Review of LOIs</td>
<td>31</td>
</tr>
<tr>
<td>7.1.7</td>
<td>CTEP LOI Review Criteria</td>
<td>31</td>
</tr>
<tr>
<td>7.1.8</td>
<td>After LOI Approval</td>
<td>32</td>
</tr>
<tr>
<td>7.1.9</td>
<td>Information about the Status of an LOI</td>
<td>32</td>
</tr>
<tr>
<td>7.1.10</td>
<td>CTEP Career Development LOI</td>
<td>32</td>
</tr>
<tr>
<td>7.2</td>
<td>The Drafting of a Protocol</td>
<td>32</td>
</tr>
<tr>
<td>7.2.1</td>
<td>Title Page</td>
<td>32</td>
</tr>
<tr>
<td>7.2.2</td>
<td>Schema</td>
<td>33</td>
</tr>
<tr>
<td>7.2.3</td>
<td>Objective(s)</td>
<td>33</td>
</tr>
<tr>
<td>7.2.4</td>
<td>Background and Rationale</td>
<td>33</td>
</tr>
<tr>
<td>7.2.5</td>
<td>Patient Eligibility Criteria</td>
<td>33</td>
</tr>
<tr>
<td>7.2.6</td>
<td>Pharmaceutical Information</td>
<td>34</td>
</tr>
<tr>
<td>7.2.7</td>
<td>Treatment Plan</td>
<td>35</td>
</tr>
<tr>
<td>7.2.8</td>
<td>Procedures for Patient Entry on Study</td>
<td>35</td>
</tr>
<tr>
<td>7.2.9</td>
<td>Adverse Events List and Reporting Requirements</td>
<td>35</td>
</tr>
<tr>
<td>7.2.10</td>
<td>Dose Modification for Adverse Events</td>
<td>35</td>
</tr>
<tr>
<td>7.2.11</td>
<td>Criteria for Response Assessment</td>
<td>35</td>
</tr>
<tr>
<td>7.2.12</td>
<td>Monitoring of Patients</td>
<td>35</td>
</tr>
<tr>
<td>7.2.13</td>
<td>“Off-Study” Criteria</td>
<td>36</td>
</tr>
<tr>
<td>7.2.14</td>
<td>Statistical Considerations</td>
<td>36</td>
</tr>
<tr>
<td>7.2.15</td>
<td>Records to be Kept</td>
<td>36</td>
</tr>
<tr>
<td>7.2.16</td>
<td>Participation</td>
<td>36</td>
</tr>
<tr>
<td>7.2.17</td>
<td>Multicenter Trials</td>
<td>37</td>
</tr>
<tr>
<td>7.3</td>
<td>Informed Consent</td>
<td>38</td>
</tr>
<tr>
<td>7.4</td>
<td>Protocol Templates</td>
<td>39</td>
</tr>
<tr>
<td>8</td>
<td>Protocol Review and Approval at CTEP</td>
<td>40</td>
</tr>
<tr>
<td>8.1</td>
<td>The Protocol and Information Office (PIO)</td>
<td>40</td>
</tr>
<tr>
<td>8.2</td>
<td>How to Submit a Protocol</td>
<td>40</td>
</tr>
<tr>
<td>8.3</td>
<td>IRB Approval</td>
<td>40</td>
</tr>
<tr>
<td>8.4</td>
<td>Protocol Review</td>
<td>41</td>
</tr>
<tr>
<td>8.4.1</td>
<td>Scheduling the Protocol for Review</td>
<td>41</td>
</tr>
<tr>
<td>8.4.2</td>
<td>Review by the CTEP Protocol Review Committee</td>
<td>41</td>
</tr>
<tr>
<td>8.4.3</td>
<td>The Review of the Protocol</td>
<td>41</td>
</tr>
<tr>
<td>8.4.4</td>
<td>The Review of the Informed Consent</td>
<td>42</td>
</tr>
<tr>
<td>8.4.5</td>
<td>The Review of Regulatory and Administrative Concerns</td>
<td>42</td>
</tr>
<tr>
<td>8.4.6</td>
<td>The Review by the Pharmaceutical Collaborator</td>
<td>42</td>
</tr>
<tr>
<td>8.4.7</td>
<td>The Consensus Review</td>
<td>42</td>
</tr>
<tr>
<td>8.4.8</td>
<td>Responding to CTEP Consensus Review</td>
<td>42</td>
</tr>
<tr>
<td>8.5</td>
<td>Protocol Document Approval</td>
<td>43</td>
</tr>
<tr>
<td>8.6</td>
<td>Amendments</td>
<td>43</td>
</tr>
<tr>
<td>8.7</td>
<td>Study Status</td>
<td>43</td>
</tr>
<tr>
<td>8.8</td>
<td>Reactivation of Studies</td>
<td>44</td>
</tr>
</tbody>
</table>
9 Ordering Investigational Agents from NCI ................................................................. 45
  9.1 How to Place Agent Orders ....................................................................................... 45
  9.2 Particular Points to Note ........................................................................................ 45
  9.3 Routing of Agent Requests ..................................................................................... 46
  9.4 Affiliates and Agent Orders ..................................................................................... 46
  9.5 Requests for Nonresearch (Treatment) Use of Investigational Agents ..................... 47
  9.6 Requests for Nonclinical (Laboratory) Use of Investigational Agents ...................... 47
  9.7 Status of Investigational Agents Following FDA Marketing Approval ..................... 47

10 Responsibility for Reporting Results to CTEP .......................................................... 48
  10.1 Introduction ............................................................................................................. 48
  10.2 Report Requirements of CTEP Supported Trials .................................................. 48
      10.2.1 Clinical Trials Monitoring Service (CTMS) ..................................................... 48
      10.2.2 Clinical Data Update System (CDUS) ............................................................ 49
      10.2.3 Adverse Events ............................................................................................... 50
      10.2.4 Study Status ................................................................................................. 50
      10.2.5 Amendments ............................................................................................... 50
      10.2.6 Publications ................................................................................................. 50
      10.2.7 Inventions .................................................................................................... 50
  10.3 Record Retention ..................................................................................................... 51
  10.4 Reporting to IRBs ................................................................................................... 51

11 Adverse Events ............................................................................................................. 52
  11.1 Expedited Reporting of Adverse Events .................................................................. 53
  11.2 Expedited Adverse Events with Commercially Available (Non-Investigational) Agents .................................................................................................................. 53
  11.3 Routine Reporting of Adverse Events ..................................................................... Error! Bookmark not defined.

12 The Investigator and Protocol Chair: Roles and Responsibilities ............................. 54
  12.1 The Investigator ...................................................................................................... 54
      12.1.1 The FDA Form 1572 .................................................................................... 54
      12.1.2 Responsibilities of an Investigator for Human Subjects Protection ............... 55
  12.2 The Protocol Chair ............................................................................................... 55
      12.2.1 Responsibilities .......................................................................................... 55
      12.2.2 Who May Serve as a Protocol Chair .......................................................... 56

13 Affiliate Investigators .................................................................................................. 57
  13.1 Affiliate Investigators Definition .......................................................................... 57
  13.2 Requirements of an Affiliate Investigator ............................................................. 57
  13.3 Responsibilities of Affiliate Investigators .............................................................. 57
13.4 Responsibilities of Clinical Sites for Affiliates ............................................................ 58
  13.4.1 The Cooperative Groups ............................................................................... 58
  13.4.2 The Principal Investigator Responsibilities for Affiliate Investigators in 
          Cooperative Group Protocols ........................................................................ 58
  13.4.3 Cancer Centers .............................................................................................. 59

14 Who May Order Agent from PMB, Write Patient-specific Orders for 
Investigational Agents, and/or Administer Investigational Agents .................. 60
  14.1 Ordering Agent from PMB ......................................................................................... 60
  14.2 Writing a Patient-specific Orders ............................................................................... 60
  14.3 Administration of Investigational Agents ................................................................... 61

15 Accountability and Storage of Investigational Agents ............................................ 62
  15.1 Procedures for Agent Accountability and Storage ..................................................... 62
  15.2 Investigational Agent Returns ................................................................................... 63
  15.3 Verification of Compliance ....................................................................................... 64
  15.4 Handling of Antineoplastic Agents .......................................................................... 64

16 Monitoring and Quality Assurance .............................................................................. 65
  16.1 Introduction .............................................................................................................. 65
  16.2 Protocol Compliance ................................................................................................. 65
    16.2.1 Cooperative Groups ....................................................................................... 65
    16.2.2 Cancer Centers .............................................................................................. 65
    16.2.3 CTEP Clinical Agent Development Contractors ............................................ 66
  16.3 Data Accuracy ........................................................................................................... 66
  16.4 Procedural Requirements .......................................................................................... 66
  16.5 Components of the Quality Assurance Program Implemented by CTEP .......... 67
    16.5.1 Monitoring ...................................................................................................... 67
    16.5.2 The On-Site Auditing Program: Purpose and Procedures ................................. 67
  16.6 Informed Consent and the Monitoring Program ........................................................ 68
  16.7 Dealing with Problems Identified During On-Site Audits ........................................... 69

17 Nonresearch or Treatment Referral Protocol Use of Investigational Agents .... 70
  17.1 Special Exceptions .................................................................................................... 70
  17.2 Treatment Referral Center (TRC) ............................................................................ 71
18 Appendices

Appendix I ........................................................................................................................................73
NCI-Cooperative Group-Industry Relationship Guidelines

Appendix II ........................................................................................................................................74
Phase 0 Studies

Appendix III .......................................................................................................................................76
Policy Statement: The Conduct of Phase 1 and 2 Trials in Children

Appendix IV .......................................................................................................................................81
Key Contact Information

Appendix V .......................................................................................................................................83
Informed Consent Checklist

Appendix VI .......................................................................................................................................86
CTEP Glossary

Appendix VII ....................................................................................................................................90
National Study Commission on Cytotoxic Exposure: Recommendations for Handling Cytotoxic Agents

Appendix VIII .....................................................................................................................................95
National Cancer Institute Procedure of Investigational Agents Acquired for Compassionate (Special Exception) Treatment of Individual Patients

Appendix IX .......................................................................................................................................98
Guidelines for Treatment Regimen Expression and Nomenclature
1 Introduction

This manual explains the policies and implementing procedures for the conduct of therapeutic clinical trials sponsored by the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI). Sponsorship or support of clinical trials includes funding, regulatory support and/or agent distribution. Oncologists, nurses, pharmacists, research administrators, and data managers should find the information in this manual useful in practical matters connected with protocol drafting and submissions, reporting requirements, agent accountability, and a host of other subjects.

The Cancer Therapy Evaluation Program (CTEP) of the DCTD (http://dctd.cancer.gov) is responsible for implementing and monitoring the clinical development of new anticancer agents. CTEP’s policies are intended to ensure patient safety while providing the National Cancer Program with the most effective new agent development program possible. Some policies reflect the regulatory requirements of the Food and Drug Administration (FDA) and the Department of Health and Human Services (DHHS). Others have been developed based on policies at the Institute level, consensus among CTEP staff, the NCI Board of Scientific Advisors, and leaders in the community of clinical investigators. Specific policies and procedures continue to evolve; through them CTEP, DCTD, NCI aims to provide a flexible, responsive system within the constraints imposed by regulation and the program’s size and scope.

In addition to the scientific and medical issues involved in planning and conducting clinical research, CTEP has two additional major responsibilities:

(1) Sponsorship of Investigational New Drug Applications (INDs) and
(2) Oversight of the contracts, grants and cooperative agreements under which most clinical testing takes place.

In this manual we refer to DCTD as the IND sponsor and the "proprietor" of the investigational agent development program and to CTEP where the efforts of the CTEP staff are specifically involved. The use of NCI is reserved for more general contexts, including overall support of clinical trials.

The CTEP web site (http://ctep.cancer.gov) is an excellent additional resource for current information on CTEP policies, forms/templates and initiatives. Familiarity with CTEP’s organization and the primary responsibilities of each branch or office may help you understand how CTEP functions.

We welcome readers’ comments on this manual’s content and how future updates can make this manual more useful.
2 Sponsors, Clinical Trial Sites, and the Investigator

When investigators perform clinical trials, two elements are crucial – the trial’s sponsor and the clinical trial site. The next two sections (Section 2 and Section 3) discuss the purposes and features of each.

- We describe DCTD’s role as a sponsor of investigational agent trials.
- Specifically, we review CTEP’s responsibility for overall direction of the process of investigational agent development and its practical implementation.
- We outline the basis of the relationship between DCTD, pharmaceutical collaborators, and investigators during the conduct of clinical trials.
- We also discuss the clinical trial site’s vital role in support of the investigator. As is the case with all types of research, clinical trials require a substantial institutional commitment.

2.1 The Sponsor

Development of new anticancer agents is a long and complex process, but successes have been significant. The fact that some patients with aggressive neoplasms now have long term survival is the best possible evidence that agents with selectivity against cancer can be identified and used effectively. On the other hand, the oncology community is well aware that for many tumor types, systemic treatment is unsatisfactory. The motivation to develop better therapy is therefore as powerful as ever. With the increased understanding of the malignant process due to recent and anticipated advances in molecular biology and biochemical pharmacology, we have every reason to expect that the development of new agents will proceed along increasingly rational lines.

The process of new agent development is often divided into preclinical and clinical components. Although this division is operationally useful, continual interplay exists between these arenas. Evidence of synergy or the effectiveness of combined modality approaches in experimental models, for example, has provided the major motivation for a large number of clinical trials. The converse is also true; clinical observations have also given rise to new lines of basic investigation.

Historically, the NCI has been one of the most important effectors in the discovery and development of new anticancer agents. NCI's prominent role in new cancer agent development has no parallel elsewhere in developmental pharmacology. The justification for such intensive involvement of a Government agency in research and development is clear: significant improvement in cancer treatment is in the public interest. NCI is the largest clinical trials sponsor focused on cancer treatment and diagnosis, and currently has a significant number of new agents in various stages of clinical testing or preclinical development.

As part of this massive effort, NCI funds a clinical trials network that includes Cooperative Groups and Consortia, new agent development contractors, and investigators at Cancer Centers and University hospitals and Specialized Programs of Research Excellence (SPOREs). More than 11,000 investigators from approximately 3,000 institutions participate in this effort.

In the United States, clinical research with investigational agents is carefully regulated. The regulatory authority for assuring public safety in matters relating to investigational
drugs and biologics rests with the Food and Drug Administration (FDA, http://www.fda.gov/). FDA regulations, which are specific implementations of the Food, Drug, and Cosmetic Act and the Public Health Service Act define the terms under which clinical work with investigational drugs and biologics may proceed (see 21 CFR 312 and 21 CFR 600). Because these regulations have the force of law, all those involved in clinical trials with investigational agents must heed these laws, including NCI, pharmaceutical collaborators, and investigators. An organization or an individual that assumes these legal responsibilities for supervising or overseeing clinical trials with investigational agents is termed an IND sponsor. In the United States, the DCTD and pharmaceutical collaborators most commonly sponsor such research in cancer. The designation obviously implies a substantial commitment of resources.

In addition, the Public Health Service Act mandates a number of safeguards for the rights and welfare of individuals who are involved as research subjects. Department of Health and Human Services (DHHS) regulations, administered by the Office for Human Research Protections (OHRP), DHHS, specify requirements in addition to those of the FDA to ensure adequate human subject protection. Clinical investigators and institutions taking part in the clinical trials network are responsible for meeting the requirements of the HHS regulations. In addition, institutions conducting clinical trials must also abide by the Health Insurance Portability and Accountability Act (HIPAA).

As a sponsor of investigational agents, DCTD, and specifically CTEP, is responsible for seeing that clinical trials proceed safely and rationally from the initial dose-finding studies to a definitive evaluation of the role of the new agent in the treatment of one or more specific cancers. Fulfillment of this goal obviously requires active participation of DCTD staff throughout the entire process.

2.2 How NCI Funds Research
A full discussion of the means by which NCI funds research is beyond the scope of this manual. Whether support comes from investigator-initiated grant, contract, or cooperative agreement, however, the peer review process is central. Government officials can provide monies to investigators only in the context of mechanisms involving peer review; this process requires formal application by the investigator and (usually) multiple levels of evaluation. Once an application is approved, the NCI cannot provide more funding than is stipulated by the judgment of peer review and the NCI Board of Scientific Advisors. Additional awards can, of course, be made after review and formal approval of a supplemental application. Provision of investigational agents is separate from clinical study funding. However, CTEP will make a good faith attempt to supply investigational agents required for funded research proposals.

2.3 Preclinical Development of Investigational Agents
trials and relevant pre-clinical studies. More about SPOREs can be found at http://trp.cancer.gov/.

2.4 Collaboration between DCTD and the Pharmaceutical Collaborators
Many of the anticancer agents in CTEP’s pipeline is a co-development venture with a pharmaceutical collaborator. Collaboration between DCTD and the pharmaceutical industry may occur at any step along the new agent development process. Private companies often submit agents to DCTD for testing and joint development. Agents may be submitted for antitumor screening, preclinical toxicology, or clinical testing. Conversely, if DCTD discovers an agent, a pharmaceutical collaborator is sought early in development, since DCTD does not market new agents. Early pharmaceutical collaborator involvement permits substantial cost-sharing between public and private sectors, and can hasten the availability of effective agents by several years. In addition, DCTD aggressively pursues clinical trials in patient populations with underserved cancer treatment.

Development plans for new agents, therefore, are usually a collaborative effort between DCTD and the pharmaceutical collaborator. The DCTD and pharmaceutical collaborator formalize their collaboration in an agreement, with usually a Cooperative Research and Development Agreement (CRADA) or Clinical Trials Agreement (CTA). The model CRADA and its appendices can be found at http://ctep.cancer.gov/industryCollaborations2/model_agreements.htm. In this joint effort, DCTD and the private sector have a common goal: defining a new agent’s contribution to cancer treatment as precisely and expeditiously as possible. Clinical investigators’ opinions are often sought while formulating development plans for an agent. The timely approval of a new agent by a New Drug Application (NDA) or a Biologic License Application (BLA) by the FDA is in the public's interest. However, there may well be differences between these partners in sponsoring certain kinds of trials. The complex three-way relationship among clinical investigators, the DCTD, and private industry means coordinating efforts, establishing priorities, and allocating limited resources. To facilitate interactions, CTEP has developed guidelines on the nature of the relationship between the participants. The guidelines, which formally recognize the private sector’s involvement in and support of clinical trials, is summarized in "NCI-Cooperative Group-Industry Relationship Guidelines" (See Appendix I), http://ctep.cancer.gov/industryCollaborations2/guidelines.htm.

2.5 Private Support of Trials Supported by NCI Funding
As private support for clinical trials in cancer becomes more widespread, investigators and Cooperative Groups holding grants, contracts, or cooperative agreements from NCI should carefully consider the allowable allocation of resources provided by a private entity for a trial already receiving NCI support. Investigators and Cooperative Groups must make certain that Federal funds are not used to cover those costs of research also supported by private resources. Grants management personnel at NIH and auditors from DHHS are required to scrutinize such arrangements closely and may take steps to recover Federal funds if they have been used inappropriately.

In the specific case of the clinical Cooperative Groups, the Terms of Award of NCI's Cooperative Agreements permits them to accept industrial support, provided that industry funds are used for the support of additional costs not funded by the NCI. Such
costs might include additional laboratory tests, correlative studies, specimen collection or special requirements for data collection.

In the case of NCI-funded phase 1 and phase 2/3 trials, private provision of resources for tasks not supported by Federal funds may also be appropriate; investigators should discuss all such requests with CTEP.

2.6 Private Support of Trials Sponsored but Not Funded by NCI
Private support of a trial sponsored under a DCTD-held IND is appropriate under certain circumstances. However, the protocol/group chair and the private firm should draft a written agreement, sending a copy of the draft agreement to the Associate Chief, Regulatory Affairs Branch (RAB), CTEP for review. In general, CTEP will favor the provision of data from trials of this kind to a pharmaceutical collaborator. These arrangements may not be exclusive (i.e., may not serve to prohibit release of data to another party); unless CTEP previously agreed with the pharmaceutical collaborator that exclusivity is appropriate. In any case, the investigator’s obligations to DCTD as the sponsor, as detailed throughout this manual, remain unchanged.

2.7 The Investigational New Drug Application (IND)
Any organization or individual investigator seeking to sponsor clinical trials with investigational agents must first submit an IND to the FDA. The use of the term “sponsor” is generally reserved for organizations assuming broad responsibilities for the development of a new agent. It is also possible for individual investigators to hold an IND (see 21 CFR 312.6, “sponsor-investigator”). The IND is the legal mechanism under which investigational agent research is performed in the United States. No investigational agents may be administered to patients for research in the U.S. without an active IND.

The FDA’s regulations for drugs and biologics found in 21 CFR 312 and 21 CFR 600, respectively, (http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfdocs/cfcr/CFRSearch.cfm) specify an IND sponsors’ obligations. The DCTD, while a component of an agency in the DHHS, is just as accountable, e.g. as a pharmaceutical company for meeting these obligations.

The sponsor’s initial IND submission to the FDA is a lengthy document that sets forth the experimental rationale for human testing, based on results of animal pharmacology and toxicology studies, manufacturing data, purity and stability information, and provides an initial plan of clinical investigation.

The IND is the official record at the FDA of the sponsor's clinical research with the agent. Under FDA regulation, DCTD must maintain the IND as an accurate, timely repository of all information concerning the agent’s clinical use, including all clinical protocols, clinical protocol amendments, adverse events, and an annual report on all clinical trials and any new relevant preclinical (particularly toxicologic) data. Obviously this means that no one can use an investigational agent without the IND sponsor’s knowledge and prior approval.

After a sponsor submits an IND, FDA has 30 days to complete its review. If FDA has safety concerns, it may place a hold on the initiation of a clinical trial(s) with the agent. Please note that these are matters between the sponsor and the FDA. An investigator at
a clinical site may not initiate patient treatment on a protocol using DCTD-sponsored agents until he or she has received written notice of approval from CTEP.

2.8 The Marketing Application

After clinical trials have shown that the new agent is safe and effective, the formal process by which this occurs in the U.S. is FDA approval of a marketing application (New Drug Application for small molecule agents or a Biologic License Application for biological agents). These are submitted by a pharmaceutical company; as noted previously, NCI does not submit NDAs or BLAs since it does not market products. The applicant seeks approval from FDA for one or more specific indication(s). Review and approval of an NDA or BLA are based on demonstration of safety and efficacy assessed from detailed reports of the clinical trials, particularly randomized controlled studies. A new agent’s contribution to the treatment of a disease is demonstrated unambiguously if the agent is the only variable between the treatments.

The specific endpoints that constitute satisfactory evidence of efficacy (e.g., response rate, quality of life, survival) have been addressed in a published paper prepared by FDA and NCI entitled "Commentary Concerning Demonstration of Safety and Efficacy of Investigational Anticancer Agents in Clinical Trials." This paper was prepared with input and advice from the Oncologic Drugs Advisory Committee of FDA (a panel of outside experts in clinical oncology) and the Board of Scientific Counselors of the DCTD (a panel of outside experts in preclinical and clinical oncology). A copy of this paper is available at http://jco.ascopubs.org/cgi/content/abstract/9/12/2225.

The approval of the NDA or BLA is a critical milestone not only for the pharmaceutical company but also for the clinical investigator, the practicing oncologist, NCI, and the general public. An affirmative decision by the FDA permits the pharmaceutical company to market and promote the agent for the approved indication(s). Once an agent is marketed, no Federal regulation prevents licensed physicians from prescribing it for any indication they deem appropriate.

For the NCI, NDA or BLA approval marks a step forward in the development of effective cancer therapies. Following approval the NCI usually continues to sponsor further research with the agent for other indications or disease settings.
3 The Clinical Trial Site and the Investigator

3.1 Definition and Purpose of a Participating Site for Clinical Trials
A clinical trial site is an entity that assumes a broad range of responsibilities and functions for the support of clinical trials conducted under its name. Examples of a clinical trial site include a single institution (i.e., hospital, clinic), Cancer Centers (i.e. a university), Cooperative Groups Consortia and SPOREs. The clinical trial site supports investigators as they develop, organize, implement and analyze clinical trials. The clinical trial site assumes responsibility for research quality, both in concept and execution, and ensures patient safety.

An effective clinical trial site enhances the investigator's research in several specific ways. It provides assistance in developing protocols and obtaining approval by sponsoring agencies. It often offers centralized data management and statistical consultation. An effective clinical trial site should also provide the opportunity for internal peer review and quality assurance.

The clinical trial site enhances its own scientific credibility by assuming responsibility for the quality of the scientific ideas and the care with which they are tested. These activities may also be an economical way of supporting multiple clinical investigations simultaneously.

3.2 Activities of a Participating Site

3.2.1 Protocol Development-Scientific Review and Biostatistical Consultation
Many clinical trial sites have internal procedures for review of each clinical trial's science, either at the concept stage or at the time a protocol is written. These reviews are distinct from the task of the Institutional Review Board (IRB), which are directed at patient protection and may or may not provide critical scientific review. Ideally, scientific review assists investigators focus their ideas. It may also help identify other useful scientific resources within the clinical trial site. As a whole This process should facilitate research and help test new ideas. Sites that conduct phase 3 trials should conduct additional scientific and statistical review due to the substantial commitment of time, patients, and resources involved.

All clinical trial designs should be based on sound statistical principles. Issues such as sample size, stopping rules, endpoints, and the feasibility of relating endpoints to objectives are pivotal to a successful trial. Statistical review should be provided by experts at the clinical trial site.

3.2.2 Protocol Administration
Most protocols require multiple levels of approval. Since policies may change with time; clinical trial sites should assist investigators and ensure they obtain these approvals. Establishment of a centralized mechanism for submitting and tracking a protocol through the necessary approvals, including the IRB, saves individual investigators time and effort that is better directed elsewhere. A clinical trial site engaged in CTEP-supported protocols must assume responsibility for communicating status changes, amendments, results reports, publications, and other pertinent protocol administration information to CTEP.
3.2.3 Establishment of an Affiliate Program

An affiliate investigator is a physician who participates in a clinical trial organized by a major institution and has satisfied all criteria for affiliate membership as defined by the primary institution (see Section 13). Engaging affiliate investigators often contributes to cancer clinical trial success. The clinical trial site must be as concerned about the quality of research performed by its affiliate investigators as it is with that of its own staff. The Principal Investigator must oversee affiliate investigators closely.

CTEP has established a set of guidelines to assist clinical trial sites in developing a policy toward affiliate investigators (see Section 13). Each clinical trial site participating in study agent trials supported by CTEP and/or sponsored by DCTD may develop its own affiliate policy in accord with these guidelines, provided they meet all CTEP Guidelines.

The most important components of these guidelines are that the clinical trial site should, (a) define qualifications necessary for affiliate investigators and (b) periodically review their performance. Such review of performance should include site visits by investigators from the clinical trial site.

3.2.4 Agent Accountability and Storage

Although FDA regulation holds the investigator accountable for the proper use of investigational agents and ongoing reporting of study agents with the investigator, designated staff may assume these responsibilities for investigators. Regardless, a study’s principal investigator is ultimately responsible for compliance with Federal requirements (see Section 15).

3.2.5 Reporting of Results to CTEP

Investigators on CTEP-supported studies (or organizations that assume responsibility for investigators) must provide the following to CTEP:

- adverse events
- protocol amendments
- regular and final study results
- publications
- protocol status changes

The summaries and status of all CTEP studies must be reported via the reporting mechanism best suited for the study. Section 10 provides additional detail on reporting guidelines. The Cooperative Groups and Consortia inform CTEP of this information directly. In all cases, the protocol chair is responsible for reporting to CTEP.

3.2.6 Data Management and Statistics

Since most cancer clinical trials involve professional staff other than the protocol chair, the institution must integrate proper collection of clinical data into their medical practices. Data collection is best done as data are generated; this practice promotes protocol compliance and permits the protocol chair to monitor the study's progress. For these reasons, data management organized and supported at the department or institution level is usually more efficient and reliable than that which is left to the individual investigator. CTEP does not require centralized data management by institutions performing CTEP-supported trials, but is highly recommended. In the experience of
CTEP’s site visit monitoring program (see Section 16), institutions that provide central support for data management tend to have better quality than those without.

3.2.7 Quality Assurance
Clinical trials investigators are obligated to take appropriate steps to protect the integrity of science and the safety of human subjects (study participants). Selecting responsible investigators and research staff is the best way to protect against protocol deviations or poor data quality.

Quality assurance includes prevention, detection, and action from the beginning of data collection through publication of the results. Special efforts should be made to assure protocol adherence, adequate assessment of eligibility, compliance with protocol treatment and regulatory requirements, and complete collection of data on the primary outcome measures. Another goal of a quality assurance program is to detect problems by implementing routine monitoring procedures and periodic data audit.

These activities take many forms. Section 16 describes existing CTEP and Cooperative Group procedures for quality assurance. CTEP encourages even single institutions to establish internal quality assurance programs. CTEP staff will assist and provide advice to any clinical trial site that wants to develop these programs.

3.2.8 Biomarker and Imaging Studies
Clinical trials now often use laboratory assays or imaging modalities to assess or investigate novel biomarkers. These investigational biomarkers are specific to the disease or the agent (as opposed to routine measurements of normal organ function such as CBC, serum albumin, etc.), but they are not yet part of the generally accepted diagnostic algorithm for the disease. Exceptions include the relatively few biomarkers that are currently accepted, such as the ER/PR and HER2 status of breast cancers. A biomarker may be integral to the trial, or it may be included as either an integrated or correlative study.

An integral biomarker is a test that must be performed on all subjects in real time for the trial to proceed, such as one that is used to establish eligibility, to assign treatment or to stratify the case for randomization. For integral biomarkers, laboratory or imaging tests must meet performance standards suitable for clinical practice (see Performance Standards Reporting Requirements for Essential Assays in Clinical Trials, http://www.cancerdiagnosis.nci.nih.gov/pdf/PACCT_Assay_Standards_Document.pdf). The investigator(s) responsible for biomarker measurements must be identified. By law, investigators must employ a CLIA-certified laboratory to perform any laboratory test if the result will be used to assign treatment, or will be reported to the patient or his/her physician at any time; additional state or local regulations may apply. Information about the integral biomarker should be included in the protocol in the sections for Objective(s), Background and Rationale and Statistical Considerations, and in other sections of the document as appropriate (e.g., Patient Eligibility Criteria). Trial registration procedures and accrual targets must consider anticipated turn-around times for test results and expected rates of test failure. It is essential that the protocol include clear and complete instructions for the acquisition, processing and shipment of specimens and/or imaging data. Refer to Concept Checklist for Phase 3 Trials with Essential Biomarker/Imaging Assays (http://restructuringtrials.cancer.gov/files/BIQSFP_Announcement_12_12_08.pdf) [currently posted as part of 2009 BIQSFP announcement] for additional guidance.
Integrated biomarkers are not used to determine treatment in the trial, but are clearly identified as part of the trial from the beginning and are intended to identify or validate tests planned for use in future trials. Integrated tests are performed on all subjects, and the study includes complete plans for specimen or image collection, laboratory measurements and statistical analysis. The investigator(s) responsible for biomarker measurements must be identified. Even if laboratory test results are not used to determine treatment, if the results will be reported to the patient or his/her physician at any time, then the test must be performed in a CLIA-certified laboratory; additional state or local regulations may apply. As for integral biomarkers, information about the test should be included in the protocol's Objective(s), Background and Rationale and Statistical Considerations sections, and in other sections as appropriate (e.g., Special Studies or an Appendix). It is essential that the protocol document itself include clear and complete instructions for the acquisition, processing and shipment of specimens and/or imaging data; if specimen collection is mentioned in more than one section of the protocol (for example, in both Procedures for Patient Entry on Study and in an Appendix), be careful to maintain consistency in the instructions.

Correlative or ancillary laboratory or imaging studies may be retrospective or exploratory. To enhance opportunities for high-quality retrospective studies, which can be exceptionally informative, investigators are encouraged to build plans for specimen collection and tissue banking into clinical trials. Correlative studies of tests that do not meet the criteria above for either integral or integrated biomarkers may be embedded in the protocol. See Guidelines for Correlative Studies in Clinical Trials (http://ctep.cancer.gov/protocolDevelopment/default.htm#ancillary_correlatives) for information that should be included in the protocol for embedded correlative studies.
4 Phase 1 Trials

The Development of a Clinical Trial

The following three sections explain the policies for phase 1, 2 and 3 clinical investigations with CTEP study agents. For each phase, we outline the scientific objectives for CTEP-supported clinical trials. We also describe which physicians are eligible to study and administer study agents. These two aspects of agent use—study and administration—are formally separate issues. In general, eligibility to study CTEP study agents has been restricted to institutions and investigators approved by peer review; these individuals may include grantees, contractors, Cooperative Group members, physicians affiliated with approved cancer centers, and recipients of investigator-initiated clinical research project grants (RO1, PO1). The application of this general rule to each phase of agent development is explained in detail. Except in certain explicitly defined circumstances outlined in the following sections, the administration of study agents is restricted to these investigators. Information regarding the use of investigational agents in phase 0 studies is found in Appendix II.

For investigational agents involving a pharmaceutical collaborator and a DCTD-sponsored IND, the Investigational Drug Steering Committee (IDSC) is consulted to develop a strategic clinical development plan. The IDSC membership includes principal investigators from NCI phase1 U01 and phase 2 N01 contracts, as well as representatives from Cooperative Groups. Its members include experts in biostatistics, imaging, radiation oncology, and clinical and preclinical pharmacology. The IDSC subgroups assist CTEP with early phase trial prioritization, and address critical scientific issues for the trials (http://ctep.cancer.gov/SpotlightOn/Investigational_Drug_Steering_Committee.htm).

4.1 Scientific Policies of CTEP

4.1.1 Planning of Phase 1 Trials

CTEP plans the phase 1 development of each agent prospectively, basing schedule selection and starting doses for phase I clinical trials on experimental data. Generally, each schedule is examined in not more than two studies.

From the results of the phase 1 and clinical pharmacology studies, CTEP and its collaborators (investigators, pharmaceutical collaborators and IDSC) decide which schedule to bring forward into phase 2. If the need exists, they may comparatively examine a second schedule later in selected tumors to better define the therapeutic index.

4.1.2 Objectives

Phase 1 trials determine a safe and/or biologically effective dose for phase 2 trials and help define adverse effects on normal tissues. In addition, these trials examine the agent's pharmacology which may reveal evidence of antitumor activity. Anticancer agents are not tested in patients unless preclinical activity studies have demonstrated evidence of significant activity in laboratory animals or an appropriate in vitro model.
Animal toxicology studies conducted prior to phase 1 trials provide the investigator with
• estimates of a starting dose for clinical trials
• prediction of the agent’s likely effects (desired and adverse) on normal tissues

These studies provide investigators with information that helps focus clinical observation
of the patient. The phase 1 dose is increased gradually by defined procedures until a
level is found that
• produces limiting but tolerable adverse events, or
• finds pharmacodynamic (PD) evidence of target effect, and/or
• finds clear signs of therapeutic activity.

Phase 1 studies may have multiple endpoints, including determination of a biologically
effective dose, but usually increase doses to some level of normal tissue toxicity. Phase
1 trials define acute effects that occur with a relatively high frequency on normal tissues.
Continued careful observation during phase 2 and 3 trials is essential to identify less
frequent acute adverse effects, as well as cumulative and chronic adverse events.

4.1.3 Patient Selection
Patients eligible for phase 1 trials must have confirmed malignant disease that is not
effectively treated by conventional forms of therapy or for which there is no standard
treatment. Initially, patients should have normal organ function so the investigator may
reliably distinguish agent effects from disease effects.

In the presence of major organ impairment, drug treatment may increase adverse effects
due to decreased clearance or additive injury to the organ. Since most anticancer agents
will ultimately be used in some patients having impairment of major organ function
(particularly cardiac, hepatic, and renal), it is reasonable to explore their use. CTEP
sponsors specific phase 1 trials explicitly designed to determine safe and tolerable
doses in patients who have organ impairment and to determine potential toxicities (see
Section 4.1.10). CTEP usually supports such trials selectively after the initial trials in
patients with normal organ function.

After successful completion of phase 1 trials in adults with normal and abnormal
physiology, CTEP initiates other types of studies. These studies include those in
pediatric populations and elderly patients. Such attempts are aimed at identifying a
range of maximally tolerated doses (MTDs) or biologically effective dose for each agent.

Typically, phase 1 studies are performed in both women and men. If gender-specific
pharmacologic differences exist, these differences must be demonstrated and
characterized. In some situations, pharmacogenomic differences in drug metabolism or
target effects may alter toxicity or efficacy of the agent in different ethnic populations,
requiring separate analyses of drug effects in these ethnic groups.

4.1.4 Schedule Selection
Several factors determine the number of separate schedules studied in phase 1 trials. These
include evidence of schedule dependence in experimental in vivo systems;
pharmacokinetics, mechanism of action, if known; and existing clinical data with similar
compounds suggesting superiority of a particular schedule. Agents that are highly
schedule-dependent in preclinical models are usually brought into phase 1 trials on the
putative optimal schedule.
Because the correlation between schedule dependence in preclinical models and the clinic is not firmly established, however, some agents may be candidates for a broader array of schedules. DCTD is prospectively evaluating the ability of experimental models to predict the schedule dependence of activity, adverse effects, and pharmacokinetics. For agents showing no particular schedule dependence in preclinical models, two extremes of schedules (e.g., single bolus dose per course and 5-day continuous infusion) are sometimes examined.

4.1.5 Starting Dose
The starting dose of a phase 1 trial is based on preclinical toxicology studies. Numerous formulas to calculate a starting dose exist, for example, a fraction of the MTD in the most sensitive species tested or the no adverse effect level (NOAEL). Investigators would discuss their rationale for the proposed starting dose with CTEP.

4.1.6 Dose Escalation
Doses are generally escalated according to a schema in which incremental increases in dose decrease as biologic activity becomes evident. Often, a modified Fibonacci plan is employed. However, when the goal is to escalate to a biologically effective dose as rapidly as possible, a number of accelerated titration, continual reassessment method, and other designs allow rapid dose escalation in the absence of limiting toxicity. A frequent phase I design employs successive dose doubling until a Grade 3 adverse event or two instances of a Grade 2 adverse event are seen. The exact schema may be affected by the steepness of the dose toxicity curve in animal models or, for trials of combinations of agents, the steepness of the single-agent dose toxicity curves. In all cases, the goal is to arrive at the recommended phase 2 dose with the fewest number of escalations consistent with patient safety; this approach minimizes the number of patients receiving biologically inactive doses. CTEP is actively evaluating other methods of dose escalation, based on the use of pharmacodynamic markers to determine target effects, and the accelerated titration designs for phase 1 clinical trials found at http://linus.nci.nih.gov/~brb/Methodologic.htm.

When there is sufficient concern about anticipated adverse events, a minimum of three patients not previously treated with the new agent should be entered at each dose level. In these cases, escalation to the next level should not occur until the safety of the current level has been established. This may require observation of at least three patients for the entire course interval (e.g., 3 – 5 weeks). For many trials, however, escalation can proceed with one or two patients per level provided no Grade 3 or repeated Grade 2 adverse events have yet been seen in the study. Intra-patient dose escalation should be considered for use wherever it is deemed safe. At least six patients should be treated at the recommended phase 2 dose. The incidence of dose limiting toxicity acceptable for a recommended dose should be specified in the protocol (e.g., <33%).

4.1.7 Pharmacokinetics
Pharmacokinetic determination of drug levels and metabolism of parent drug and principal metabolites during phase I studies can confirm optimal schedules for drug administration; determine the principal routes of human metabolism; predict populations at particular risk for drug toxicity; and suggest whether flat dosing or BSA-based dosing of drug is appropriate for a particular agent. The role of pharmacokinetics in phase 1 trials is now receiving increasing emphasis, with specific focus on the possible use of
such data to guide dose escalation. Investigators developing phase 1 trials should consider pharmacokinetic determinations an integral part of their study. Investigators with questions regarding suitable PK methodologies for their trials should check with the Investigational Drug Branch (IDB) staff physician before writing a protocol.

4.1.8 Studies to Determine Pharmacodynamic Effects
Pharmacodynamic (PD) analysis of the biochemical and physiologic effects of anticancer drugs on the body, and on specific drug targets in the cancer cell, is an increasingly important component of early phase cancer trials. Rational, efficient development of endpoints of drug effect on target, pathway, and downstream biological processes can:

- lead to more rapid and efficient development of targeted cancer therapeutics,
- help determine the biologic effective dose of the agent.

Determination of PD endpoints can be linked to the therapeutic effects of the investigational agent and help provide proof of concept for target modulation. PD biomarkers in early clinical trials inform the rational selection of the agent’s dose and schedule, and may explain or predict clinical outcomes. (Adv Cancer Res. 2007;96:213-68).

4.1.9 Imaging Studies to Determine Pharmacodynamic Effects
Increasingly, imaging technology is able to perform functional or molecular imaging of cancers. These modalities visualize physiological, cellular, or molecular processes in tumors. They allow observation of anticancer agents’ effects on tumors, permitting treatment monitoring and providing evidence of target effects. DCTD’s Cancer Imaging Program (CIP) is an innovative biomedical program to advance understanding of cancer imaging. CIP supports and advises innovative imaging correlates to early phase clinical trials by funding projects in key areas and developing protocols for imaging studies of anticancer drug effects (http://dctd.cancer.gov/ProgramPages/cip/default.htm). CTEP and CIP often collaborate on clinical studies that combine an investigational study agent and an imaging component.

4.1.10 Phase 1b Studies
CTEP supports phase 1b studies for the initial combination of investigational agents with standard anticancer agents or with other targeted therapies. These combination trials are often started after initial trials of the investigational agent have shown evidence of tolerability and some evidence of single-agent activity. Single agent studies may be unnecessary in situations where the new investigational agent acts as a cytotoxicity potentiator, lacking expected inherent anticancer activity. Investigators should provide a strong rationale for the drug combination, supported by preclinical studies, for proposed trials. IND agents may be combined if there is sound evidence to support this study design. These combination investigational agent studies are evaluated on a case-by-case basis.

4.1.11 Phase 1 Organ Dysfunction Trials
Special populations are generally excluded from studies of investigational agents because dosing or scheduling information is unknown or patients are considered too frail to tolerate treatment. Many oncology drugs are approved by the FDA with limited PK/PD information in patients with organ dysfunction. Cancer patients who have renal or hepatic organ dysfunction may require dose reductions or modifications. The number of cancer patients with impaired hepatic or renal function eligible for protocols specifically evaluating organ dysfunction is limited. Involving well-coordinated, multicenter groups with access to experienced phase 1 investigators can significantly shorten accrual time
for organ dysfunction studies. The National Cancer Institute’s Organ Dysfunction Working Group is available to assist investigators interested in such studies with investigational anticancer agents, and standards for such trials are being developed (Clinical Trials in Special Populations, in: Principals of Anticancer Drug Development, in press).

4.2 Who Is Eligible to Study Phase 1 Agents
Currently, two groups of investigators are eligible to study phase 1 agents: phase 1 U01 cooperative agreement investigators (Section 4.2.1) and qualified investigators with peer-reviewed expertise in the conduct of early clinical trials (Section 4.2.2).

Selection of phase 1 investigators is a competitive process, with preference given to those with relevant expertise, ability to correlate clinical and laboratory biologic studies, and ability to complete a high-quality study in a timely fashion. Selection of investigators is an open and competitive process and all appropriate investigators are welcome to apply.

The NIH has grant mechanisms to support junior faculty embarking upon a career in clinical research. The Career Development LOI is intended to increase the LOI success rate and to facilitate junior investigators’ career development. LOIs submitted by junior investigators are prioritized favorably when compared to LOIs submitted by more experienced investigators. Since a successful outcome requires the submission of an approvable LOI, junior investigators are particularly encouraged to obtain CTEP Investigational Drug Branch staff input during LOI preparation. Information about the Career Development LOI is found on the CTEP web site, in the CTEP forms, templates and documents section.

Please refer to Appendix III for the conduct of phase 1 and 2 trials in the pediatric population.

4.2.1 Cooperative Agreement Awardees or Contractors
Phase 1 clinical trials may be supported by grants, cooperative agreements or contracts. Currently, U01 cooperative agreements support phase 1 clinical trials solicited by the NCI. Investigators are selected through competitive peer review of their cooperative agreement applications submitted in response to periodic solicitations from DCTD. These cooperative agreements are usually funded for 5 years.


When NCI seeks applications for a contract, a Request for Proposal (RFP) is issued. We publish a notice of RFP availability in the Commerce Business Daily at http://cbdnet.gpo.gov/ and FedBizOpps at https://www.fbo.gov/. These contract solicitations can also be found on the Office of Acquisition Management and Policy at National Institutes of Health at http://oamp.od.nih.gov/. Active contract solicitations are listed by Institute under the “Contract Opportunities” link on this web site.
4.2.2 Other Phase 1 Investigators
Qualified investigators with peer-reviewed expertise in the conduct of early clinical trials are also eligible to conduct unsolicited phase 1 trials. Investigators are usually selected because of unique expertise or research experience relevant to the agent or the availability of certain patient populations or laboratory facilities to perform special studies. These clinical studies are usually performed as investigator-initiated research using the R21, R01 or P50 grant funding mechanisms. Grants can be submitted as investigator initiated research applications or in response to a Program Announcement (PA) or Funding Opportunity Announcement (FOA). These opportunities may be found at either http://grants.nih.gov/grants/guide/index.html or http://www.grants.gov/applicants/find_grant_opportunities.jsp.

In all cases, such investigators must have demonstrated competence in conducting phase 1 studies with anticancer agents. Ad hoc phase 1 investigators must fulfill all CTEP requirements for trial conduct, as defined in this section, and for reporting of data as described in Section 10.

4.3 Which Organizations Can Conduct Phase 1 Studies
Phase 1 trials are most commonly conducted by single institutions. Multicenter trials with a new single agent having an unknown adverse event profile are usually conducted most safely in a single center. In unique situations, phase 1 trials may require multiple institutions, such as with many pediatric phase 1 studies (see Appendix III), and with agents that are targeted specifically for a single disease or limited subpopulation of cancer patients.

4.4 Who Is Eligible to Administer Phase 1 Agents
All phase 1 agents must be administered only at institutions listed on the approved protocol’s cover page and must be administered under the protocol chair’s supervision. Investigators must not send these agents to referring physicians, except with CTEP’s written permission. The protocol must describe any part of the treatment that will be administered at a site other than the study center in detail.

4.5 How to Obtain Information about Phase 1 Agents

4.5.1 Investigator’s Brochure
This document contains all relevant information about the agent, including animal screening, preclinical toxicology, detailed pharmaceutical data, pharmacology and mechanism of action. The brochure also contains information about the clinical adverse events observed in clinical trials. CTEP has an Investigator’s Brochure for each investigational agent it sponsors. CTEP provides these routinely to investigators who are approved to conduct a clinical trial of the agent at the time the LOI is approved, and when the Investigator’s Brochure is updated. When necessary, investigators with approved LOIs or protocols may obtain the Investigator’s Brochure from the Pharmaceutical Management Branch (ibcoordinator@mail.nih.gov).

4.5.2 Investigational Drug Branch (IDB) Physicians
Each CTEP investigational agent is assigned to an IDB staff physician, who prepares the solicitation for initial clinical trials and coordinates its clinical development under DCTD sponsorship. Phase 1 investigators are advised to discuss a proposal with this physician.
before writing a formal LOI. IDB staff members welcome investigator queries prior to submission of an LOI for phase 1 trials, as well as during the subsequent development of a clinical trial protocol (see Section 7). Relevant contact information can be found in Appendix IV.

4.5.3 Career Development LOI
The Career Development LOI is intended to increase the LOI success rate and to facilitate junior investigators’ career development. The process includes LOI prioritization and documentation of mentorship and institutional support.

Eligibility:

1. The PI should have a major interest in and intend to develop a career in clinical research.
2. He/she should be within 7 years of completion of fellowship training and a faculty member (fellows may not serve as PIs on studies) at an institution with a successful track record in conducting cancer clinical trials (Note: PIs of NCI Cooperative Group proposals are also eligible).

Additional information regarding the Career Development LOI may be found at the CTEP web site:

4.5.4 Other Information
Phase 1 investigators should carefully read the sections relevant to writing a protocol with phase 1 agents:

- **Section 7** The Drafting of a Protocol
- **Section 8** Protocol Review and Approval at CTEP
- **Section 9** Ordering Study Agents from NCI
- **Section 10** Responsibility for Reporting Results to CTEP
- **Section 12** The Investigator and Protocol Chair: Roles and Responsibilities
- **Section 15** Accountability and Storage of Investigational Agents
- **Section 16** Monitoring and Quality Assurance
5 Phase 2 Trials

5.1 New Agent Development Considerations

5.1.1 Planning and Coordination of Phase 2 Trials by CTEP
As a sponsor, DCTD must devise and implement plans for phase 2 trials of novel therapeutics. An adequate phase 2 plan, while conceptually straight-forward, is often difficult to execute. A reasonable plan presupposes answers to the following questions:

- What doses and schedules emerging from phase 1 ought to be carried forward into phase 2?
- What diseases should be targeted for testing?
- How does the new agent fit into CTEP’s priority list for various targeted disease studies?
- How does the new agent fit into the priorities of the clinical investigators who form the core of the NCI-supported clinical trials network?
- How can the CTEP assure that each agent is adequately tested in each disease that is studied? How many studies should be mounted in each disease category? What kinds of patients are suitable for study entry? What are suitable stopping rules for phase 2 trials?
- How should we perform phase 2 studies if there are limited supplies of the new agent?
- What important laboratory correlates can be made within the context of a clinical trial?
- How can the proposed study be completed within a suggested timeline (i.e. multicenter vs. single center)?

CTEP staff collaborates with each agent’s industrial sponsor and the Investigational Drug Steering Committee (IDSC) during late phase 1 to plan phase 2 development; CTEP announces the plan via solicitation of LOIs.

5.1.2 Single Agent Phase 2 Studies
A phase 2 study:
1. determines whether an agent has antitumor activity and
2. estimates the response rate in a defined patient population.

Well-designed phase 2 trials limit enrollment to just the number of patients needed to ensure detection of a medically significant level of activity.

Phase 2 studies are disease-oriented. Various tumor types are tested in phase 2 as distinct clinical entities, as each has differing prognostic factors, eligibility requirements, and patterns of responsiveness to a particular agent. As there may be many unknown or uncontrollable factors contributing to variability in outcome, CTEP attempts to sponsor two phase 2 trials in each tumor type.

The goal of these initial phase 2 trials is to determine whether the new agent has activity against particular cancers. These trials, therefore, serve as a screen for further study. For this reason, investigators must make every effort to avoid false results. Although false-positive results are certainly undesirable, false-negative phase 2 results are also damaging, as they may delay significantly or prevent discovery of a potentially useful antitumor agent.
CTEP has based its guidelines concerning eligibility requirements on patient characteristics that appear to have a particular impact on likelihood of response. Specifically, for initial phase 2 studies, we currently seek trials that restrict patient eligibility to the minimum extent of prior therapy consistent with current medical practice. If an agent’s MTD is well characterized, protocols for its initial phase 2 trials should restrict patient entry in the following ways:

- For diseases that currently lack effective systemic therapy (e.g. liver and pancreas), trials should be limited to patients with no prior chemotherapy.
- For diseases in which systemic therapy may cause objective tumor regression but has little or no impact on survival, entry of patients with no prior therapy will also be sought, whenever possible (e.g. carcinomas of the head and neck, cervix, esophagus, prostate, bladder, large bowel, kidney, stomach, non-small cell lung, and melanoma).
- For diseases that are potentially curable with systemic treatment (e.g. acute leukemias, diffuse non-Hodgkin's lymphomas, Hodgkin's disease, testicular cancer, limited small cell lung cancer, and ovarian cancer), patients having the minimum extent of prior treatment consistent with current ethical standards of care are selected.

This policy will have the following desirable consequences:

- Patients initially entered into phase 2 trials will have the best chance of benefit from treatment and should be able to tolerate any adverse effects of therapy better than patients with poorer performance status, agent-resistant disease, and possible compromised major organ function from prior chemotherapy.
- Fewer patients are exposed to inactive agents.
- The chance of missing potentially active agents will be minimized.

Clearly, the population of patients defined in this way is highly selected, and the results of these initial trials will not necessarily represent the agent’s activity in the general population of patients with the disease in question. Once a new agent shows significant activity in this initial, relatively favorable, subset of patients, eligibility criteria in subsequent studies will permit entry of patients with less favorable prognostic characteristics, so that such patients may have an opportunity to benefit from an active agent. In this second stage of the new agent's phase 2 evaluation, a more accurate assessment of its activity in the general population of patients with cancer may be obtained.

If an agent shows promising anti-tumor affects, CTEP may perform a “Special Response Review.” The audit may be conducted at CTEP or on-site. Auditors are selected to participate according to their expertise, pharmaceutical representatives and IDB staff may also be present. Selecting only responding patients, the investigator(s) presents a written and oral summary and review of each claimed responding patients. The coordinating site is responsible for providing all materials, such as MRIs, scans and all tumor measurements according to the response criteria and evaluation schedule stated in the protocol. CTMB prepares a full report including patient summaries, tumor measurements and endpoint results. The CTMB-prepared final report is approved by the lead expert auditor and the CTEP agent or disease coordinator. The PI may include a statement in subsequent manuscripts that CTEP has verified the responses. This statement may not be used if all claimed responding patient’s results were not verified.
5.1.3 Combining Agents
We believe that the most rational approach to development of a new cancer agent is reserving its combination with another agent(s) until it has shown reproducible evidence of activity in at least two single-agent trials in a disease. Alternatively, or in addition, investigators may propose combinations when a rationale firmly grounded on laboratory evidence is relevant to the clinical circumstance.

In the past, oncologists developed many agent combinations intuitively; they combined two, three, or more putatively active agents in uncontrolled studies of antitumor effect and adverse effects. To be sure, some very real therapeutic advances were achieved by this process. However, the lack of a systematic, stepwise approach and the frequent absence of proper control groups often left the oncology community in the uncertain position of not knowing whether results with a particular regimen represented progress or not. A new agent’s overall impact on efficacy and adverse events may remain unclear without a systematic approach. Ultimately, when available data do not elucidate each new agent’s specific contribution, the process of NDA or BLA approval is impeded.

Intelligently designed and flexible new agent development programs must provide room for both approaches. Well-conceived small pilot trials testing new hypotheses will always have an important place in cancer’s developmental therapy. We shall, however, continue to pay close attention to the rationale behind all proposed combinations. We will also continue to ask whether certain proposals for therapeutic research might not be better approached by a phase 3 design rather than phase 2.

In the past, activity was the most common basis for a single agent’s inclusion in a combination. CTEP now considers other rationales as well. For example, we consider radiosensitizers or substantial laboratory evidence of synergy between two cancer agents. This is particularly compelling if it is consistent with a putative mechanism of action. Alternatively, an agent inert against cancer might be added because of evidence that it alters a second (anticancer) agent’s pharmacodynamics or pharmacokinetics. Agents can also be tested as both chemotherapeutics and radiosensitizers. In such cases, CTEP will carefully assess the rationale and evidence offered in support of a proposal.

When investigators submit combination studies to CTEP for review, therefore, it is particularly important to state the proposal’s goals, background, and rationale clearly.

- If experimental results in the laboratory are the basis for the study, they should be relevant to the clinical circumstance and cited in adequate detail.
- If preliminary clinical results are the motivation, they should be similarly cited; unpublished results should be provided as part of the background or in an attachment to the protocol document.
- If the trial proposes a feasibility pilot, the protocol should state clearly what kinds of results the investigators would regard as medically significant and where they would propose to go next if a significant result is obtained.

A detailed plan of a follow-up study or detailed speculations about likely outcomes is not necessary at this stage of review. Rather, we are seeking an understanding of how the pilot proposal will fit into a strategy of development of the new therapeutic idea.
5.1.4 Randomized Phase 2 Studies
A randomized controlled trial is the study design that can provide the most compelling
evidence that the study treatment causes the expected effect on human health. This
study design has become a common practice to conduct "active comparator" studies
(also known as "active control" trials). In other words, when a treatment exists that is
clearly better than not treating the subject (i.e. giving them the placebo), the alternate
treatment would be a standard-of-care therapy. The study would compare the 'test'
treatment to standard-of-care therapy. Comparison to a control arm is most useful when
there is little prior information on expected efficacy rates and can also be useful for end
points that can be heavily influenced by patient selection, such as TTP and PFS.
However, except in very rare cases, a larger phase 3 study will be required to definitively
establish clinical benefit. Although it will not be definitive, the phase 2 randomized
control design will often aid decisions on whether to pursue further study of the treatment
and guide the design of additional trials.

5.2 Protocol Considerations

5.2.1 Single Disease Studies
Each tumor should be considered for phase 2 study separately. In general, this means
that there should be separate protocols for each tumor type. If a compelling reason
supports including several under one protocol, such as uncommon tumors, then
investigators should include separate statements for each tumor type regarding: (a)
eligibility requirements, including extent of prior treatment, (b) acceptable sites for
measurable disease, (c) response criteria, and (d) accrual objectives.

5.2.2 Eligibility Requirements
- Tumor Types: For each proposed tumor type there should be separate
  statements on eligibility.
- Prior Therapy: Because it is clear that the extent of prior cytotoxic chemotherapy
  is an important determinant of response probability, CTEP seeks initial trials that
  restrict patient eligibility to minimal prior therapy that is still consistent with good
  medical practice. (see Section 5.1.2)
- Measurability of Disease: To define quantitatively the antitumor activity of an
  agent, patients in phase 2 trial must have measurable disease parameters.

In certain diseases, common sites of involvement are either not bidimensionally
measurable or assessment techniques do not permit quantifiable measurement. Under
these circumstances, investigators may evaluate tumor response without quantification;
in such cases, having more than one observer assess responses is particularly
desirable. Examples include bone metastases, lymphangitic pulmonary disease, and
many parenchymal brain lesions.

Performance Status:
Under most circumstances, entry to initial phase 2 studies should be confined to patients
who are largely ambulatory (ECOG < 2). Patients should be expected to survive a
sufficient period of time for adequate observations to be made.

Organ Function:
Evidence that major organ function is normal is required. This includes creatinine level of
≤1.5 ULN, cardiac function at least Grade 2, pulmonary function moderately
compensated, and no neurologic, gastrointestinal or endocrine impairment that would compromise the safe use of the investigational agent.

**Gender:**
Where appropriate, the study should enroll both women and men. NIH policy requires that women and members of minority groups must be included in all NIH-supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification establishes inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. Please include a separate section regarding the “Inclusion of Women and Minorities” that describes the inclusion of women and members of minority groups appropriate to the study’s scientific objectives. Within the protocol, the investigators must describe the proposed study population’s composition in terms of gender and racial/ethnic group, and provide a rationale for selecting such subjects. The investigator must include a table in the protocol text.

**5.2.3 Accrual and Statistical Considerations**
Investigators should specify each study’s accrual goals in advance, and state the proposed maximum number of patients explicitly. They must provide justification for the target sample size, in terms of precision of estimation or levels of type I and type II error. CTEP recommends multistage designs for distinguishing an unacceptable level of response from a promising level (e.g., Fleming, *Biometrics* 38:143 (1982); Simon, *Controlled Clinical Trials* 10:1, (1989)). Investigators should anticipate the accrual rate of eligible patients realistically, and describe mechanisms that are in place for early stopping of negative trials.

For cases where randomized phase 2 studies are preferable, Rubinstein LV et al. (JCO 2005 23: 7199) describes an exploratory study design (“randomized phase 2 screening design”) which may be useful. This design applies, in particular, to situations where there is interest in adding an experimental agent to a standard therapy for a particular cancer. The design would facilitate conducting a trial comparing regimen A (standard therapy) to regimen A plus the new agent.

**5.3 Which Organizations can Conduct Phase 2 Studies?**

**5.3.1 Cooperative Groups**
All registered physicians of the Cooperative Group, including those at full member institutions, in Community Clinical Oncology Programs (CCOP) (http://prevention.cancer.gov/programs-resources/programs/ccop), Cooperative Group Outreach Programs (CGOP), at cancer control, or at affiliate institutions may participate as investigators on CTEP’s phase 2 and phase 3 trials. However, a Cooperative Group may have policies that restrict investigators’ participation.

**5.3.2 Cancer Centers**
Physicians with current/active registration with CTEP at institutions designated as comprehensive or clinical Cancer Centers by the NCI may participate on CTEP’s phase 2 and phase 3 trials. Such physicians may be:

- Staff physicians within the Center;
• Physician members of CCOPs for which that center is the research base; and
• Physicians affiliated with Cancer Centers (see Section 13 for further details on the affiliate policies of CTEP).

5.3.3 Affiliates
Physicians affiliated with a clinical site may participate as investigators on CTEP’s phase 2 and 3 clinical trials provided that:
• The affiliation is formalized and its terms are in writing and based on the CTEP policies on affiliates. (see Section 13);
• Each investigator is registered with CTEP upon submission of a signed FDA Form 1572, Supplemental Form for Investigator Registration, and Financial Disclosure Form (see Section 12 and http://ctep.cancer.gov/forms/index.html).

5.3.4 New Agent Development Contractors and Cooperative Agreement and Grant Awardees
This category includes those with phase 1 or phase 2/3 contracts or cooperative agreements awards and NCI-funded Consortia including (a) Adult CNS Phase 1/2 Clinical Trials Consortium, (b) AIDS Malignancies Clinical Trials Consortium, (c) Pediatric Phase 1 Clinical Trials Consortia and (d) Pediatric Brain Tumor Clinical Trials Consortium. This category also includes investigator-initiated grants to study new agents (e.g. R01, R03, R21 and P01).

5.3.5 Multicenter Phase 2 Trials
CTEP expects that phase 2 trials will be performed only at the proposing clinical site. If a protocol chair wishes to collaborate with other institutions not formally affiliated with his or her clinical site, the protocol should include a description of the procedures by which the collaborating institutions will manage the conduct of the protocol. The investigator should list each institution and the name of responsible investigator at each on the protocol face sheet. The protocol should specifically address issues described in Section 7.2.14.

5.4 Who is Eligible to Administer Phase 2 Agents
For a particular clinical protocol, physicians who may prescribe and administer DCTD investigational agents are:
• those registered with CTEP (see Section 14.1);
• members of any research base or formally designated affiliate listed on the protocol’s face sheet; and
• others who are individually named on the protocol’s face sheet.

5.5 Restriction on Participation in Phase 2 Studies
CTEP may restrict the testing of any investigational agent to a limited number of locations. Although most new agents proceed to a phase 2 program open to all eligible investigators, some are restricted to single centers, specific centers or specific investigators. Such restrictions may remain until a safe, reliable phase 2 dose has been defined and CTEP and the investigator community are confident that the agent is ready for general testing among all investigators. Inadequate agent supply may also prompt restrictions.
5.6 How to Obtain Information about Phase 2 Agents

5.6.1 Investigator’s Brochure
This document contains all relevant information about the agent, including animal screening, preclinical toxicology, detailed pharmaceutical data, pharmacology and mechanism of action. The brochure also contains information about the clinical adverse events observed in clinical trials. CTEP has an Investigator’s Brochure for each investigational agent it sponsors. CTEP provides these routinely to investigators who are approved to conduct a clinical trial of the agent at the time the LOI is approved, and when the Investigator’s Brochure is updated. When necessary, investigators with approved LOIs or protocols may obtain the Investigator’s Brochure from the Pharmaceutical Management Branch (ibcoordinator@mail.nih.gov).

5.6.2 IDB Physicians
CTEP assigns each DCTD investigational agent to an IDB staff physician, who is responsible for coordinating the agent’s clinical development. When an investigator has important concerns about the design of a contemplated trial, he or she should contact that physician.

5.6.3 Clinical Research Pharmacists
The Pharmaceutical Management Branch has a staff of clinical research pharmacists who interact closely with IDB and Clinical Investigations Branch (CIB) staff physicians. Clinical research pharmacists are available to provide pharmaceutical and agent information data on DCTD investigational agents. (See Appendix IV for contact information).
6 Phase 3 Trials

6.1 Scientific Policies of CTEP

If investigators observe a study agent’s significant activity in any disease during phase 2, further clinical trials usually compare the experimental therapy’s efficacy with that of a standard or control therapy. If reasonable standard treatment can be defined for the disease in question, we generally wish to know whether the new agent or therapy constitutes a significant contribution in terms of patient benefit. A variety of trial designs may be suitable, according to the state of the art treatment in the particular disease. Those that are most satisfactory are controlled trials that compare the new agent to a standard single agent or a standard regimen plus the experimental agent to the standard regimen alone. Regardless of the design selected, however, an appropriate control group must exist and relevant endpoints must be used to measure relative effects. Of greatest medical importance are relative survival and quality of life. Other measures, such as complete remission rate or disease-free survival, may also be of interest.

These studies, which attempt to isolate a new agent’s role in the treatment of a specific cancer, are of obvious importance to pharmaceutical collaborators because the results are pivotal in applications to register the agent for commercial distribution. They are of equal importance to the oncology community, because such approval makes the agent generally available for patient care. These trials’ results may also be of great medical importance. If the control group is properly selected such trials may yield valuable information for the care of cancer patients.

Every protocol must contain a section that discusses the study design and the plan for data analysis. The investigator should state the study’s major objectives as hypotheses to be tested, and a target sample size should be clearly specified. They should justify the sample size goal in terms of precision of estimation or of levels of type I and type II error. In a phase 3 study, it is insufficient simply to give the number of patients to be accrued on each arm. The protocol should specify the test to be used to compare the treatment groups, and the probabilities of drawing incorrect conclusions when performing this test with the proposed sample size should be given. The magnitude of improvement in outcome that can be reliably detected using the planned sample size should also be specified. The accrual rate of eligible patients per year that can be realistically anticipated should be stated and documented. The protocol should describe specific statistical plans for interim analysis of accumulating data. Phase 3 randomized trials supported by NCI are required to have a Data Monitoring Committee (Data and Safety Monitoring Board) with organization, responsibilities and operations consistent with NCI policy (http://deainfo.nci.nih.gov/grantspolicies/datasafety.htm) and CTEP policy (http://ctep.cancer.gov/branches/ctmb/clinicalTrials/monitoring_coop_ccop_ctsu.htm) for therapeutic trials conducted by the cooperative groups. The plan for the Data Monitoring Committee to monitor interim results should be indicated in the protocol.

If evaluation of treatment effect will require use of nonrandomized controls, a thorough description of the control group to be employed should be part of the protocol. This description should include a detailed discussion of comparability issues and analytic techniques.

6.2 Who Is Eligible to Conduct Phase 3 Trials
Any source eligible to submit a phase 2 trial (see Section 5.2) as well as other NCI-sponsored investigators (e.g., SPORE investigators) may submit phase 3 trials, but the NCI disease-specific Steering Committee that oversees the particular disease area and/or CTEP must evaluate and approve the phase 3 trial concept. Because sample sizes required for such studies are usually quite large, a multicenter approach is usually the only feasible way to conduct such a trial. It is expected, therefore, that the clinical trials Cooperative Groups will be the major clinical site for such trials (or another entity that is conducting the trial in collaboration with a Cooperative Group). Proposals for phase 3 studies should document very specific accrual potential. Furthermore, if the proposal includes a collaboration with NCI-sponsored institutions not formally affiliated with a Cooperative Group/clinical site, the protocol should include a description of procedures by which the collaborating institutions will manage the conduct of the protocol. It is expected that in most cases this will also include a collaboration with one of the clinical trials Cooperative Groups (see Section 7.2.14).

6.3 Eligibility Requirements

Phase 3 clinical trials must include a review of the available evidence to show whether or not clinically important gender or race/ethnicity differences in the response to the intervention are expected. The trial’s design must reflect the current state of knowledge about expected differences. Phase 3 clinical trials are, in addition, required to provide valid analysis to measure differences of clinical or public health importance in intervention effects based on gender or racial/ethnic subgroups where evidence supports differences.

Investigators should consider the following circumstance when planning a phase 3 clinical trial:

- Prior data strongly indicate that the intervention will show significant clinical or public health differences among gender, racial, and/or ethnic subgroups. In this case, the proposed phase 3 trial’s primary question(s) to be addressed and design must specifically accommodate these differences. For example, if men and women are thought to respond differently to an intervention, the phase 3 trials must be designed to answer two separate primary questions, one for men and the other for women, with adequate sample size for both.

- Prior data strongly support no significant clinical or public health differences among subgroups from the intervention. In this case, gender, race, and/or ethnicity will not be required as subject selection criteria. However, the inclusion of gender, racial, and/or ethnic subgroups is still strongly encouraged.

- Prior data neither strongly support nor negate the existence of significant clinical or public health differences among groups. In such cases, the phase 3 trial must include sufficient and appropriate gender, racial, and/or ethnic subgroups, so that valid analysis of the intervention effects on subgroups can be performed. However, the trial will not be required to provide high statistical power for each subgroup.

Cooperative Group Phase 3 studies:

Effective October 1, 1995, all phase 3 protocols must include accrual targets for males, females, and minorities (protocol specific accrual targets for phase 1 and 2 studies are NOT required). The accrual targets should reflect the expected accrual over the life of the study. The NCI suggests the accrual targets be based on data from similar trials.
completed by the Cooperative Group during the previous 5 years. Accrual targets should resemble the gender, racial, and ethnic composition of the U.S. population as closely as possible. A worksheet, including a description of the currently recognized HHS racial and ethnic categories, is attached for your reference.

Protocols that do not address the above gender and minority issues will be returned without Protocol Reviewed Committee (PRC) review.

**Planned Gender and Minority Inclusion:**
### Accrual Targets

<table>
<thead>
<tr>
<th>Ethnic Category</th>
<th>Sex/Gender</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Females</td>
<td>Males</td>
</tr>
<tr>
<td>Hispanic or Latino</td>
<td>+</td>
<td>=</td>
</tr>
<tr>
<td>Not Hispanic or Latino</td>
<td>+</td>
<td>=</td>
</tr>
<tr>
<td>Ethnic Category: Total of all subjects</td>
<td>(A1)</td>
<td>+</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Racial Category</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>American Indian or Alaskan Native</td>
<td>+</td>
</tr>
<tr>
<td>Asian</td>
<td>+</td>
</tr>
<tr>
<td>Black or African American</td>
<td>+</td>
</tr>
<tr>
<td>Native Hawaiian or other Pacific Islander</td>
<td>+</td>
</tr>
<tr>
<td>White</td>
<td>+</td>
</tr>
<tr>
<td>Racial Category: Total of all subjects</td>
<td>(A2)</td>
</tr>
</tbody>
</table>

(A1 = A2) (B1 = B2) (C1 = C2)

Accrual Rate: ________________ pts/month
Total Expected Accrual: ________________ Min ________________ Max
Projected Start Date of Study: ________________

### HHS Racial and Ethnic Categories

I. **American Indian or Alaskan Native**: A person having origins in any of the original peoples of North America, and who maintains cultural identification through tribal affiliation or community recognition.

II. **Asian or Pacific Islander**: A person having origins in any of the original peoples of the Far East, Southeast Asia, the Indian subcontinent, or the Pacific Islands. This area includes China, India, Japan, Korea, the Philippine Islands, and Samoa.

III. **Black, not of Hispanic Origin**: A person having origins in any of the black racial groups of Africa.

IV. **Hispanic**: A person of Mexican, Puerto Rican, Cuban, Central or South American, or other Spanish culture or origin, regardless of race.

V. **White, not of Hispanic Origin**: A person having origins in any of the original peoples of Europe, North Africa, or the Middle East.

Special Populations:
Individuals from special populations (minorities, cancer survivors, HIV+ individuals, pregnant and breast-feeding women) can NOT be arbitrarily excluded from participation on a study. All exclusions must be justified based on establishment that inclusion is inappropriate with respect to the health of the research subjects or the purpose of the research.

### 6.4 Coordination of Planning with the Clinical Investigations Branch (CIB), CTEP
The Clinical Investigations Branch (CIB) of CTEP is responsible for scientific oversight and coordination of large, multicenter clinical trials exploring innovative disease therapeutics and biomarkers. CIB partners with public and private entities to expand...
clinical trial participation to all populations. Large clinical trials involve years of effort and a substantial expenditure of resources. Accordingly, a certain amount of coordination is necessary for the optimal planning of specific studies of this type.

CIB staffs are well positioned to advise investigators about the existence of other proposed or ongoing studies that are closely related or even identical to studies being planned. In addition, CIB staff can advise investigators contemplating large-scale trials concerning the proposed trial's concordance with CTEP program goals. CIB staff can evaluate investigators' ideas for clinical trials before they invest time and energy to develop a complete protocol. Although investigators proposing phase 1 and phase 2 studies using CTEP resources are required to submit a Letter of Intent (LOI), for phase 3 studies, CTEP requires investigators to submit a written Concept using a phase 3 Concept Submission Form (http://ctep.cancer.gov/forms/docs/concept_submission.doc). The NCI disease-specific Steering Committee overseeing that disease area and/or CTEP must evaluate Concepts for phase 3 studies.

In general, these provide a description of the proposed study, including the hypothesis to be investigated, its rationale, and relevant design considerations. CTEP can then formally review and provide a written Program Concept Review commenting on study originality and programmatic interest.

### 6.5 Cancer Trials Support Unit (CTSU)

In response to the Armitage Report, a 1997 report from the NCI’s Clinical Trials Program Review Group, the Cancer Trials Support Unit (CTSU) was established to:

1. Facilitate physician and patient access to NCI-sponsored clinical trials through an efficient enrollment procedure that helps cross-Group accrual and permits non-Group members to enroll patients on NCI-sponsored trials;
2. Streamline data entry and collection for clinical trials using standard case report forms and reporting; and
3. Reduce regulatory and administrative burdens on clinical trials by unifying and standardizing Group membership rosters and institutional review board (IRB) approvals.

The CTSU includes all clinical trials Cooperative Groups that study cancer treatments and allows the members of any Cooperative Group to participate in any phase 3 trial (or selected phase 2 trial) led by a Cooperative Group that is available on the CTSU clinical trials menu. In general, all Cooperative Group phase 3 trials are available on the CTSU menu. In addition, the CTSU has other initiatives. These include:

- the CTSU Independent Clinical Research Site (CICRS) Program which allows some investigators/institutions that do not belong to a Cooperative Group to participate in Group trials
- the Clinical Research Network (CRN) which is a pilot program supporting trials for other NCI-sponsored clinical trials networks.

Additional information on the CTSU can be found on its web site at https://www.ctsu.org/.
7 The Letter of Intent, Concept, and Drafting of a Protocol

Planning and Execution of a Clinical Trial

The following five sections describe the investigator’s responsibilities for implementation of a clinical trial, from drafting the protocol to study completion. They guide the protocol chair and participating investigators and outline NCI policies on their responsibilities in clinical trial execution.

7.1 The Letter of Intent (LOI) or Concept

7.1.2 Definition
The Letter of Intent (LOI) is an investigator's declaration of interest in conducting a phase 1 or 2 trial (excluding randomized phase 2 trials of at least 100 patients?) with a specific investigational agent in a particular disease. CTEP's approval of the LOI reserves that "slot" for the investigator's protocol if it is submitted within a defined time frame. Approval also signifies agreement that the investigator shall submit a protocol based on the terms stated in the LOI. The Concept serves the same purpose for phase 3 and randomized phase 2 trials (>100?).

7.1.3 Purpose
CTEP has devised the LOI system to maximize the efficiency and fairness by which it allocates experimental agents to investigators for study. Proper use of the system ensures a steady flow of new agents into the clinical trials system. It enables CTEP to plan the development of several agents simultaneously. For investigators, the LOI system also saves time and effort, because its use should spare them from writing a protocol unlikely to be approved. Protocols submitted subsequent to favorable review of an LOI are much more likely to be approved without request for major modification, because many of the crucial features of a phase 2 proposal must be specified in the LOI itself. The LOI system also is used for submission of combination pilot studies. In these cases, reviews typically focus on the rationale for agent combinations, the proposed sample size, and the adverse events of each agent when given alone. The system also provides the investigator with an opportunity to explore the proposal with CTEP staff at the concept stage.

7.1.4 Ground Rules for the LOI System
Investigators must submit LOIs for phase 1 or 2 trials that include a CTEP investigational agent according to the following schedule:

- Agents Beginning Phase 1 - In advance of the IND submission, CTEP will announce the availability of an agent, issue a request for proposals for phase 1 trials and provide a deadline for the submission of LOIs.
- Agents Beginning Phase 2 - In late phase 1, CTEP will issue a request for proposals for initial phase 2 trials including a deadline for submission of LOIs.
- All Other Phase 2 Trials - After this deadline has passed, investigators may submit LOIs at any time.

Each phase 1 or 2 protocol must be preceded by an approved LOI. Our experience demonstrates that protocols submitted without a previously approved LOI are more likely to be rejected as unnecessarily duplicative or needing major modification. If a phase 1 or 2 protocol is submitted without a prior LOI having been submitted, CTEP notify the the
proposer that the submission will not be reviewed. Please refer to http://ctep.cancer.gov/protocolDevelopment/letter_of_intent.htm for additional information on LOIs.

7.1.5 Submission of LOIs
In order to review the LOI properly, CTEP must have the following information:
- Principal Investigator (PI);
- Lead Group/Institution;
- Other Participating Groups/Institutions;
- Requested CTEP study agent(s);
- Tumor type;
- Patient characteristics, including extent of prior therapy, performance status, and abnormal organ function permitted (if any);
- Phase of study;
- Treatment plan—Agents, doses and schedule of administration;
- Rationale/hypothesis;
- Proposed correlative studies;
- Endpoints/statistical considerations;
- Proposed samples size;
- Estimated monthly accrual;
- Accrual documented by prior (similar) trials; and
- List of competitive studies
- PI Opt In/Out of the Investigational Drug Steering Committee (IDSC) process

Investigators should provide this information on the LOI Submission Form found on the CTEP web site http://ctep.cancer.gov/protocolDevelopment/letter_of_intent.htm#instructions and submit it to the Protocol and Information Office, CTEP (pio@ctep.nci.nih.gov).

The protocol chair and either the Group chair or the Group's executive officer must cosign Cooperative Group LOIs.

The contract principal investigator must cosign Agent development contractor LOIs.

We encourage protocol chairs to submit, where appropriate, a letter with the LOI that explains the rationale, where not obvious, or any unique features of the study in greater depth. Such additional explanation is not usually necessary for single agent phase 2 trials but may assist in the review of more complex proposals involving experimental agents.

7.1.6 Review of LOIs
On receipt of a LOI, CTEP sends an acknowledgment to the investigator. The CTEP Protocol Review Committee (PRC) reviews Letters of Intent, and issues a letter of approval or disapproval to the Principal Investigator within approximately 30 days of submission.

7.1.7 CTEP LOI Review Criteria
At the time of LOI review, the PRC has information on other investigators' studies in that agent/disease combination, and submitting investigator's other studies in the proposed disease. The committee considers the following in its deliberations:
• The rationale for the study (especially for combinations of agents);
• Study design, including dose, schedule, and comparison groups, if relevant;
• The study population’s characteristics, particularly the extent of prior chemotherapy and performance status;
• The feasibility of the projected accrual, including an assessment of the investigator’s past performance in that tumor type;
• Competing studies of the investigator in that disease;
• All other protocols and LOIs for that agent/disease combination from other sources; and
• Any unique features to the proposal.

CTEP issues a letter of approval or disapproval to the proposer.

7.1.8 After LOI Approval
Following approval of an LOI, the LOI Principal Investigator has 30 days to submit a protocol (60 days for Cooperative Groups) that conforms to the plan agreed to at the LOI stage of development. After the 60-day period has expired, CTEP will not be bound by previous LOI approval.

7.1.9 Information about the Status of an LOI
Further information about the status of a particular LOI may be obtained by contacting the CTEP LOI Coordinator (pio@ctep.nci.nih.gov Attn: LOI Coordinator).

7.1.10 CTEP Career Development LOI
The Career Development LOI is intended to increase the LOI success rate and to facilitate junior investigators’ career development. The process includes LOI prioritization and documentation of mentorship and institutional support.

Eligibility:

3. The PI should have a major interest in and intend to develop a career in clinical research.
4. He/she should be within 7 years of completion of fellowship training and a faculty member (fellows may not serve as PIs on studies) at an institution with a successful track record in conducting cancer clinical trials (Note: PIs of NCI Cooperative Group proposals are also eligible).

Additional information regarding the Career Development LOI may be found at the CTEP web site: http://ctep.cancer.gov/protocolDevelopment/letter_of_intent.htm#instructions.

7.2 The Drafting of a Protocol
A protocol is a clinical experiment’s detailed written plan. This section details the essential features of a protocol. Careful attention to the following material will expedite CTEP’s review of your protocol.

7.2.1 Title Page
The protocol face sheet is the primary source of identifying information for the Protocol and Information Office (PIO) of CTEP, for the agent distribution system, for the IND file
at the FDA, and for the listing of the protocol in the Physician Data Query (PDQ) system. Each protocol submitted to CTEP, therefore, must have a title page or face sheet that contains the following items:

- Version date of document
- Local protocol number (i.e., institution or group number) if applicable
- Title of study
- A single protocol chair who will be responsible for interactions with CTEP for the study, including his or her name, institution/Cooperative Group, address, phone and fax numbers, and e-mail address (A trainee may not be protocol chair—see Section 12.2.2)
- Full name of institution/Group submitting the study
- List of each participating institution/Group/CCOP, and
- For Pharmaceutical Management Branch, CTEP, DCTD-supplied agents, a list of each agent by name, NSC number, and IND number.
- Cooperative Groups may summarize by specifying “all Group members” or “restricted to…” and list institutions.
- Protocols from sources other than the Cooperative Groups should specify each institution or site participating in the study, together with a responsible physician’s telephone number and e-mail address. Add info on Phase 2 Consortia
- All multicenter trials must include the CTEP Multicenter Guidelines which can be found on the CTEP web site at: http://ctep.cancer.gov/industryCollaborations/monitoring_multicenter.htm (see Section 7.2.17)

7.2.2 Schema
All treatment studies should include a brief schema depicting the treatment regimen(s).

7.2.3 Objective(s)
The objectives should be stated clearly, generally as hypotheses to be tested. The study design should be capable of answering the questions posed by the objectives. The statistical section should clearly state how the data will be analyzed in relation to each of the objectives. The hypotheses to be tested in ancillary studies also must be clearly stated, and the statistical section should address analyses of the data in relation to these hypotheses.

7.2.4 Background and Rationale
Sufficient background information should be included so that the study’s rationale is clear. Unpublished data relevant to the rationale should be included in either this section, or, if extensive, as an appendix to the protocol. In addition to the background and rationale included for therapeutic aspects of a study, information should be provided to support ancillary studies to be performed. The rationale should be clearly stated for studying particular correlations between tumor characteristics and outcome measurements (response to therapy, disease-free survival, overall survival, etc.). The choice of the particular techniques to be used should also be justified.

7.2.5 Patient Eligibility Criteria
Patient eligibility criteria have been discussed previously (Section 4.1.3 and Section 5.2.2). Studies with objective response as an endpoint should include clear statements specifying whether tumor sites to be followed for response must be measurable, what criteria must be fulfilled to consider disease measurable, whether evaluable disease is
permitted, and if so, at what sites. For ancillary studies, this section should include information regarding the choice of tumor sampling technique. For example, will aspiration biopsies be sufficient, or will surgical samples be required? How much tissue will be needed? What measures will be imposed to assure that the histopathologic diagnosis is not compromised? How will issues of tumor heterogeneity be addressed? What biases may be introduced by the sampling techniques and the amount of tissue required for the studies proposed?

7.2.6 Pharmaceutical Information
A separate pharmaceutical section is required for each agent. The content of the pharmaceutical section is dependent on whether the agent is investigational or commercial. A Pharmaceutical Data Sheet (PDS) is prepared by Pharmaceutical Management Branch (PMB) for most investigational agents. Regardless of whether the PMB data sheet is used, the following information about an agent is required in the protocol.

Investigational Agent Pharmaceutical Section
This section should include the following:

- **Product Description** - Include the available dosage forms, ingredients, and packaging as appropriate. Also state the agent’s supplier. For investigational agents sponsored by the Division of Cancer Treatment and Diagnosis, NCI, the supplier will be NCI and CTEP will have prepared a Pharmaceutical Data Sheet suitable for copying and pasting into the document as the pharmaceutical section for that agent.
- **Solution Preparation** (how the dose is to be prepared) - Include reconstitution directions and directions for further dilution if appropriate.
- **Storage Requirements** - Include the requirements for the original dosage form, reconstituted solution and final diluted product, as applicable.
- **Stability** - Include the stability of the original dosage form, reconstituted solution and final diluted product, as applicable.
- **Route of Administration** - Include a description of the method to be used and the rate of administration if applicable. For example, continuous intravenous infusion over 24 hours, short intravenous infusion over 30 to 60 minutes, intravenous bolus, etc. Describe any precautions required for safe administration.

Commercial Agent Pharmaceutical Section
This section should include the following:

- **Product description**: State the agent’s supplier, i.e., commercially available.
- **Preparation** (how the dose is to be prepared): Investigators may refer the reader to the package insert for standard preparation instructions. If the agent is to be prepared in a ‘non-standard’ or protocol-specific fashion, the reconstitution directions and instructions for further dilution must be included. Appropriate storage and stability information should be included to support the method of preparation.
- **Route of administration**: Briefly describe how the agent will be administered in this protocol. For example, continuous intravenous infusion over 24 hours, short intravenous infusion over 30 to 60 minutes, intravenous bolus, etc.
- **Adverse Events**: The investigator may refer the reader to the agent’s package insert. Note: The Informed Consent document should contain a list of all
expected adverse events that the patient is likely to experience. All adverse events in the informed consent should be written in laymen’s terms.

7.2.7 Treatment Plan
Describe the protocol treatment clearly so all staff involved in the treatment of patients and in the conduct of the study can follow it. See Appendix IX, Guidelines for Treatment Regimens: Expression and Nomenclature.

7.2.8 Procedures for Patient Entry on Study
Procedures for patient entry, whether randomized or nonrandomized, should be specified. Required information includes a description of the randomization process and the patient characteristics and stratification factors (if any) to be provided at the time of entry. Patients must be registered on study prior to beginning treatment.

7.2.9 Adverse Events List and Reporting Requirements
Include a list and description of the Reported Adverse Events and Potential Risks observed in pre-clinical and clinical studies. This information can be found in the Investigators Brochure for investigational agents or the package insert for commercial agents. For investigational agents supplied by CTEP, DCTD, the Comprehensive Adverse events and Potential Risks list (CAEPR) and Agent Specific Adverse Event List (ASAEL) must be included.

Instructions for reporting adverse events should be included in the protocol text, both for routine adverse event reporting as well as the expedited reporting of serious adverse events. (See Section 11)

7.2.10 Dose Modification for Adverse Events
The plan of dose change for adverse events should be stated for each study agent. Dose modification criteria should be described in terms of NCI Common Terminology Criteria for Adverse Events (CTCAE).

Protocol Authors must carefully review all investigational agents Investigator’s Brochures, ASAEL as well as CTEP’s “Comprehensive Adverse Events and Potential Risks” list (CAEPR) to be sure that they have included all reasonable measures to monitor expected adverse events. If the protocol includes an agent for which CTEP has prepared a CAEPR and ASAEL, the investigator must include the CAEPR and ASAEL in the protocol even if CTEP is not supplying the agent. These documents must be in the format provided and must be unaltered.

7.2.11 Criteria for Response Assessment
The criteria for scoring responses should be included. These should be specific for both measurable and evaluable disease. Disease-specific criteria are often required and should clearly indicate acceptable means of measurement, i.e., CAT scans, radio-nuclide scans, ultrasound, etc.

7.2.12 Monitoring of Patients
Specify how patients will be followed for assessment of treatment-related adverse events and therapeutic effect. A table of follow-up parameters that incorporates the schedule is particularly useful. The current version of the Common Terminology Criteria
for Adverse Events (CTCAE) should be used when developing new DCTD-sponsored trials.

7.2.13 “Off-Study” Criteria
Criteria for terminating protocol treatment and/or removing a patient from treatment or from study should be specified.

7.2.14 Statistical Considerations
An adequate statistical section discusses the study design in relation to the objectives of the study and the plan for the evaluation of the data, specifically:

- Method of randomization (if used) and stratification
- Total sample size justified for adequate testing of primary and secondary hypotheses
- Error levels (alpha and beta) in phase 3 studies
- Differences to be detected for comparative studies
- Size of the confidence interval to be constructed around the estimated outcome
- Estimated accrual rate and/or study duration, with supporting documentation
- Stopping guidelines, including statistical and administrative procedures for monitoring the progress of the trial to implement early termination for very positive results, or for results sufficiently negative to preclude the eventual achievement of statistically significant positive results
- Expected outcome parameters as appropriate (response rate, time to progression, survival times, etc.)
- Primary endpoint for interim and final analysis (for phase 3 studies)
- Clear specification of primary and secondary (e.g. subset) hypotheses
- Maximum number of patients
- Statistical analysis based on minority/gender.
- Plan for analysis

7.2.15 Records to be Kept
Specify the document on which each of the following is to be recorded, where it is to be sent, and on what schedule:

- On-study information, including patient eligibility data and patient history
- Flow sheets, or other forms for interim monitoring
- Specialty forms for pathology, radiation, or surgery when required, and
- Off-study summary sheet, including a final assessment by the treating physician.

7.2.16 Participation
All protocol treatments and observations will be made by investigator-physicians affiliated with a clinical site (refer to Section 3), and registered with CTEP. Under certain defined circumstances, it may be appropriate for interim treatments to be administered by certain physicians not registered with CTEP (other than trainees, who are assumed to be under the supervision of a registered investigator). In such cases, the protocol should state:

- Precisely what responsibilities those physicians will assume, including response assessment, and adverse event reporting
• How dose modifications will be decided and reported, and the mechanism by which data needed for evaluating adverse events and response will be transmitted to the registered investigator responsible for the patient, and
• The intervals at which a patient should be evaluated by a physician-investigator at the clinical site

See Section 14 for further details concerning which physicians may actively participate in a clinical trial involving CTEP-supplied investigational agents.

7.2.17 Multicenter Trials

CTEP Multicenter Guidelines
If an institution wishes to collaborate with other participating institutions in performing a CTEP sponsored research protocol, then the following guidelines must be followed. CTEP Multicenter Guidelines can be found on the CTEP web site at: http://ctep.cancer.gov/industryCollaborations/monitoring_multicenter.htm

Responsibilities of the Protocol Chair:
• The Protocol Chair will be the single liaison with the CTEP Protocol and Information Office (PIO) and is responsible for
  o coordinating, developing, submitting, and receiving approval for the protocol and subsequent amendments.
  o rewriting or modifying the protocol
  o assuring that all participating institutions are using and identical, current version of the protocol.
• The Protocol Chair is responsible for the overall conduct of the study at all participating institutions and for monitoring its progress. The Protocol Chair must assure that all reporting requirements to CTEP are properly adhered to.
• AdEERS is programmed for automatic electronic distribution of reports to the following individuals: Study Coordinator of the Lead Organization, Principal Investigator, and the local treating physician. AdEERS provides a copy feature for other e-mail recipients.
• The Protocol Chair is responsible for the timely review of Adverse Events (AE) to assure safety of the patients.
• The Protocol Chair will be responsible for the review of and timely submission of data for study analysis.

Responsibilities of the Coordinating Center:
Each participating institution will have an appropriate Federal Wide Assurance (FWA) on file with the Office for Human Research Protections (OHRP), HHS. The Coordinating Center is responsible for assuring that each participating institution has a valid up to date FWA and must maintain copies of IRB approvals from each participating site. Prior to protocol activation at each participating institution, the coordinating center must submit documentation of initial IRB approval to the CTEP PIO. The Coordinating Center is responsible for
• assuring that each participating site has obtained IRB approval before the site registers its first patient
• ensuring each participating site is accruing a representative sample consistent with the estimate of population representation in the site’s geographical location
for race and ethnic groups as determined by the Census Bureau to assure overall target goals are met.

- preparing all submitted data for review by the Protocol Chair.
- maintaining documentation of AE reports using one of two options for AE reporting:
  - (1) participating institutions may report directly to CTEP with a copy to the Coordinating Center; or,
  - (2) participating institutions report to the Coordinating Center who in turn reports to CTEP. The Coordinating Center will submit AE reports to the Protocol Chair for timely review.

Audits may be accomplished in one of two ways (1) source documents and research records for selected patients are brought from participating sites to the Coordinating Center for audit; or, (2) selected patient records may be audited on-site at participating sites. If the NCI chooses to have an audit at the Coordinating Center, then the Coordinating Center is responsible for having all source documents, research records, all IRB approval documents, NCI Drug Accountability Record forms, patient registration lists, response assessments scans, x-rays, etc. available for the audit.

**Inclusion of Multicenter Guidelines in the Protocol:**
The protocol must include the following minimum information:

- The title page must include the name and address of each participating institution and the name, telephone number and e-mail address of the responsible investigator at each participating institution.
- The Coordinating Center must be designated on the title page.
- Central registration of patients is required. The procedures for registration must be stated in the protocol.
- Data collection forms should be of a common format. Sample forms should be submitted with the protocol. The frequency and timing of data submission forms to the Coordinating Center should be stated.
- Describe how AEs will be reported from the participating institutions, either directly to CTEP or through the Coordinating Center.

**Drug Ordering:**
Except in very unusual circumstances, each participating institution will order DCTD-supplied investigational agents directly from CTEP. Investigational agents may be ordered by a participating site only after the initial IRB approval for the site has been forwarded by the Coordinating Center to the CTEP PIO.

**7.3 Informed Consent**
Each informed consent document must be protocol-specific and contain the elements required by Federal regulation (21 CFR 50.25). These regulations do not specify the language of the document but provide a list of elements that must be addressed in the text of the consent form. The Risk List provided by CTEP for an investigational agent must be incorporated into the consent. CTEP will not approve a protocol if its informed consent form fails to address each of these elements adequately.

The use of a model informed consent by a clinical site can ensure inclusion of the essential elements and permits tailoring of the protocol-specific elements to the needs of individual studies. Individual institutions may make minor changes to model informed
consent forms. However, the informed consent document’s originator must approve any changes in risks or alternative procedures.

Protocol authors should be certain that the description of expected adverse events is complete and balanced and reflective of the treatment plan to be used. Consult the Comprehensive Adverse events and Potential Risks list (CAEPR) and Investigator’s Brochure for information about expected adverse events for investigational agents, and the package insert for commercially available agents. Adverse events of other modalities used in the study (e.g., radiotherapy, surgery) must also be described. Additionally, all CAEPRs with a January 1, 2009 or later version date will be accompanied by a lay terms risk list that can be inserted directly into the informed consent document. Additional terms may be included, or the terms on the risk list may be combined, but no terms may be deleted from the risk list when inserting it into the document.

In response to concerns that many informed consent documents for cancer clinical trials have become complex, lengthy, and difficult to understand, NCI convened a working group of medical, ethical, communication, and consumer experts along with officials from OHRP and FDA. The result of this initiative is the development of guidelines for writing consent documents that are more understandable to prospective research participants. They are called the Recommendations for the Development of Informed Consent Documents for Cancer Clinical Trials (http://www.cancer.gov/clinicaltrials/understanding/simplification-of-informed-consent-docs/allpages), which include a fill-in-the-blank consent form template and four sample consent forms. The Recommendations have the potential to improve the quality of informed consent in cancer clinical trials. We strongly urge you to use them as you write informed consent documents for cooperative group protocols. Also, you are encouraged to share the Recommendations with your IRBs. The templates are available as a working document on the CTEP web site under NCI Informed Consent Template. (http://ctep.cancer.gov/protocolDevelopment/).

7.4 Protocol Templates
CTEP has developed several model protocol templates. To facilitate rapid review, you are encouraged to use the NCI protocol templates which can be found on the CTEP web site. (http://ctep.cancer.gov/protocolDevelopment/templates_applications.htm). An agent specific protocol template may be available for a particular investigational agent.
8 Protocol Review and Approval at CTEP

8.1 The Protocol and Information Office (PIO)
Within CTEP, the PIO manages the review process and maintains the official record of all CTEP-supported protocols, amendments, and protocol-related communications. PIO also manages all protocol submissions to the Physician Data Query (PDQ) system and FDA. The PIO maintains more than 10,000 protocols.

All protocols and related correspondence should be sent directly to the PIO via email at pio@ctep.nci.nih.gov. The PIO will distribute all email to the appropriate CTEP physician staff. Please do not direct protocol-related materials to any other CTEP staff member as this will lengthen the time required for resolution or review.

When submitting each new protocol, please also include the current version of the Protocol Submission Worksheet, http://ctep.info.nih.gov/protocolDevelopment/default.htm. Direct all telephone calls regarding status of protocol and amendment reviews to the PIO at 301-496-1367.

8.2 How to Submit a Protocol
Send each new protocol directly to the PIO and include:
- The electronic copy of the Protocol Submission Worksheet,
- An electronic copy of a paginated, legible protocol, including a local protocol number. Please be certain the protocol document contains information about each of the topics listed in Section 7.2 and Section 7.3.

If these items are missing or incomplete, PIO will return the submission to the protocol source without review.

Upon receipt, PIO assigns an NCI protocol number to each protocol, and acknowledges your protocol submission with the NCI-assigned protocol number. You must reference this NCI protocol number in all subsequent communications with CTEP regarding this study. Assignment of this number does not imply approval; only the final approval letter signifies approval and the authorization to order investigational agents.

8.3 IRB Approval

Except for Cooperative Group and CTEP funded Consortium protocols, each protocol must have documentation of IRB approval prior to CTEP approval. Evidence of IRB approval may be submitted to CTEP at any time in the review process. If multiple institutional IRBs are involved, only the approval from the Coordinating Center need be submitted for CTEP records; of course, each investigator must meet Federal regulations for informed consent and IRB review (45 CFR 46 and 21 CFR 50 and 56).
Investigators’ failure to submit evidence of IRB approval is a major cause of delay in protocol approval. The documentation requirements are satisfied by completion of Form 310, or by a letter specifying:

- The study title
- The protocol chair and the institution’s assurance number; i.e., the assurance number issued by the OHRP, DHHS
- Date of IRB review
- The dated signature of an institutional official, usually the IRB chair.

8.4 Protocol Review
CTEP must review and approve every protocol involving CTEP-supplied investigational agents or studies receiving NCI support or funding. We review each protocol for completeness, scientific merit, duplication of existing studies, patient safety, and adequacy of regulatory and human subjects protective aspects.

CTEP will inform the protocol source if the protocol is incomplete, or the investigator/institution is ineligible under the proposed category of sponsorship. CTEP will not review the study for scientific content.

8.4.1 Scheduling the Protocol for Review
The PIO schedules the protocol for review by the Protocol Review Committee (PRC). The cutoff date for protocol receipt is Tuesday at 5 pm. Protocols that are complete and eligible are abstracted into the CTEP system and scheduled for review within four weeks.

8.4.2 Review by the CTEP Protocol Review Committee
The CTEP PRC reviews all protocols. This committee, composed of CTEP’s professional staff and consultants from other NCI divisions, and chaired by the Associate Director, CTEP, meets weekly and usually reviews 10 to 20 documents (protocols, LOIs and concepts) at each session.

Each protocol is assigned a minimum of five reviewers; as many as six to seven may be required for complex multimodality protocols. The protocol and informed consent form are reviewed by an oncologist(s), biostatistician, pharmacist and regulatory affairs professional(s) with expertise in informed consent issues.

8.4.3 The Review of the Protocol
The PRC discusses the protocol after hearing the reviews of each assigned reviewer and makes a decision that the science and safety of the study are:

- Approved as written;
- Approved with recommendations - CTEP asks the investigator to consider points raised in the consensus review, but the investigator is not obligated to revise the study. If changes are made prior to activation of the study, the investigator must send CTEP an activation amendment that details any changes in the CTEP-approved document;
- Approval deferred pending revisions - The PRC has significant questions about the proposed study. It cannot be accepted unless the investigators satisfactorily address the concerns of the written consensus review. The investigator should submit a revised protocol within two weeks of receipt of the consensus review (Section 8.4.7);
Disapproved - In the judgment of the PRC, the protocol cannot be approved even with major revisions.

8.4.4 The Review of the Informed Consent
The PRC also reviews the informed consent document to be certain that:
- The document includes all required elements of informed consent mandated by Federal regulation; and
- The description of potential benefits and adverse events is complete and accurate.
Investigators should communicate changes made to the consent document resulting from a CTEP review to their IRBs.

It is not CTEP’s intent for their informed consent review to supplant IRB review. Provided the consent document meets the requirements of regulation and law and contains sufficient information to enable an individual to make an informed choice, the local IRB approval of the content is generally to be regarded as definitive.

Individual institutions may make minor changes to the CTEP-reviewed informed consent form. However, by the originator of the informed consent document must approve any changes in risks or alternative procedures.

8.4.5 The Review of Regulatory and Administrative Concerns
The PRC reviews each protocol to assure proper instructions for reporting adverse events are included, an accurate and up-to-date pharmaceutical section is provided, and necessary instructions for multicenter trials are given, if appropriate.

8.4.6 The Review by the Pharmaceutical Collaborator
In cases where a Pharmaceutical Collaborator is involved, CTEP forwards protocols received to the Collaborator for review and comment approximately two weeks before it is reviewed by the PRC. CTEP discusses Collaborator comments if they are received before the Protocol Review Committee meeting. They give them due consideration, and comments from either Collaborator or the CTEP staff that are agreed upon in the PRC meeting are included in the consensus review.

8.4.7 The Consensus Review
After the PRC meeting, the primary reviewer generates a consensus review that states the PRC’s collective concerns. PIO sends this consensus review with a cover letter stating the summary PRC decision to the protocol originator within approximately 30 days of receipt of a complete protocol.

8.4.8 Responding to CTEP Consensus Review
If the protocol or the informed consent requires revisions, the investigator should send a revised submission to the PIO. A complete submission includes the revised protocol and informed consent with a cover letter that details the responses to the points raised in the consensus review. If CTEP reviewers find the response satisfactory, then the protocol goes forward for final approval.

CTEP’s consensus reviewer may choose to send the revised protocol back to the full PRC for further consideration. If the PRC still does not accept the protocol, CTEP sends a letter to the investigator detailing remaining CTEP concerns. The investigator should
respond to this re-review in the same way as described for the initial consensus review. This process continues until the science, regulatory, and administrative aspects, and informed consent are each accepted or the study is withdrawn or disapproved. Each evaluation of a revised study requires an average of 10 to 30 days.

8.5 Protocol Document Approval

Upon final acceptance of the protocol and the informed consent, as indicated by the concurrence of the consensus reviewer and appropriate CTEP staff, CTEP sends a letter of protocol approval to the protocol originator.

Please note that protocol approval will not be given by telephone. Although CTEP staff may discuss the study with protocol chairs, they should consider nothing official until they receive written notice via email. After PIO sends written approval, PMB will accept orders for investigational agents. All approved protocols using DCTD-sponsored agents are submitted to the FDA as part of the IND file.

8.6 Amendments

Any change to the approved protocol document must be documented point by point in a cover letter, and a replacement page(s) or a revised protocol document and informed consent submitted to the PIO. Please reference the NCI protocol number, date each amendment, and document version number sequentially for each study. Upon receipt, CTEP staff reviews each amendment. Further detailed guidance on amendment submissions can be found in the CTEP Amendment Request Submission Policy: http://ctep.info.nih.gov/protocolDevelopment/default.htm#amendments.

8.7 Study Status

Investigators should communicate changes in study status to the CTEP PIO immediately. The following list shows the categories of study status recognized by CTEP and PDQ:

- AP (Approved) – Protocol has received final CTEP approval.
- AC (Active) – Trial is open to accrual.
- TC (Temporarily Closed to Accrual) – Protocol is temporarily not accruing.
- TB (Temporarily Closed to Accrual and Treatment) – Protocol is temporarily not accruing and patients are not receiving therapy.
- CA (Closed to Accrual, Patients still on Treatment) – The protocol has been closed to patient accrual. Patients are still receiving therapy.
- CB (Closed to Accrual, All Patients have Completed Treatment) – The protocol has been closed to patient accrual. All patients have completed therapy, but patients are still being followed according to the primary objectives of the study. No additional investigational agents are needed for this study.
- CP (Completed) – The protocol has been closed to accrual, all patients have completed therapy, and the study has met its primary objectives. A final study report/publication is attached or has been submitted to CTEP.
- AD (Administratively Completed) – The protocol has been completed prematurely (e.g., due to poor accrual, insufficient agent supply, IND closure). The trial is closed to further accrual, and all patients have completed protocol treatment. A final study report (see below) is not anticipated.
8.8 Reactivation of Studies

Protocols that are temporarily closed require written CTEP approval before reactivation if they are:

- Temporarily closed for reasons of patient safety or regulatory issues; or
- Closed for reasons of peer review, site visit, or other NCI-initiated reasons.

Protocols that are temporarily closed to accrual by the clinical site based on early stopping rules do not require CTEP approval for reactivation.
9 Ordering Investigational Agents from NCI

- The DCTD/CTEP will provide study agents for use in CTEP-approved protocols, Special Exception and Treatment Referral Center (TRC) requests (see Section 17.1 and Section 17.2) to registered investigators who have current FDA 1572, Supplemental Investigator Data, and Financial Disclosure Forms, http://ctep.cancer.gov/forms/index.html, and CVs on file with PMB (see Section 12.1). Unless the protocol is conducted by an NCI Cooperative Group, the PMB will not send agents to assistant investigators who are not named on the protocol or who have not filed a FDA Form 1572.
- Sites will only use study agents supplied by DCTD to treat patients entered onto CTEP-approved protocols for which the DCTD has agreed to supply agent.

9.1 How to Place Agent Orders

- Complete the following information on the Clinical Drug Request Form NIH-986, http://ctep.cancer.gov/forms/index.html:
  - Investigator name and NCI-assigned investigator number
  - Telephone and fax numbers, and e-mail address of investigator and/or individual preparing form
  - NCI-assigned protocol number
  - NSC number, current inventory as indicated on Drug Accountability Record Form (DARF), agent name, strength and dose form, and quantity requested
  - The patient ID code and initials (if the protocol is blinded)
  - Date and signature of the investigator or designee. No matter who may be delegated to sign this form (e.g. the pharmacist), the investigator remains responsible for the disposition of all investigational agent shipped under his or her name
- Note the following also:
  - Only one agent may be entered on each line on the form
  - If the same agent is needed for more than one protocol, use a separate line for each protocol
  - Indicate the one official shipping address to which the agent is to be sent
  - Submit orders to the Pharmaceutical Management Branch (PMB) by fax at 301-480-4612

9.2 Particular Points to Note

- Complete the Clinical Drug Request form in full, typing all information. PMB will return incomplete and illegible forms to the originator.
- Use the Clinical Drug Request for all clinical agent requests, including those for Special Exception and TRC use.
- Normal PMB processing time for open label studies is two (2) working days. PMB will ship orders within two working days, based on the agent’s availability and provided there are no shipping restrictions (e.g. holidays, or thermolabile agents that are shipped Monday through Thursday only. Sites can make special arrangements for Saturday delivery by contacting PMB after faxing). Refer to individual protocols for specific ordering instructions.
- Generally allow one week for order delivery.
- Do not order more than a 2-month supply at a time.
Avoid ordering excessive quantities. CTEP will reduce the quantity shipped if the order is excessive in relation to protocol requirements, or if CTEP’s inventory is insufficient at that time.

PMB must receive requests for next day delivery before 2:00 PM Eastern Time. The order must clearly state “Next day delivery” and the ordering site must provide their express courier account number. Please telephone PMB (301-496-5725) to confirm receipt of orders requesting next day delivery.

Due to added quality control steps taken to protect the blind, next day delivery is not available for blinded studies.

9.3 Routing of Agent Requests
- Investigators should submit agent requests directly to the Pharmaceutical Management Branch.
- Cooperative Groups: Some Cooperative Groups require sites to route agent requests through the operations office. Check the protocol and with your Cooperative Group operations office to determine its policies.

9.4 Affiliates and Agent Orders
- Investigators at affiliated institutions or clinics should order CTEP-supplied investigational agents directly from PMB. PMB’s policy of shipping investigational agents to the investigator's institution or practice site assures that all investigators receiving investigational agents are registered with PMB; simplifies agent tracking and accountability; minimizes correspondence delays in emergencies; assures agent integrity; reduces administrative workload; and eliminates secondary shipping expenses.
- PMB policy allows centralized pharmacies to receive study agents for redistribution to local satellite institutions and affiliated investigators who are registered with PMB and have designated such a “central pharmacy” as their shipping address. Sites should coordinate such arrangements with the PMB.
  - The central pharmacy must ensure that all investigators receiving investigational agents have a current FDA Form 1572 on file with PMB.
  - Satellites must maintain dispensing records.
  - Local satellite institutions or affiliates must be serviced by bonded institutional couriers or the study staff.
  - CTEP-supplied study agents must not be repackaged or forwarded by mail or express courier.
  - Institutions that are separated geographically, requiring investigational agents to be mailed, are not considered satellites for agent accountability purposes and should receive investigational agents directly from PMB.
    - These sites may order directly or in some situations, the central pharmacy may fax the orders to PMB for delivery to participating investigators.
  - CTEP policy forbids secondary distribution of study agents to other physicians, or transfer of investigational agents between institutions. CTEP intends that study agents be distributed directly to investigators. If under exceptional circumstances emergency transfer seems justified, explicit pre-approval by the Pharmaceutical Management Branch is required.
  - If investigators wish to use a local oncologist to administer some treatments for late phase 2 or phase 3 trials, they must contact the Pharmaceutical Management Branch for assistance. In such situations,
the local oncologist(s) must register with PMB and be covered by an appropriate IRB. PMB will ship the agents directly to the local investigator with the enrolling physician’s approval.

- Finally, CTEP may approve a special distribution arrangement for certain unusual circumstances.

### 9.5 Requests for Nonresearch (Treatment) Use of Investigational Agents
- Requests for use of DCTD investigational agents under TRC or Special Exception categories must satisfy certain requirements. These considerations are detailed in Section 17.1 and Section 17.2 of this manual.

### 9.6 Requests for Nonclinical (Laboratory) Use of Investigational Agents
- Clinical trials staff cannot take investigational agents for non-clinical or laboratory use from supplies received for CTEP sponsored clinical trials. Interested investigators should direct their requests for nonclinical use of investigational agents for preclinical or laboratory experiments to the Pharmaceutical Management Branch.
- The investigator must provide the following information in writing via e-mail to pmbafterhours@mail.nih.gov with the subject line “INHU request”:
  - A brief description of the study, including how the agent will be used and for what purpose.
  - The NCI clinical trial number if the non-clinical use is in support of an already approved NCI clinical trial.
  - How the agent should be provided (as formulated or unformulated product) as well as the quantity needed to perform the study.
  - The investigator’s contact information, including the shipping address.
  - FedEx number (or other courier account number) for shipping the agent to the study site.
  - The following statement must be included in all non-clinical requests, "The [agent name] will not be used in humans or food-producing animals."

Once you provide this information, PMB will evaluate your request. If it is approved, PMB will forward it to the Regulatory Affairs Branch for execution of a Material Transfer Agreement if required. The Regulatory Affairs Branch will contact you if an MTA is necessary.

### 9.7 Status of Investigational Agents Following FDA Marketing Approval
In many instances, the DCTD continues to evaluate agents in ongoing clinical trials after they have received FDA marketing approval for a particular tumor indication in an attempt to identify more effective therapeutic regimens. In addition, physicians who have initially registered a patient to receive an agent under a TRC or Special Exception protocol before an agent is approved by FDA may continue to receive the agent at no cost from CTEP for the registered patient. This is not a firm policy; it depends on the cooperation of the manufacturer (sponsor) supplying the agent.

Commercially-available agents supplied to investigators or physicians under an NCI protocol, including a TRC, or Special Exception protocol, are still considered study agents. Therefore, the same accountability requirements for study agents in place prior to the agent's approval continue to apply.
10 Responsibility for Reporting Results to CTEP

10.1 Introduction
Investigators who test IND study agents have an important responsibility: timely, accurate reporting of data from investigational agent trials to the trial sponsor. Prompt provision of these reports is not an arbitrary requirement. The information contained in them informs CTEP about the agent’s development progress, sometimes suggesting promising new directions. In addition, CTEP requires investigators to meet obligations under FDA regulations to
(a) monitor the study and
(b) submit reports of current findings
Failure to comply with these reporting requirements is a serious breach of the agreement that each investigator makes in signing the FDA Form 1572, http://ctep.cancer.gov/forms/index.html, and may result in suspension or termination of investigator privileges.

For all trials, investigators must report two types of data: individual patient data and study summaries. Each is briefly discussed below. Then, Section 10.2.1 details specific reporting requirements for phase 1 trials, and Section 10.2.2 details the same for phase 2 and 3 trials.

• Case Report Forms - Information about patients is recorded on case report forms or through Remote Data Entry (RDE) (or in a computerized clinical trials database) that incorporate all patient data stipulated in the protocol.

Data submitted via RDE is different than patient source documentation, usually the patient’s medical chart. The study specific case report form or computerized protocol electronic data serves as the formal and fixed data base on which the study is reported. The patient's primary medical record is generally not organized for clinical research and does not reliably contain the treating physician’s assessment of the effects of the protocol treatment. For these reasons, investigators and their staff should maintain a separate research record (i.e., case report form or well-designed clinical trials database) on each protocol patient in a real time manner.

A research record should also include the responsible physician's assessment of the treatment effect (e.g., response category) and judgment as to whether any medical events in the patient's course were treatment-induced (i.e., agent-related adverse events).

Procedures for reporting study data vary according to the type of study and category of sponsorship. They are outlined below for the three phases of clinical agent development. Adverse events are reported through the Adverse Event Expedited Reporting System (AdEERS) using the Common Terminology Criteria for Adverse Events (CTCAE) and is discussed in Section 11.

10.2 Report Requirements of CTEP Supported Trials

10.2.1 Clinical Trials Monitoring Service (CTMS)
Clinical Trials Monitoring Service (CTMS) reporting is required for all early phase 1 studies and some selected phase 2 trials. The criteria to determine if a study is early
phase 1 include the first time the agent is used in human studies or the first time a new
agent combination is used in humans or the first time an agent or combination is used in
a specific patient group (e.g., children). CTEP staff will advise the site on the reporting
mechanism to use for each trial.

For each patient on trial, investigators must maintain data in an electronic format. All
information specified in the protocol should be recorded and must be maintained in real-
time. The site submits these forms electronically on a biweekly basis to CTMS of CTEP.
The biweekly submission includes case report updates on patients actively on study and
data on all new patients entered since the last submission.

These reporting requirements apply to all phase 1 trials of agents newly entering clinical
trial, including adult and pediatric studies. The protocol chair will receive a full report of
his or her study from the CTMS. The CTMS provides CTEP with summary information
on all trials in the database for each agent. The CTMS analyzes the data from phase 1
trials for timeliness of submission and completeness and provides monthly reports of this
analysis to CTEP investigators. The CTMS data is also loaded monthly into the Clinical
Data Update System (CDUS).

10.2.2 Clinical Data Update System (CDUS)
The quarterly Clinical Data Update System (CDUS) is the primary clinical trial data
resource for DCTD and the Division of Cancer Prevention (DCP).

This includes all:
- DCTD/DCP-sponsored Cooperative Group and Community Clinical Oncology
  Program (CCOP) Research Base treatment trials using DCTD-supplied study
  agents;
- DCTD/DCP- sponsored, supported or funded Cooperative Group and CCOP
  Research Base treatment trials using non-NCI agents;
- DCTD/DCP-grant funded non-Cooperative Group (Cancer Center or other
  institution) trials (if CDUS reporting is a grant requirement) using non-NCI agents;
- DCTD/DCP-sponsored Cooperative Group and CCOP Research Base non-
treatment trials (accrual >100 patients.); and
- DCP-sponsored CCOP Research Base cancer prevention and control trials.

Investigators should refer to their individual document for guidance on the specific data
reporting system required.

Abbreviated CDUS
The abbreviated CDUS requires quarterly submission of protocol administrative
information (e.g., status) and patient-specific demographic data (e.g., gender, date of
birth, race, etc.).

Complete CDUS
The complete CDUS data set includes information obtained in the abbreviated CDUS
data set as well as patient administrative information (e.g., registering institution code,
patient treatment status), treatment information (e.g., agent administered, total dose per
course), adverse event (AE type and grade), and response information (e.g., response
observed, date response observed).
A complete discussion of the CDUS reporting requirements is found in the CDUS Instructions and Guidelines on the CTEP web site at the following address: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/cdus.htm.

10.2.3 Adverse Events
The importance of reporting adverse events (AE) cannot be overstated. Section 11 discusses these requirements in detail. Some types of events must be reported within 24 hours via the Adverse Event Expedited Reporting System (AdEERS). (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adeers.htm)

10.2.4 Study Status
The principal investigator or their designee must communicate study status changes promptly in writing to the CTEP PIO using the Protocol Status Update Form (See Section 8.7). Telephone discussions with CTEP physician staff are not considered formal notice of status changes.

10.2.5 Amendments
All protocol amendments must be submitted and approved by CTEP prior to implementation (see Section 8.6).

10.2.6 Publications
Investigators must provide all manuscripts reporting the results of DCTD-supported clinical trials to CTEP for immediate delivery to the pharmaceutical collaborator for advisory review and comment prior to submission for publication. The pharmaceutical collaborator will have 30 days from the date of receipt for review. An additional 30 days may be requested by the pharmaceutical collaborator in order to ensure that confidential and proprietary data, in addition to the company's intellectual property rights, are protected.

Abstracts to be submitted by investigators must be sent to CTEP for forwarding to the pharmaceutical collaborator for courtesy review with sufficient time to allow the collaborator at least three days for review. Before submitting a paper for publication or otherwise publicly disclosing information concerning an agent under an NCI collaborative agreement. Investigators must send any such disclosure, marked CONFIDENTIAL, to the Coordinator, Research & Development Agreements, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program, National Cancer Institute [Telephone 301-496-7912; NCICTEPpubs@mail.nih.gov] RAB will coordinate and expedite the pharmaceutical collaborator's review.

Investigators must send any publication resulting from a DCTD-sponsored study to the Protocol and Information Office, CTEP, identifying the protocol by the NCI protocol number and grant/contract number.

10.2.7 Inventions
Clinical investigators are required to report any inventions relating to studies under an NCI-funded protocol, before public disclosure to National Institutes of Health (NIH), Division of Extramural Inventions and Technology Resources (DEITR), OPERA, Office of Extramural Research (OER), 6705 Rockledge Drive, Suite 310, MSC 7980, Bethesda, MD 20892-7980 Attn: Director, DEITR. The report should be in sufficient detail so as to enable the government to evaluate any potential contributions in the technological advances by NCI scientists. To allow more effective evaluation, the NCI asks that the
investigator send an additional copy of the invention report to: Coordinator, Research & Development Agreements, Regulatory Affairs Branch, Cancer Therapy Evaluation Program, DCTD, NCI, Executive Plaza North, Suite 7111, Bethesda, MD 20892 [NCICTEPpubs@mail.nih.gov].

Information regarding the intellectual property options agreed to by the Investigator's Institution to the pharmaceutical collaborator can be found at http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm.

10.3 Record Retention
FDA regulations require investigator to keep all research records (including patient charts, case report forms, x-rays and scans that document response, IRB approvals, signed informed consent documents and all agent accountability records) for at least 2 years after an NDA or BLA has been approved for that indication, or the CTEP, DCTD IND has been withdrawn from the FDA. CTEP will notify investigators when these events occur. This requirement is an explicit part of the FDA Form 1572, http://ctep.cancer.gov/forms/ (see Appendix V).

10.4 Reporting to IRBs
All studies supported in any way by CTEP must be under the auspices of an IRB that has obtained an approved Federal Wide Assurance (FWA) issued by the Office for Human Research Protections (OHRP), HHS.

Each investigator must report any problems, serious adverse events, or proposed changes in the protocol that may affect the investigation’s status patients’ willingness to participate in it to his or her IRB. At intervals appropriate to the study’s degree of risk, the investigator must report to the IRB. These intervals must be no less frequent than once a year, and when the study is complete.
11 Adverse Events

Because many anticancer agents have narrow therapeutic indexes, adverse events commonly accompany treatment. Cancer patients often exhibit signs and symptoms attributable to cancer or its complications. A medical event’s definition and identification as an adverse event related to a cancer agent present special problems for the investigator and sponsor.

The most current version of the DCTD Common Terminology Criteria for Adverse Events (CTCAE) (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm) should be used in reporting adverse events when initiating new DCTD-sponsored trials.

For DCTD-sponsored trials, each protocol document should include a section giving detailed instructions for reporting adverse events. The timelines for adverse event reporting are based on factors such as whether the event was expected and/or serious and the phase of the study.

11.1 Expedited Reporting of Adverse Events

All expedited AEs are reported to CTEP via the web-based Adverse Event Expedited Reporting System (AdEERS) (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adeers.htm). The operational definitions and guidelines for reporting adverse events (AEs) for anticancer agent trials are available on this web site.

The prompt reporting of AEs to CTEP is the responsibility of each investigator engaged in clinical research with investigational agents supplied by the DCTD. Investigators are encouraged to submit reports even if there is only a suspicion of an agent effect. Timely and accurate reporting of AEs is necessary so that DCTD can collate information from diverse sources and quickly disseminate the information to investigators working with the agent. The centralization of information on real or suspected AEs makes possible a much more accurate determination of the degree to which a suspected event is in fact agent-induced. Finally, regulations require DCTD to report to FDA all findings regarding AEs occurring in trials under its sponsorship.

For CTEP supported studies, a physician drug monitor in the Investigational Drug Branch reviews each submitted AdEERS report, including the investigator’s assessment. This review may result in a request for further information from the investigator. Each submitted AE report is classified according to its likely relation to the agent, and to the patient's underlying disease. Based on this assessment, a decision is made concerning the need for further action.

The prime consideration is whether the new findings affect the safety of patients enrolled in ongoing trials. If so, CTEP takes immediate steps to notify the investigator community, the FDA and the pharmaceutical collaborator simultaneously.

In addition, other measures may be taken, including:

- Communicating the new information by sending written notice directly to investigators
• Altering existing research by modification of protocols or discontinuing or suspending one or more trials
• Investigating the reaction by initiating special clinical or preclinical studies
• Altering the process of informed consent by modifying existing informed consent forms and/or informing patients of new findings.

11.2 Expedited Adverse Events with Commercially Available (Non-Investigational) Agents
For studies sponsored and/or funded by NCI involving commercially available agents not provided under an IND, investigators should follow protocol-specific guidelines for expedited reporting. All Cooperative Groups must report these AEs to the FDA via the AdEERS abbreviated pathway for commercial agents. The specific reporting guidelines are available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adeers.htm

11.3 Routine Reporting of Adverse Events
The reporting of serious AEs is in addition to and does not supplant the reporting of routine adverse events as part of the regular scientific report of the results of the research protocol. Reporting of adverse events should be in accord with the procedures for reporting results described in Section 10.
12 The Investigator and Protocol Chair: Roles and Responsibilities

The Organization of a Clinical Trial

12.1 The Investigator

More than fourteen thousand physicians are currently eligible to receive DCTD-sponsored investigational cancer agents. Most are eligible because they are investigators supported by a peer-reviewed NCI-funded grant, contract, or cooperative agreement. Each investigator agrees to certain essential principles of participation in clinical trials with investigational agents. These principles are contained in an agreement, the FDA Form 1572, http://ctep.cancer.gov/forms/index.html, which is defined by FDA regulation.

Return the completed forms to:
Pharmaceutical Management Branch, CTEP
Division of Cancer Treatment and Diagnosis, NCI
Executive Plaza North, Room 7149
6130 Executive Boulevard, MSC 7422
Bethesda, Maryland 20892-7422

12.1.1 The FDA Form 1572

In signing the FDA Form 1572, the investigator assures CTEP that the clinical trial will be conducted according to ethically and scientifically sound principles. More specifically, a signed FDA Form 1572 commits the investigator to the following obligations or tasks:

- Investigators provide a *statement of the education and experience* on the FDA Form 1572 which qualifies them to perform the study.
- Investigators assure that a properly constituted IRB will be responsible for the *initial and continuing review and approval of the study*. Any changes in the research protocol will require IRB approval, and all unanticipated problems involving risks to human subjects must be reported to the IRB. Such changes must also be approved by CTEP (Section 8.6).
- Investigators are responsible for proper, secure storage of investigational agents and must *maintain adequate agent accountability records* (Section 15).
- Investigators are required to *prepare and maintain adequate and accurate case histories* designed to record all observations and other data pertinent to each patient (Section 10).
- Investigators must *furnish reports to the CTEP as the investigational agent sponsor* (Section 10). In the case of multicenter studies, the coordinating center and the protocol chair are responsible for the generation of these reports. Investigators are responsible for submitting data to the coordinating center.
- *Investigators are responsible for promptly reporting AEs according to protocol guidelines, which are based on attribution level, grade and expectedness. Some AEs that are unexpected and severe require reporting through AdEERS within 24 hours. (Refer to Section 11)*
CTEP has devised a detailed policy statement that adapts this necessarily broad language to the setting of cancer clinical trials.

- Investigators shall maintain agent accountability records and case histories for 2 years following the date an NDA or BLA is approved for that indication or, for at least 2 years after the IND is withdrawn. CTEP will notify investigators when an IND has been withdrawn (see Section 10.3).
- Upon the request of a scientifically trained and properly authorized employee of the DHHS (either FDA or NCI), investigators will make records available for inspection and copying.
- Investigators certify that they will personally conduct or supervise the clinical trials. If other physicians administer investigational agents, they will do so only under the investigators’ direct supervision. Each attending physician who meets the DCTD investigator definition is required to be registered with CTEP by submitting a completed FDA Form 1572 to PMB annually.
- Investigators certify that they will inform subjects or their representatives that agents are being used for investigational purposes and will obtain the written consent of the subjects or their locally authorized representatives.
- Investigators assure CTEP that they will not initiate studies until the IRB has reviewed and approved them.

### 12.1.2 Responsibilities of an Investigator for Human Subjects Protection
Investigators' responsibilities for IRB review deserve special mention. Each investigator who participates in NCI-sponsored clinical research must have the research approved by an IRB that has an approved Federalwide Assurance (FWA) issued by OHRP. The DHHS regulations specify the procedures the investigator and his or her institution must follow to protect human subjects; they include IRB composition and function, as well as the basic elements of the informed consent document. All clinical research sponsored by DHHS must be in compliance with these regulations (Title 45, Code of Federal Regulations, Part 46 [http://www.access.gpo.gov/nara/cfr/waisidx_01/45cfr46_01.html](http://www.access.gpo.gov/nara/cfr/waisidx_01/45cfr46_01.html) and Title 21, Parts 50 and 56, [http://www.access.gpo.gov/nara/cfr/waisidx_01/21cfr50_01.html](http://www.access.gpo.gov/nara/cfr/waisidx_01/21cfr50_01.html), and [http://www.access.gpo.gov/nara/cfr/waisidx_01/21cfr56_01.html](http://www.access.gpo.gov/nara/cfr/waisidx_01/21cfr56_01.html). Within DHHS, the Office for Human Research Protections (OHRP), [www.hhs.gov/ohrp](http://www.hhs.gov/ohrp), administers these regulations with each institution. The OHRP negotiates assurances of compliance with HHS regulations for the protection of human subjects. Under an assurance, the IRB is authorized to review and approve research. Each investigator who participates in NCI-sponsored research must conduct the research at an institution with an OHRP-approved assurance.

### 12.2 The Protocol Chair

#### 12.2.1 Responsibilities
The chair or Group designee of a clinical trial assumes certain responsibilities in addition to those of the participating investigator. Specifically, these include:

- Writing the protocol document
- Assuring that necessary approvals are obtained, including those of the IRB, the sponsor (DCTD), and any others for the protocol and subsequent amendments
- Monitoring the study during its execution, which includes:
  - Reviewing each case record to confirm eligibility
  - Reviewing each case record to determine compliance with the protocol
o Reporting adverse events
o Determining any necessary changes in the protocol and the informed consent documents and submitting them as protocol amendments to the clinical site and to CTEP
o Monitoring accrual to the study and stopping the study when the requirements of the study design have been fulfilled
o Reporting study status changes to CTEP (see Section 8.7).
• Analyzing Results: By assessing each case to determine eligibility, evaluability, adverse events, protocol compliance, and outcome (this assessment should be independent of that of the treating investigator)
• Reporting Results to CTEP: Results should be presented in fully analyzed and tabulated form. The protocol chair bears the primary responsibility for this task. In Cooperative Group trials, of course, the statistical center is the protocol chair’s most important collaborator in fulfillment of reporting requirements.

12.2.2 Who May Serve as a Protocol Chair?
Since protocol chairs are responsible for meeting all NCI requirements for IND agent research, as stated in this manual, protocol chairs must be fully qualified investigators. Trainees may not serve as protocol chairs.
13 Affiliate Investigators

The participation of physicians who collaborate with major institutions in clinical trials is an important component of the NCI program. The NCI, the clinical Cooperative Groups, CCOP Research Bases and many Cancer Centers recognize these participants’ contributions. To assure and maintain the high quality of clinical research conducted by the clinical trials organizations, it is important to maintain a strong relationship between these affiliate investigators and the clinical site.

To accomplish this objective, clinical site administrative policies and procedures must give participating investigators easy access to accurate and timely information on matters of scientific importance. They must also guide investigators to comply with Federal regulations. The following guidelines can assist clinical sites in formulating specific policies for strengthening the relationship between affiliate investigators consistent with these goals. The content of the following guidelines applies to affiliates of any clinical site.

We recommend that each clinical site develop a formal affiliate policy consistent with these guidelines.

13.1 Affiliate Investigators Definition
An affiliate investigator of a clinical site is a physician who:
- Participates in research clinical trials organized by the clinical site, and
- Has satisfied all criteria for affiliate membership as defined by the clinical site.

13.2 Requirements of an Affiliate Investigator

All affiliate investigators:
- Must have demonstrated competence in the treatment of cancer patients as defined by the clinical site
- Must have the ability to accrue a minimum number of patients as set by the clinical site
- Must have established a close cooperative professional relationship with the clinical site through regular participation in group meetings and/or educational sessions sponsored by the clinical site
- Must have successfully passed a probation period during which time the affiliate investigator has demonstrated:
  - Ability to enter patients on protocol
  - Ability to comply with the protocol
  - Ability to provide accurate and sufficient data to the clinical site
  - Ability to adhere to the procedures and standards of the clinical site and the CTEP
- Must have an appropriate OHRP assurance for the protection of human subjects (Section 12.1.2).

13.3 Responsibilities of Affiliate Investigators
The affiliate investigator must adhere to the procedures of the clinical site and CTEP for the conduct of clinical research by:
- Meeting the record keeping policies of the clinical site
- Making certain that each protocol has the full approval of an authorized IRB prior to involvement of human subjects
- Making certain that each patient signs and is given a copy of the IRB-approved consent form. The consent forms should be maintained on file by the affiliate investigator
- Complying with CTEP and FDA policies concerning investigational agents use, which include as a minimum:
  - Annually filing a signed FDA Form 1572, [http://ctep.cancer.gov/forms/index.html](http://ctep.cancer.gov/forms/index.html), a signed Supplemental Investigator Data Form, a signed Financial Disclosure Form, and CV with CTEP
  - Observing DCTD policy and procedures for the proper and secure storage of investigational agents, including maintaining NCI Agent Accountability Records, [http://ctep.cancer.gov/forms/index.html](http://ctep.cancer.gov/forms/index.html).
  - Agreeing that primary medical records of patients may be audited in accordance with the policies of the clinical site, CTEP, and FDA (Section 16).

### 13.4 Responsibilities of Clinical Sites for Affiliates

#### 13.4.1 The Cooperative Groups
The Cooperative Groups have the following responsibilities for their affiliate investigators:
- Maintaining an accurate and up-to-date list of all member institutions and affiliate investigators
- Informing CTEP of important actions regarding membership status of its member institutions and affiliate investigators
- Reviewing performance of all members in periodic and timely fashion (including on-site data audits)
- Assuring that all members, full and affiliate, are in compliance with CTEP policies and DHHS regulations
- Ensuring that each affiliate institution/investigator has registered an Federal Wide Assurance with the OHRP, [http://www.hhs.gov/ohrp/policy/](http://www.hhs.gov/ohrp/policy/).
- Ensuring that full local IRB approval has been obtained prior to allowing registration of patients on any protocol and on a continuing basis

#### 13.4.2 The Principal Investigator Responsibilities for Affiliate Investigators in Cooperative Group Protocols
The principal investigator in Cooperative Groups has the following responsibilities for affiliate investigators:
- Assuring the Cooperative Group that the affiliate member's performance meets the procedures and standards of the clinical site
- Informing the Cooperative Group of important changes in affiliate member relationships
- Agreeing to site-visit the affiliate as deemed necessary by the Cooperative Group
- Providing the affiliate with accurate and timely information on matters of scientific importance
- Communicating to affiliates in a timely manner all policies (and any changes in policy) on the conduct of clinical research.
13.4.3 Cancer Centers
The Cancer Centers have the following responsibilities for their physician members and
for their affiliate (see Section 13.1) institutions:
- Maintaining an accurate and up-to-date list of members and affiliates
- Informing CTEP of important actions taken regarding membership status of its
  members and affiliate investigators
- Conducting periodic and timely review of the performance of all members and
  affiliate investigators (including audits of affiliate data)
- Agreeing to site-visit the affiliate investigator in accord with CTEP policies
- Assuring that all members and affiliate investigators are in compliance with CTEP
  policies and guidelines (http://ctep.cancer.gov/industryCollaborations2/default.htm#guidelines_for_collaborations)
  and FDA regulations
- Ensuring that each affiliate institution/investigator has registered an appropriate
  assurance with the OHRP, http://www.hhs.gov/ohrp/policy
- Ensuring that full local IRB approval has been obtained prior to allowing
  registration of patients on any protocol and on a continuing basis
- Communicating to affiliate investigators all policies and changes in policy on the
  conduct of clinical research in a timely manner.
14 Who May Order Agent from PMB, Write Patient-specific Orders for Investigational Agents, and/or Administer Investigational Agents

CTEP restricts distribution of investigational agents to sites where physicians are registered as investigators with CTEP. Specifically, *secondary distribution of investigational agents from registered investigators to unregistered physicians is prohibited*. All patients on clinical trials involving the use of investigational agents must receive all treatments with these agents from a registered investigator.

The reason for this policy is clear. Physicians who treat patients as part of a clinical trial must have a commitment to the trial’s goals and to the clinical research’s methodological requirements. They must be experienced in the evaluation of therapeutic results and adverse event manifestations of anticancer therapy. The major issue, therefore, in the conduct of a clinical trial is:

All investigators participating in trials supported by CTEP must be formally registered with their clinical site (i.e., Cooperative Group or Cancer Center) and with CTEP. Investigators register with CTEP by completing a FDA Form 1572, a Supplemental Investigator Data Form, CV, and a Financial Disclosure Form, [http://ctep.cancer.gov/forms/](http://ctep.cancer.gov/forms/).

The following sections discuss ordering agent, writing patient-specific orders, and administering CTEP-supplied investigational agents.

14.1 Ordering Agent from PMB

Only those physicians who are registered with the NCI, have an active registration status, and are listed on the title page of a protocol (single or multi-institution trials) or are a member of a Cooperative Group participating on the trial may order agent from PMB once the trial is approved. Physicians may name specific individuals on their Supplemental Data form who may serve as ordering or shipping designees in their stead.

14.2 Writing a Patient-specific Orders

Patient-specific orders for investigational agents should be written by NCI-registered investigators participating on the specific trial. If other licensed prescribers write orders, the registered investigator who is officially participating on the trial must co-sign the order.

When writing orders for CTEP-supplied study agents, investigators should comply with their local policies and procedures. It is good clinical practice to include the following information (in addition to the information generally needed for any order) on each order for an investigational agent:

- The identifying number of the protocol on which the patient is being treated.
- The fact that the appropriate supply of study agent should be used; this is particularly important when the study agent is commercially available to avoid error.
- A reminder for staff to check to protocol to determine the source of the study agent; often, study agents are supplied by more than one source.
14.3 Administration of Investigational Agents

Registered health professionals, including physicians in training, may administer investigational agents under the direct supervision of a registered investigator holding a current FDA Form 1572. In such cases, the registered investigator assumes complete responsibility for the use of these agents.

CTEP recognizes that it is convenient for a Cooperative Group member or Cancer Center physician to ask a local physician to administer protocol treatment to a patient who may have traveled long distances to the clinical site for initial consultation. We believe that this approach is ultimately detrimental to the clinical research effort unless the investigator maintains very careful surveillance. If close monitoring is impossible, it seems much more sensible to require that all treatments be administered by registered investigators. Physicians will have to consider carefully whether a patient being evaluated for study will be able to receive each treatment at the hands of a registered physician. We are confident, however, that the benefits of this policy, in terms of both patient safety and integrity of the research data, far outweigh the disadvantages and are in the long term best interests of both patients on clinical trials and the DCTD’s agent development program.

If an investigator requests and the PMB approves the use of a local medical doctor (LMD), the LMD must:

A. be an active, registered NCI Investigator.
B. agree to treat the patient in accordance with the protocol.
C. notify the Responsible Investigator of all adverse events and submit all required protocol data to the Responsible Investigator as outlined in the protocol. The LMD will function as an “affiliate investigator.”
D. have IRB approval or be covered under the Responsible Investigator’s IRB.
E. maintain drug accountability records.

The Responsible Investigator must:

A. be an active registered NCI investigator.
B. remain the principal investigator for all protocol treatment, patient care, and for all data collection and protocol evaluations for the patient receiving LMD care.
C. inform his/her IRB that the LMD will be treating one of his/her protocol patients.
D. verify that the patient has tolerated the therapy without excessive toxicity at a stable dose level prior to PMB’s approval of LMD.
E. remain responsible for all treatment decisions and for the collection and submission of the study data in accordance with the approved protocol.
F. inform the Cooperative Group’s Operations Office and seek their approval if the patient is being treated under a “NCI Cooperative Group” protocol.
G. inform the PMB when the patient withdraws from the protocol or protocol treatment is discontinued.
15 **Accountability and Storage of Investigational Agents**

The investigator is responsible for the proper and secure physical storage and record keeping of investigational agents received from CTEP. Specifically, the investigator must:

- Maintain a careful record of the receipt, use and final disposition of all investigational agents received from CTEP, using the NCI Agent Accountability Record Form (DARF), [http://ctep.cancer.gov/forms/](http://ctep.cancer.gov/forms/).
- Store the agent in a secure location, accessible to only authorized personnel, preferably in the pharmacy
- Maintain appropriate storage of investigational agents to ensure their stability and integrity
- Return unused investigational agents to PMB at study completion or upon notification that an agent is being withdrawn

The intent of the agent accountability procedures described in this section is to ensure that agents received from DCTD are used only for patients entered onto approved protocols. FDA regulation requires the record keeping described in this section. Investigators are ultimately responsible for the use of investigational agents shipped in their name. Even if a pharmacist or chemotherapy nurse has the actual task of handling these agents upon receipt, the investigator remains the responsible individual and has agreed to accept this responsibility by signing the FDA 1572, [http://ctep.cancer.gov/forms/index.html](http://ctep.cancer.gov/forms/index.html).

Investigators, clinical trials personnel and interested parties can find a training module that addresses the intricacies of investigational agent accountability on the CTEP web site, [www.ctep.cancer.gov](http://www.ctep.cancer.gov), in PMB’s section under “Investigational Drug Handling Slide Show” ([http://ctep.cancer.gov/branches/pmb/idh_slideshow.htm](http://ctep.cancer.gov/branches/pmb/idh_slideshow.htm)). This training module covers ordering, accounting for, and returning investigational agents. In addition, the PMB section of the web site also includes a “Frequently Asked Questions” section that can help sites deal with common problems.

15.1 **Procedures for Agent Accountability and Storage**

Investigators or their designees must maintain a Drug Accountability Record Form (DARF) for every CTEP-supplied agent. A copy of the DARF may be found at [http://ctep.cancer.gov/forms/index.html](http://ctep.cancer.gov/forms/index.html).

- Store each investigational agent separately by protocol. If an agent is used for more than one protocol, investigators or their designees should maintain separate physical storage for each protocol. Remember that CTEP provides and accounts for agents on a protocol-by-protocol basis.
- Maintain separate accountability records if
  - an agent is used for more than one protocol; maintain a DARF for each protocol
  - CTEP supplies multiple agents for a protocol; maintain a DARF for each agent
  - A protocol employs different strengths or dosage forms of a particular agent (e.g., an agent with a 1-mg vial and a 5-mg vial would require a different DARF for the 1-mg vial than for the 5-mg vial); maintain a DARF for each strength or dosage form
• Agents are stored in various places, e.g., main pharmacy, satellite pharmacy, physician’s office, or other dispensing areas; maintain a separate DARF at each location

• Document other transactions (e.g., receipt of agent, returns, broken vials, etc.) on the DARF.

• Refer to individual protocols for ordering and storage information for CTEP-supplied agents. **It is important to note that procedures for agent accountability may differ when PMB provides patient-specifically labeled supplies (e.g., the supplies for a double-blind randomized clinical trial).** Please refer to the individual protocol or call PMB at 301-496-5725 if questions arise.

• DCTD-supplied investigational agents may be transferred, within an institution (intra-institutional transfer) from a completed DCTD protocol to another DCTD-approved protocol that employs the same agent, formulation and strength.

• Complete and fax (301-402-0429) an NCI Investigational Agent Transfer form, [http://ctep.cancer.gov/forms/index.html](http://ctep.cancer.gov/forms/index.html), to the Pharmaceutical Management Branch (PMB) for each agent transfer.

• Submit transfer forms within 72 hours of the actual transfer.

• Transfer of DCTD-supplied investigational agents from active protocols requires prior PMB approval (telephone 301-496-5725). (See PMB Policy and Guideline on the CTEP Home Page.)

• Inter-institutional transfer of DCTD investigational agents (transfer between institutions) is forbidden unless the PMB specifically pre-approves or authorizes such transfer.

PMB is seeing more subtle differences (yellow vs. brown tablets, micronized powder vs. soft gelatin capsule, investigational vs. commercial label) that might not be readily apparent to you (the site). A site could execute an after-hours emergency transfer without realizing that a subtle difference was a concern, and subsequently, PMB would be unable to approve the transfer. **PMB strongly recommends obtaining approval before transferring any agent.**

### 15.2 Investigational Agent Returns

Many investigators are not aware that unused investigational agents must be returned to the IND sponsor. DCTD, as the investigational agent sponsor, is responsible for investigational agent accountability, which includes receipt, distribution, and final disposition of all investigational agents. Investigators are required to return agents if:

- The study is completed or discontinued
- The agent is expired
- The agent is damaged or unfit for use (e.g., loss of refrigeration)

In situations where a DCTD agent is no longer required for a completed or discontinued protocol, DCTD procedures permit the transfer to another DCTD-sponsored protocol that is using the identical agent, formulation and strength through completion of the NCI Transfer Investigational Agent Form, NIH-2564-1, [http://ctep.cancer.gov/forms/index.html](http://ctep.cancer.gov/forms/index.html), see Section 15.1.

In situations where you have excess inventory or agent that will expire before it can be used, and you have another DCTD protocol(s) using the identical agent, please contact the Pharmaceutical Management Branch (301-496-5725) for assistance in transferring...
the agent to another DCTD-sponsored study. Otherwise, return the agents as stated in
the steps below.

To return investigational agents to DCTD:
1. Package the agents securely to prevent breakage (enclose within a zip-lock bag)
2. Complete the Return Drug List Form, NIH-986. Save a copy for your records.
3. Send to the NCI Clinical Repository at the address indicated on the Return Drug
Form within 90 days of the agent’s expiration or closure of the study. Since
agents are not re-used upon return, rush delivery and maintenance of labeled
storage temperatures is unnecessary.

15.3 Verification of Compliance
Investigators are reminded that auditors will review compliance with procedures to
ensure proper agent usage during site visits conducted under the monitoring program.
Specifically, auditors will
• check for appropriate maintenance of the agent accountability system
• spot-check agent accountability records by comparing them with the patients’
medical records to verify that the agents were administered to a patient entered
in the recorded protocol
• compare actual inventory with DARF balances

15.4 Handling of Antineoplastic Agents
There has been considerable concern about the potential risk of chronic exposure to
low-level concentrations of antineoplastic agents among health care workers routinely
handling these agents. The potential mutagenic activity of antineoplastic agents has
been examined in vitro and in vivo. Urinary alkylating and anthracycline agents have
shown mutagenic activity in experimental systems, whereas this has not been
demonstrated for most of the antimetabolites and vinca alkaloids. Reports indicate that
workers who handle antineoplastic agents may absorb them. In addition, some
compounds are carcinogenic in animals and are suspected of being so in humans, but
only in patients receiving the agent at therapeutic levels.

No clear evidence indicates, however that chronic exposure to low-level concentrations
of antineoplastic agents has been carcinogenic in health-care workers. Nevertheless, it
would seem prudent to consider the adoption of certain precautions in the procedures of
workers handling these agents. Several professional organizations have reviewed the
data on this subject in an attempt to develop guidelines for safe handling. While there
are now several published sets of guidelines, they do not differ significantly.

We have reproduced the Recommendations for Handling Cytotoxic Agents, by the
National Study Commission on Cytotoxic Exposure in Appendix VII. Please note that
these are guidelines and do not have regulatory or legal force. They are included for
your consideration and information.
Other pertinent references include:
• ASHP Guidelines on Handling Hazardous Drugs. Available at:
• The CDC NIOSH has a very comprehensive list of recent articles at
16 Monitoring and Quality Assurance

16.1 Introduction
Monitoring is a key component of any clinical trials program. Quality assurance and monitoring are concerned with the execution of a trial, rather than its conception, and with the quality of the data that support the scientific conclusions. http://ctep.cancer.gov/branches/ctmb/default.htm.

Many individual activities are part of quality assurance, and investigators have recognized some of them as vital to the integrity of clinical trials for years. In particular, the quality control of pathology and radiotherapy has been part of the Cooperative Group program for a long time. More recently, investigators have increasingly recognized the importance of verifying the accuracy of other classes of data.

We shall now discuss in more detail the items that form the major focus of the DCTD-sponsored quality assurance effort. Note that the first two classes of concern (protocol compliance and data accuracy) are really central problems in clinical trials methodology. The fact that they are assessed intensively by the on-site audit program should in no way divert attention from their essential importance to the scientific content of clinical trials. Additional information may be found at the CTEP Clinical Trials Monitoring Branch web site http://ctep.cancer.gov/branches/ctmb/default.htm.

16.2 Protocol Compliance

16.2.1 Cooperative Groups
The groups have recognized the importance of assessing the extent of protocol compliance for many years. One of the first areas to receive attention was the confirmation of diagnosis. Today, all groups have Pathology Committees or Reference Panels for selected studies; central pathology review reduces one important source of variability in trial results. Furthermore, most Cooperative Groups have quality control in radiotherapy, which consists at least of reviews of port films by group radiotherapists. These reviews are best done prospectively, so that errors can be detected in time to alter subsequent treatment. In the Cooperative Groups, the medical oncology committee or the protocol chair reviews case report forms to establish whether dose adjustments have followed protocol guidelines, and whether appropriate study tests have been obtained.

In most Cooperative Groups, the protocol chair also reviews each case to determine eligibility, evaluability, and validity of response and adverse event assessment. In some cases, the statistical office accomplishes one or more of these tasks. All of these assessments are performed through review of submitted case report forms.

16.2.2 Cancer Centers
The majority of Cancer Centers have organized procedures to assess protocol compliance centrally and systemically (Section 3, Clinical Sites). The CTEP on-site audit program evaluates protocol compliance as part of its monitoring visits. Indeed, this is a major focus of a monitoring visit to a Cancer Center, along with the administrative review for central data management, protocol development, and data collection.
16.2.3 CTEP Clinical Agent Development Contractors
Protocol compliance is assessed by the Clinical Trials Monitoring Service (CTMS). phase 1 and phase 2/3 contractors submit raw data to CTMS, which reviews it carefully for extent of compliance with the protocol. Reports of these evaluations are provided to the investigator and to CTEP.

16.3 Data Accuracy
The importance of verifying the accuracy of the basic data elements used in the analysis of study endpoints is obvious. Data accuracy is assessed during on-site audits by comparison of the research record (e.g., flow sheets) with the primary patient record. Response assessment may be evaluated by examination of radiographs or scans, where relevant.

In many of the early on-site audits performed, CTEP was concerned about the absence of formalized procedures at many centers for assessing these important issues internally. Many institutions lacked central registration mechanisms to enroll patients on trials. Centralized systems of data management were often not available. Some institutions lacked clear procedures for certifying the accuracy of research data. Formal procedures for evaluating the accuracy of response assessment, for example by second-party review, were commonly lacking. As institutions have recognized the importance of these tools for the conduct of clinical trials and have brought them “on-line,” the quality of data has improved commensurately.

16.4 Procedural Requirements
As an IND sponsor, the DCTD must verify that its investigators adhere to the various procedural requirements. Specific procedural activities checked at the time of the on-site audit are:

- **Informed Consent** - Investigators must be certain that the patient signs the IRB-approved version of the informed consent before protocol-directed therapy begins. Investigators must write the consent form specifically for the protocol, addressing all elements required by Federal regulations.

- **IRB Approval** - Each protocol must have full approval by the IRB named in the assurance for the institution prior to patient entry. There should be written verification of this action and of at least annual review. The IRB must also approve substantive protocol amendments.

- **Agent Accountability** - Each investigator must assure that:
  - All DCTD-supplied IND agents must be used only for patients on the specific protocol for which the agents were requested and approved by CTEP.
  - Sites must maintain an NCI Drug Accountability Record Form (DARF), documenting the disposition of each unit of agent received from CTEP for each protocol. ([http://ctep.cancer.gov/forms/index.html](http://ctep.cancer.gov/forms/index.html))

On-site auditors will also review reporting event adverse and the quality of record keeping with particular reference to the completeness of the source documentation.

Auditors review each of these areas during on-site audits. In addition, many Cooperative Groups and Cancer Centers maintain internal procedures to assure the quality of data on their trials and assure that sites meet regulatory requirements.
16.5 Components of the Quality Assurance Program Implemented by CTEP

Information regarding the Quality Assurance and Monitoring Program may be found at the CTEP website at:

16.5.1 Monitoring

Monitoring includes following the study’s overall progress to ensure that
- projected accrual goals are met in a timely fashion
- excessive accrual is avoided
- eligibility and evaluability rates do not fall below acceptable standards
- risks of the study do not outweigh benefits.

Poor performance in any of these areas is cause for concern. Because these activities are performed during study execution, they may directly improve conduct of the trial.

The Cooperative Groups are performing these tasks according to systematic, formalized procedures. For phase 1 studies, the CTMS performs these duties.

Cancer Center studies are monitored by the CTMS with direct oversight from CTMB.

16.5.2 The On-Site Auditing Program: Purpose and Procedures

Purpose of Site Visit Audits
- Verification of data accuracy by comparing the clinical site’s primary medical records with the case report forms for analysis
- Verification of the presence of an IRB-approved consent form signed by the patient prior to the initiation of protocol therapy
- Verification of IRB approval (and at least annual review and reapproval) of each sponsored study
- Verification that procedures for agent accountability comply with federal regulations and follow CTEP procedures, including maintenance of NCI Agent Accountability Records.

Outline of Audit Procedures
- Trials to be audited are those involving DCTD investigational agents and selected prevention trials
- All audits will be conducted by persons knowledgeable about clinical trials methodology and the Federal regulations and NCI policies pertinent to clinical trials
- Audits will be randomly timed
- Audits will be conducted at an average rate of once every three years (except CTMS monitored phase 1 trials).

Adaptations of Basic Procedures to Specific Needs

These basic procedures have been adapted to the several types of clinical trials organizations supported by NCI in the following way:
- Cooperative Groups - Each Group will perform its own program of on-site audits, to be conducted by its staff and/or members with direct oversight by CTMB. CTEP or CTMS staff will attend a percentage of audits as observers.
- Clinical Agent Development Contractors - On-site audit visits are made to the phase 0, 1 and select phase 2 grantee three times each year and to the Pediatric
consortium once annually. All are site visited by the CTMS. Noncontract studies may be assigned to CTMS monitoring at the discretion of CTEP.

- **Others** - This category comprises all others performing DCTD IND agent studies, including RO1/PO1/P50 holders (conducting clinical IND agent trials as part of grant-related activity), and new agent studies groups. Audits will be conducted by teams composed of CTMS staff, CTEP staff, and outside physicians, as deemed necessary by CTEP.
- **Cancer Centers** – Audits will be conducted by teams composed of CTMS staff, CTEP staff and outside physicians. Audits will occur once every three years.

**Relationship Between the Content of the Site Visit Audits and the Type of Clinical Trials Organization.**

<table>
<thead>
<tr>
<th>Phase of Study</th>
<th>Study Monitoring</th>
<th>Reporting Mechanism</th>
<th>Auditing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 1 &amp; Select Phase 2</td>
<td>CTMS + CTEP</td>
<td>Bi-weekly CRFs to CTMS</td>
<td>CTMS Pharm.D./M.D. once per year</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monthly CTMS reports downloads to CDS</td>
<td>CTMS/CRA twice per year</td>
</tr>
<tr>
<td>Phase 2 &amp; Phase 3 Coop Grp</td>
<td>Cooperative Group + CTEP</td>
<td>CDS quarterly data submissions</td>
<td>Group physicians, CRAs, nurses once every 3 years</td>
</tr>
<tr>
<td>Phase 2 &amp; Phase 3 CC-Single Inst.</td>
<td>CTEP</td>
<td>CDS quarterly data submissions</td>
<td>CTEP + CTMS + peer physicians once every 3 years</td>
</tr>
</tbody>
</table>

**16.6 Informed Consent and the Monitoring Program**

Many have asked about the legality of outside individuals’ review of a patient's primary medical record. The answer is straightforward. No Federal law prohibits external review of a patient's medical record. The regulations of informed consent do require, however, that investigators inform patients about "the extent to which confidentiality of records will be maintained." This means that there is no rule against chart review by outsiders, but that the patient must be told what will be done. For this reason, CTEP requires that each informed consent document for investigational agent trials it sponsors include a statement with the following language, "A qualified representative of FDA and NCI may review my medical records." CTEP may also suggest including a statement that the NCI’s Pharmaceutical Collaborator (manufacturer of the agent) may have access to the records. This access may be necessary for the pharmaceutical collaborator to prepare a New Drug Application (NDA) or Biologic License Application (BLA) for an agent.
Also, please note that medical records are protected from inquiries under the Freedom of Information Act (FOIA). Even if the study is performed under Government sponsorship, records on the investigator’s premises are not subject to FOIA requests. Furthermore, patient-related records in Government files are protected from FOIA requests by the Privacy Act. As an additional measure of safeguarding, CTEP removes patient names from documents in its possession.

Each clinical site is responsible for adherence to the Health Insurance Portability and Accountability Act (HIPAA). Information regarding HIPAA for Covered Entities may be found at: http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/index.htm

16.7 Dealing with Problems Identified During On-Site Audits

CTEP and the Cooperative Groups have a full range of options in dealing with problems identified at the on-site audit. In a great majority of cases, the measures are intended to be constructive, educational, and corrective rather than punitive. The actions that are taken vary with the individual case.

All reports of on-site audits are sent to CTEP electronically. All reports are assessed by CTEP staff. When major problems are identified by a Cooperative Group audit, auditors convey this information to the group chair and CTEP for further action and investigation immediately. After requesting a written clarification, and following review of the case by the Cooperative Group and/or CTEP, CTEP may apply appropriate measures if the original assessment is confirmed. The options for action include:

- Letter of Warning
- Probationary status
- Suspension of patient entry privileges
- Immediate repeat audit
- Removal of access to investigational agents
- Notification of FDA if investigational agents are involved (FDA may conduct its own investigation)
- Notification of the Office of Research Integrity if scientific misconduct is a possibility (ORI may conduct its own inquiry/investigation)
- Notification of the Office of Human Research Protection (OHRP), http://www.hhs.gov/ohrp/policy, if issues of patient rights, informed consent, or IRB review are involved (OHRP may conduct its own investigation)

CTEP may direct the following actions in instances of suspected data fabrication or falsification or other possible scientific misconduct:

- Replacement of principal investigator
- Termination of grant or contract
- Reanalysis or retraction of published results
- Formal ORI investigation
- Debarment of investigator or other staff from future participation in PHS research.
Investigational agents that were given Group C designation by FDA had reproducible activity in one or more specific tumor types. Such an agent altered or was likely to alter the pattern of treatment of the disease and could be safely administered by properly trained physicians without specialized supportive care facilities. This information is included as history only; CTEP no longer employs the Group C mechanism.

17.1 Special Exceptions
Physicians with patients who are refractory to standard measures, who are ineligible for an ongoing research protocol, and who have a cancer diagnosis for which an investigational agent has demonstrated activity may receive the agent from CTEP as a Special Exception to the policy of administering investigational agents only under a research protocol.

Definition
The Special Exception mechanism is the functional equivalent of a single-patient IND but differs from it in that the investigator may obtain investigational agents directly from CTEP, instead of having to obtain an IND from FDA. CTEP provides this mechanism as a service to the oncology community and to cancer patients. CTEP professional and support staff commits substantial effort to maintaining the Special Exception Program.

We expect that patients treated under the Special Exception mechanism are not eligible for established research protocols. Agents available for Special Exception are always in phase 2 or phase 3 trials. CTEP does not grant Special Exceptions for phase 1 agents.

The purpose of the Special Exception mechanism is to make unapproved investigational agents that have a significant activity against specific malignancies available to cancer patients and investigators who otherwise cannot participate in a clinical trial.

Criteria for Approval of a Special Exception Request
Pharmacists of the Pharmaceutical Management Branch and physician staff members of the Investigational Drug Branch review and approve each Special Exception request on a patient-by-patient basis, based on the following considerations:

- Is there a research protocol for which the patient is eligible?
- Have standard therapies been exhausted?
- Is there objective evidence that the investigational agent is active in the disease for which the request is being made?

A review of past experience with Special Exception protocols indicated that patients experienced considerable adverse events with little significant benefit. As a result, CTEP has attempted to improve selection criteria for patients treated under Special Exception. Considerable evidence must attest to the agent’s activity for the requested indication. There should be sufficient data available to provide a reasonable expectation that the agent will prolong survival or improve the quality of life in a cohort of similar patients so treated. Reports of low response rates, or responses of brief duration, or anecdotal reports of an occasional response are not sufficient to justify approval.

- Is the agent likely to benefit this patient?
Even if the agent has been reported to be active in the disease, both the patient’s physicians and CTEP physicians must weigh the patient’s specific circumstances.

Please note that the Special Exception service may not be used as a means to obtain agents to treat a series of patients on protocol, or to do pilot work for an intended study. CTEP tracks these requests and will take whatever measures are necessary to discontinue such practices by an investigator. Agents distributed under Special Exception Service are investigational and are subject to FDA regulation and CTEP policy.

Requesting a Special Exception Agent
Requests for Special Exceptions may be made in writing or by telephone to the Pharmaceutical Management Branch. Requests must include

- The patient’s age, sex, diagnosis and date of diagnosis
- The patient's previous cancer therapy, and current clinical status
- The intended dose and schedule of the requested agent
- Any proposed concomitant cancer agents or other therapies, and pertinent laboratory data.

Explanation of why the proposed use of the investigational agent is a better choice than a commercially available agent.

Responsibilities of Physicians Administering Special Exception Agents
See Appendix VIII.

17.2 Treatment Referral Center (TRC)

Purpose
The Treatment Referral Center (TRC) is a means for NCI to provide information to community oncologists about therapeutic options for cancer patients with emphasis on referral to Cooperative Group studies or Cancer Centers. The TRC uses the PDQ, http://www.cancer.gov/search/clinical_trials, CTEP information systems databases, data supplied by the NCI-designated Comprehensive or Clinical Cancer Centers, and consultations with CTEP physicians to maintain a referral list of current active research protocols.

The TRC sometimes provides early access to investigational agents for select patient populations. When research indicates investigational treatments are promising in specific diseases (and in specific disease stages, patient populations and/or after a specific amount of prior therapy), the TRC may draft a Treatment Referral Center Protocol. TRC protocols have set criteria to determine patient eligibility while Special Exceptions are assessed on each request:

- TRC Protocols are employed for highly promising agents for a variety of cancers
- TRC Protocols are similar to simple multicenter clinical trials (large one-arm studies with relatively open eligibility and simple objectives)
- TRC Protocols are used to ensure equitable distribution of investigational agents with limited availability
- Safety and activity data are typically collected
- TRC Protocols are initially offered to the NCI-designated clinical and comprehensive Cancer Centers
When Cancer Center Investigators determine that commercially available treatment options or active clinical trials are lacking or unavailable for such patient populations, they may consider using an open Treatment Referral Center Protocol as a treatment option.

**Method**
Information will generally be provided about treatment options using the following algorithm:
- First priority will be given to suggesting the patient be referred to a major phase 2 or 3 trial (usually Cooperative Group studies).
- If the patient is ineligible for or unable or unwilling to enter a phase 2 or 3 trial, then the physician would be offered the following alternatives:
  - Referral to a participating Cancer Center for evaluation for an investigational protocol. These protocols would offer therapies with potential activity in a specific disease
  - Standard treatment options; e.g., commercially available agents
  - Special Exception agents, if available
  - Referral to the PDQ database for alternative treatment options, including phase 1 agents.

**Access to the TRC**
Physicians at participating Cancer Centers will contact the Pharmaceutical Management Branch at 301-496-5725 to contact the TRC or to register patients on TRC protocols. Registration procedures and eligibility criteria are provided in the approved TRC protocol. All investigators must register with CTEP and maintain appropriate records (discussed in Section 15 of this manual.)

More information is available on the CTEP home page (http://ctep.cancer.gov/)
Appendix I

NCI-Cooperative Group-Industry Relationship Guidelines

Information on CTEP Guidelines for collaborations with industry may be found on the web site:

http://ctep.cancer.gov/industryCollaborations2/default.htm#guidelines_for_collaborations

Information is available on:

- NCI Standard Protocol Language for Collaborative Agreements
- CTEP Interaction with Industry
- Model Agreements
- NCI - Cooperative Group - Industry Relationship Guidelines discuss the following ten topics and can be found at http://ctep.cancer.gov/industryCollaborations2/guidelines.htm

1. Proprietary Agent(s)
2. Confidentiality
3. Indemnification / Liability
4. Intellectual Property and Extramural Inventions
5. Access to Clinical Data
6. Procedures Under Which the Collaborator May Contact Cooperative Groups, Member Institutions or Individual Clinical Investigator(s):
7. Nature and Form of Information Supplied to the Collaborator
8. Cooperative Group - Collaborator Agreements
9. Publications
10. Financial Disclosure

- Intellectual Property Option Policy
Appendix II

Phase 0 Studies

Phase 0 trials are designed primarily to evaluate the pharmacodynamic efficacy, and/or pharmacokinetic properties of selected investigational agents, before initiating phase 1 testing, or to determine not to continue agent development (http://clincancerres.aacrjournals.org/cgi/content/abstract/14/12/3675). One of phase 0 trials’ major objectives is to interrogate and refine a target or biomarker assay for drug effect in human samples implementing procedures developed and validated in preclinical models (http://clincancerres.aacrjournals.org/cgi/content/full/14/12/3658). Thus, close collaboration between laboratory scientists and clinical investigators is essential to the design and conduct of phase 0 trials. Given the relatively small number of patients and tissue samples, showing a significant drug effect in phase 0 trials requires precise and reproducible assay procedures and innovative statistical methodology. Furthermore, phase 0 trials involving limited exposure of a study agent administered at low doses and/or for a short period allow them to be initiated under the Food and Drug Administration Exploratory IND guidance with less extensive preclinical toxicity data than usually required for first-in-human phase 1 studies under a standard IND (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078933.pdf).

There are several types of phase 0 trials. One type of phase 0 trial is designed primarily to show that the drug affects the target in human tumor and/or surrogate tissue or that a mechanism of action defined in nonclinical models can be observed in humans. A second type of phase 0 trial can be designed to evaluate clinically the properties of two or more structurally similar analogues directed at the same molecular target. Phase 0 trials can also serve to determine a dosing regimen for a molecularly targeted agent or a biomodulator intended for use in combination with other agents. Lastly, phase 0 trials can be designed to develop novel imaging probes or technologies to evaluate the biodistribution, binding characteristics, and target effects of an agent in humans.

Because of the very limited drug exposure, phase 0 trials offer no chance of therapeutic benefit, which can impede subject enrollment, particularly if invasive tumor biopsies are required. Although challenging, the potential barriers to enrollment can be dealt with successfully or minimized by careful attention to the protocol design and informed consent process. In addition, it may be helpful to discuss the proposed trial and obtain input from institutional bioethics staff in the development of the protocol design and consent document. In designing phase 0 trials, it is important to ensure that participation will not adversely affect a subject’s eligibility to participate in subsequent therapeutic trials or adversely delay standard therapy. In addition, receiving a drug as part of a phase 0 trial should not prohibit the subject from enrolling in other protocols with that agent or class of agents. Given the non-therapeutic nature and the very limited non-toxic drug exposure, subjects should not be required to wait the standard 4 weeks for "washout" before starting another trial. Shorter washout periods, such as 2 weeks or less, are probably sufficient. Keeping these points in mind when designing protocols can help overcome some of the potential barriers to enrollment.
Phase 0 trials do not replace phase 1 trials conducted to establish affective dose on molecular target, dose-limiting toxicities and define a recommended phase 2 dose. Nevertheless, data from phase 0 trials supplement subsequent phase 1 studies by allowing them to begin at a higher, potentially more efficacious dose, use a more limited and rationally focused schedule for PK and PD sampling, and apply a qualified PD analytic assay for assessing target modulation and reliable standard operating procedures for human tissue acquisition, handling, and processing. The timelines for data submission and thresholds for expedited adverse event reporting to CTEP may differ from phase 1 trials depending on the particular protocol. Furthermore, the exploratory IND will be withdrawn when the phase 0 trial is completed.

Well-designed and executed phase 0 trials are feasible and have great potential for improving the efficiency and success of subsequent trials, particularly those evaluating molecularly targeted agents. However, the range of resources required for the preclinical and clinical aspects of phase 0 studies, particularly those evaluating target or biomarker effects, is not available at most academic institutions. Because of the non-therapeutic nature of the trials, third party payers are not likely to cover the associated clinical care costs. At minimum, such phase 0 trials require a dedicated PD assay development laboratory and staff who have the necessary expertise in biomarker analytic assay development and validation, as well as the facilities for clinical human tissue PD and PK studies that can be done in real time. Also necessary are a well-organized system for biospecimen procurement and processing and an efficiently integrated and dedicated team of laboratory and clinical investigators with expertise in the conduct of early-phase trials.

More information about phase 0 trials can be found on the DCTD web site [http://dctd.cancer.gov/MajorInitiatives/Sep0507Phase0Workshop/workshop.htm](http://dctd.cancer.gov/MajorInitiatives/Sep0507Phase0Workshop/workshop.htm)
Appendix III

Policy Statement: The Conduct of Phase 1 and 2 Trials in Children

Introduction
For more than four decades, the NCI has supported evaluations of new agents and new treatment approaches for children with cancer. This support has contributed to the identification of curative treatments for more than 75% of children with cancer and has allowed children with cancer to have access to a broad range of new anticancer agents. However, despite these advances, in excess of 2000 children and adolescents in the U.S. continue to die from cancer each year. The pace of the decline in childhood cancer mortality slowed beginning in the late 1990s and this trend continued into the new decade. Novel treatment strategies and agents are required to identify curative treatments for these patients. An integral component of the NCI research program for children with cancer is the evaluation of new agents in pediatric phase 1 trials. Phase 1 trials are essential in order for children to benefit from recent advances in molecular biology and agent discovery that have led to the development of new classes of molecularly targeted agents.

Phase 1 trials for children differ in several fundamental ways from those performed in adult populations.

- Adult phase 1 trials are usually conducted at single institutions. Because of the relative rarity of cancer in children, pediatric phase 1 trials can rarely be performed efficiently by a single institution, and for this reason the NCI generally supports multi-institutional pediatric phase 1 trials. In multi-institutional phase 1 trials, it is essential that the flow of information between the participating institutions, the Operations/Data Center, the Study Chair, and the NCI be timely and accurate.

- Pediatric phase 1 trials also differ from adult phase 1 trials in the timing of their initiation and in their starting dose. As described in more detail below, it is common practice to begin pediatric phase 1 trials following completion of the initial adult phase 1 experience with an agent, and to begin the pediatric phase 1 trial at approximately 80% of the recommended phase 2 dose in adults.

Additional information about the design and conduct of pediatric phase 1 trials is available in published position papers and review articles Additional information about the design and conduct of pediatric phase 1 trials is available in published position papers and review articles [1-3].

Phase 2 trials for children with cancer have the objective of identifying clinically relevant activity for study agents against specific childhood cancers. Like pediatric phase 1 trials, phase 2 trials almost always require multi-institutional collaboration. Most pediatric phase 2 trials are conducted through the Children’s Oncology Group (COG). The NCI-supported COG develops and coordinates cancer clinical trials at its more than 200 member institutions, which include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG conducts phase 2 trials for the more common types of cancers occurring in children. A common strategy for pediatric phase 2 trials is to have a single trial evaluate the activity of the study agent against multiple types of childhood cancer, with each different cancer type evaluated individually within its own stratum. Typically pediatric
phase 2 trials enroll 20-30 patients per disease stratum, and they utilize standard two-stage designs.

Selection of Institutions for Participation in Phase 1 Trials
Most NCI-sponsored pediatric phase 1 trials are performed by consortia that include 10 to 20 institutions [e.g., the COG Phase 1/Pilot Consortium and the Pediatric Brain Tumor Consortium]. Members are carefully selected based on their experience in developing and participating in early phase trials, ability to carefully monitor patients treated on phase 1 studies, capabilities in reporting clinical data in a timely manner to the Operations/Data Center, resources for collection of specimens for required correlative and pharmacokinetic studies, and ability to contribute to the scientific leadership of the Consortium (e.g., pharmacokinetics, pharmacogenetics, and correlative biology). Institutions must be committed to offering patients participation in phase 1 trials, timely submission of all required data and blood/tissue specimens, and compliance with federal regulations for the protection of research subjects.

Timing of Initiation and Starting Dose for Pediatric Phase 1 Trials
Pediatric phase 1 trials commonly start once the adult recommended phase 2 dose has been established. The starting dose for adult phase 1 trials is often 10% of the dose found to be lethal to 10% of rodents in toxicology studies. This low dose is selected to minimize the risk of severe adverse events among the first humans receiving new agents. Although the initial dose escalations are large in adult phase 1 studies, it is not uncommon in these studies to evaluate ten or more dose levels before dose-limiting toxicity is reached. Completion of studies with a large number of dose levels requires a substantial number of patients. In contrast, the starting dose for pediatric phase 1 studies is usually 80% of the adult recommended phase 2 dose, and the trial escalates in 25-30% increments as successive cohorts of children are accrued to the study. By taking advantage of the adult phase 1 maximum tolerated dose (MTD) to determine the pediatric phase 1 starting dose:

- Pediatric phase 1 trials commonly require fewer than five dose levels and fewer patients to establish the pediatric MTD.
- The occurrence of unanticipated, severe adverse events at the starting dose levels is minimized, as there is considerable adult experience documenting the agent’s adverse event profile.
- All children entered onto a phase 1 study receive a dose of the agent that is near the adult phase 2 dose.

This strategy has been successfully employed for over a decade, and in most cases has allowed the efficient determination of a pediatric MTD that is 80% or more of the adult MTD. With this approach, pediatric phase 1 studies can commence at a relatively early time point in the adult development program of an agent without waiting until the adult program’s completion.

For those agents that achieve target levels in adults without causing dose-limiting toxicity (DLT), the initial pediatric experience can generally begin at the dose in adults that result in the desired biological/clinical effect. In this setting, dose escalation may be limited to a single dose level above the adult recommended phase 2 dose (RP2D). Selection of the pediatric RP2D can be based on the pharmacokinetic profile of the agent in children,
selecting a dose level that achieves adequate drug concentrations based on preclinical
and adult experience with the agent.

**Prioritization of Agents for Phase 1 Evaluation in Children**
Hundreds of new agents are currently under evaluation for cancer indications in adults. Only a small fraction of these can be evaluated in children with cancer as a result of the thankfully small number of children eligible for clinical trials evaluating new agents. Because of this increasing imbalance between the number of new agents potentially available for pediatric evaluation and the number that can actually be evaluated, it is essential to prioritize new anticancer agents for testing in children effectively.

Data from pediatric preclinical models may provide information that is useful in prioritizing new anticancer agents for testing in children. NCI supports the Pediatric Preclinical Testing Program (PPTP) based on the premise that a systematic approach to developing preclinical data for specific childhood cancers may provide sufficiently reliable data to allow prioritization of truly active agents for pediatric clinical evaluation. Detailed information about the PPTP and its testing procedures is available at the [PPTP web site](http://pptp.stjude.org/index.php), as are publications ([http://pptp.stjude.org/publications.php](http://pptp.stjude.org/publications.php)) and meeting presentations ([http://pptp.stjude.org/presentations.php](http://pptp.stjude.org/presentations.php)) describing PPTP testing results. Agent prioritization decisions can also be based on the genomic characteristics of specific childhood cancers, as genes that are consistently altered by mutation, copy number change, or loss-of-heterozygosity may highlight cellular pathways for therapeutic exploitation.

**Protocol Development and Approval**
Pediatric phase 1 protocols developed by the NCI-sponsored pediatric consortia should be preceded by a written Letter of Intent (LOI) from the Consortium to the CTEP LOI Coordinator declaring interest in conducting a particular study. The LOI should describe the hypothesis to be investigated, the general design of the contemplated trial, plus relevant information on accrual capabilities to document feasibility. Protocols are to be developed and submitted, and studies are to be conducted, in accordance with the DCTD "Investigator's Manual". Consortia Operations Centers communicate the results of the NCI's LOI and protocols reviews to their member institutions and to relevant committees. All protocols utilizing NCI-sponsored investigational agents are to be conducted in accordance with the "Intellectual Property Option to Collaborators", [http://ctep.cancer.gov/industry/ipo.html](http://ctep.cancer.gov/industry/ipo.html), and the NCI Standard Protocol Language for Cooperative Research and Development Agreements (CRADAs) and Clinical Trial Agreements (CTAs).

**Agent Distribution**
For phase 1 trials utilizing study agents distributed by CTEP, agents may be requested by the Principal Investigator (or their authorized designee) at each participating institution. Pharmaceutical Management Branch (PMB) policy requires that agent be shipped directly to the institution at which the patient is to be treated. PMB does not permit the transfer of agents between institutions (unless prior approval from PMB is obtained.) The CTEP assigned protocol number must be used for ordering all CTEP supplied study agents. The responsible investigator at each participating institution must be registered with CTEP, DCTD, through an annual submission of FDA Form 1572, a CV, the Supplemental Investigator Data Form, and the Financial Disclosure Form. If there are several participating investigators at one institution, CTEP supplied agents for
the study should be ordered under the name of one lead investigator at that institution. Agent may be requested by completing a Clinical Drug Request (NIH-986) and mailing it to the Pharmaceutical Management Branch, DCTD, NCI, EPN Room 7149, Bethesda, MD 20892 or faxing it to (301) 480-4612.

**Study Monitoring**

Pediatric consortia conducting phase 1 studies are responsible for assuring accurate and timely knowledge of the progress of each study by:

- Establishing procedures for assigning dose level (for phase 1/dose escalation studies) at the time a new patient is entered, and assuring that the required observation period has elapsed before beginning a higher dose level;
- Documenting and reporting registration, tracking, and attempts to accrue patients who fulfill NIH HHS Guidelines for accrual of women and minorities to clinical trials as specified by NIH HHS Guidelines;
- Ongoing assessment of case eligibility and evaluability, and ongoing assessment of patient accrual and adherence to defined accrual goals;
- Handling medical review, quality control, and assessment of patient data promptly;
- Reporting treatment-related morbidity (adverse events) and measures to ensure communication of this information to all parties rapidly; and
- Conducting interim evaluation and consideration of measures of outcome, as consistent with patient safety and good clinical trials practice for phase 1 and pilot studies.

**Data and Safety Monitoring Policies**


**Adverse Event (AE) Reporting**

Each pediatric consortia conducting phase 1 trials is responsible for establishment of a system for assuring timely reporting of all serious and/or unexpected adverse events. For investigational agents sponsored by the NCI, this involves reporting to the Investigational Drug Branch (IDB), CTEP via the AdEERS system, http://ctep.cancer.gov/reporting/adeers.html, according to CTEP guidelines specified in each protocol. Each of the member institutions of the consortia is responsible for implementing the procedures established for assuring timely reporting of all serious and/or unexpected adverse events.

**Site Visit Monitoring**

The pediatric consortia conducting phase 1 trials must establish an on-site monitoring program in accordance with the Clinical Trials Monitoring Branch (CTMB, CTEP). For the C.O.G. Phase 1 Consortium, this involves annual on-site auditing of member institutions by the Clinical Trials Monitoring Service (CTMS). The on-site audit program addresses issues of data verification, protocol compliance, compliance with regulatory requirements for the protection of human subjects, and investigational agent
accountability. Any serious problems with data verification or compliance with Federal regulations must be reported to the Clinical Trials Monitoring Branch immediately. The Operations/Data Center will be responsible for coordinating development of and compliance with corrective programs in response to audits.

**Pediatric Exclusivity**

Section 111 of the Food and Drug Administration Modernization Act of 1997 (the Modernization Act) created section 505A of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 355a). Section 505A permits certain marketing applications to obtain an additional 6 months of marketing exclusivity (i.e., “pediatric exclusivity”) if the applicant, in response to a Written Request from the FDA, files reports of investigations studying the use of the agent in the pediatric population. The pediatric exclusivity provisions were extended until October, 2012 by the “Best Pharmaceuticals for Children Act of 2007”. Guidance from the FDA prescribes the general need for pediatric phase 1 studies as a condition for obtaining “pediatric exclusivity” (see [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM080558.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM080558.pdf)). The guidance recommends that when planning pediatric protocols, pharmaceutical sponsors should discuss protocol designs with a pediatric cooperative study group, as these groups have experience, expertise, and resources that can help applicants optimize their study designs and accrue patients. The NCI-sponsored consortia for conducting phase 1 trials, as well as CTEP staff, are available to assist pharmaceutical sponsors in evaluating whether their agents warrant consideration for pediatric exclusivity, and if so, the design of the early phase studies that would be appropriate to conduct in order to obtain exclusivity.

**Reference List**

### Appendix IV

**Key Contact Information**

<table>
<thead>
<tr>
<th>For Overnight Commercial Carrier, use the following street address:</th>
<th>For all other U.S. Mail correspondence, the address is as follows:</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTEP/DCTD/NCI</td>
<td>Cancer Therapy Evaluation Program</td>
</tr>
<tr>
<td>Executive Plaza North, Room <strong>*</strong>__</td>
<td>Executive Plaza North, Room <strong><strong>*</strong></strong></td>
</tr>
<tr>
<td>6130 Executive Boulevard</td>
<td>6130 Executive Boulevard</td>
</tr>
<tr>
<td>Rockville, MD 20852</td>
<td>Bethesda, MD 20892</td>
</tr>
</tbody>
</table>

*Please refer to table for appropriate Room Number*

**EXAMPLE:**

<table>
<thead>
<tr>
<th>Inquiry Type</th>
<th>Room Number</th>
<th>Telephone</th>
<th>FAX</th>
<th>E-mail and/or Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocols and Amendments (Administrative Queries)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol and Information Office</td>
<td>7000</td>
<td>301-496-1196</td>
<td>301-402-0428</td>
<td><a href="mailto:PIO@ctep.nci.nih.gov">PIO@ctep.nci.nih.gov</a></td>
</tr>
<tr>
<td>Clinical Drug Requests</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Information: General Questions and Requests for Non-clinical Use of Investigational Agents</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmaceutical Management Branch</td>
<td>7149</td>
<td>301-496-5725</td>
<td>301-402-0429</td>
<td><a href="mailto:PMBafterhours@mail.nih.gov">PMBafterhours@mail.nih.gov</a></td>
</tr>
<tr>
<td>Investigational Agent Request for Special Exceptions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmaceutical Management Branch</td>
<td>7149</td>
<td>301-496-5725</td>
<td>301-402-4870</td>
<td><a href="mailto:PMBafterhours@mail.nih.gov">PMBafterhours@mail.nih.gov</a></td>
</tr>
<tr>
<td>Investigator Brochures (Registered Investigators Only)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmaceutical Management Branch</td>
<td>7149</td>
<td>301-496-5725</td>
<td>301-402-0429</td>
<td><a href="mailto:ibcoordinator@mail.nih.gov">ibcoordinator@mail.nih.gov</a></td>
</tr>
<tr>
<td>Investigator Registration Information</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmaceutical Management Branch</td>
<td>7149</td>
<td>301-496-5725</td>
<td>301-402-0429</td>
<td><a href="mailto:PMBregpend@mail.nih.gov">PMBregpend@mail.nih.gov</a></td>
</tr>
<tr>
<td>Quality Assurance, Site Visits, Monitoring and Informed Consent Issues</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials Monitoring Branch</td>
<td>6103</td>
<td>301-496-0510</td>
<td>301-480-2642</td>
<td><a href="mailto:mauerj@mail.nih.gov">mauerj@mail.nih.gov</a></td>
</tr>
<tr>
<td>Regulatory Affairs Questions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Regulatory Group</td>
<td>7111</td>
<td>301-496-7912</td>
<td>301-402-1584</td>
<td><a href="mailto:casadeij@mail.nih.gov">casadeij@mail.nih.gov</a></td>
</tr>
<tr>
<td>Agreement Questions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agreement Coordination Group</td>
<td>7111</td>
<td>301-496-7912</td>
<td>301-402-1584</td>
<td><a href="mailto:agreements@tech-res.com">agreements@tech-res.com</a></td>
</tr>
<tr>
<td>Agreement Coordination Group</td>
<td>7111</td>
<td>301-496-7912</td>
<td>301-402-1584</td>
<td><a href="mailto:NCICTEPpubs@mail.nih">NCICTEPpubs@mail.nih</a></td>
</tr>
<tr>
<td><strong>Manuscript, Abstract or Press Release Clearance</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agreement Coordination Group</td>
<td>7111</td>
<td>301-496-7912</td>
<td>301-402-1584</td>
<td><a href="mailto:NCICTEPpubs@mail.nih">NCICTEPpubs@mail.nih</a></td>
</tr>
</tbody>
</table>

**Disease Related Questions (Cooperative Groups and Phase 3 Trials)**


**Agent Related Questions (Early Phase Clinical Trials)**


**Possible Scientific Misconduct**

| Clinical Trials Monitoring Branch | 6103 | 301-496-0510 | 301-480-2642 | mauerj@mail.nih.gov |

**Clinical Grants and Contracts**

Appendix V

Informed Consent Checklist

Required Elements

For phase 3 trials, the NCI Informed Consent Template must be used as found at the following URL: http://www.cancer.gov/clinicaltrials/understanding/simplification-of-informed-consent-docs/page3. The Template should be followed as closely as is feasible for trials in other phases. In all cases, the informed consent document should be in layman’s terms and formatted on each page to allow for adequate white space to facilitate reading and comprehension.

The Template has been designed to comply with 45 CFR 46.116 (a) and (b) however when it is not feasible to use the Template, the above cited regulations mandate the following basic elements of informed consent information be provided to each study participant:

1. A statement that the study involves research, including the following:
   • State which agent(s), treatment(s), or delivery technique(s) is/are experimental?
   • Briefly state the study’s purpose(s) in layman’s terms.
   • State the study participant’s expected duration of participation in study (e.g., the patient will be treated until there is evidence that therapy is no longer effective).
   • Provide a brief description of necessary procedure(s) to be performed (e.g., X-rays, lab evaluations, etc.) and indicate the frequency of each (e.g., tests which are part of regular care, tests which are part of regular care however done more frequently, etc.). An exhaustive list is not necessary.
     1. Identify any procedures which are experimental.
     • State in specific terms the route of administration of each agent/drug (e.g., I.V., oral, continuous infusion, etc.)
     • State estimated time of delivery of each agent/drug or time of procedure (e.g., 5 minutes, 30 minutes, 24 hours, etc.)

2. State which reasonably foreseeable risks or discomforts are attributed to a specific agent(s), drug(s), or procedure(s). For phase 3 trials, the risks should be listed by regimen. For CTEP supplied investigational agents the lay terms in the Risk List must be used in the informed consent.

3. Describe any benefit(s) to the study participant or others which may reasonably be expected from participation in the study.

4. Disclose appropriate alternative treatment(s) or procedures that might provide benefit to the study participant (e.g., conventional chemotherapy, radiation therapy, hormonal therapy, surgery, etc.).
5. Describe to what extent confidentiality of records will be maintained. Organizations that may look at and/or copy medical record for research, quality assurance, and data analysis include:
   - Relevant organizations like study sponsor, pharmaceutical company collaborators, local IRB, etc.
   - The National Cancer Institute (NCI) and other government agencies, like the Food and Drug Administration (FDA), involved in keeping research safe for people.

6. Explanation as to whether compensation and/or medical treatments are available if study-related injury occurs and if so, what they consist of and where additional information may be obtained.

   Provide explanation of whom to contact, including contact information, for answers to pertinent questions about the research, research subject’s rights, and whom to contact in the event of a research-related injury.

7. Clearly state that participation is voluntary.
   - State that refusal to participate will involve no penalty or loss of benefits
   - State that the study participant by discontinue participation in the study at any time without penalty and will involve no loss of benefits to which the patient is entitled.

Additional Elements

When it is not feasible to use the Template, the above cited regulations mandate the following additional elements of informed consent information be provided to each study participant, when appropriate:

1. State that unforeseeable risk(s) to the study participant (or to the study participant’s embryo or fetus) may be involved. For CTEP supplied investigational agents the lay terms in the Risk List must be used in the informed consent.
2. Describe circumstances under which the investigator may end the study participant’s participation without regard to his or her consent.
3. Describe any additional costs the study participant may incur due to participation in the study.
4. Describe the consequences of the study participant’s decision to withdraw from the study and procedures that might be necessary to permit a safe and orderly end of participation.
5. Include a statement that the investigator will discuss significant new findings learned during the course of the research that may change the study participant’s willingness to continue to participate in the study with the study participant.
6. State the approximate number of study participants involved in the study.

Suggested Elements

1. Number the pages, including the total number of pages, so study participants can verify they have all pages.
2. Describe risks as outlined in the Template: ‘Likely’, viewed as occurring in greater than 20% of study participants; ‘Less Likely’, viewed as occurring in less than or equal to 20% of study participants; ‘Rare but Serious’ side effects that occur in less than 2-3% of study participants however may require hospitalization or may be irreversible, long-term, life-threatening, or fatal. Side effects that occur in less than 2-3% of study participants and are not serious, as described in the previous sentence do not have to be included. Agent related adverse events that are at termed possible or greater must be included in the consent in lay terms.

3. Include Information about companion studies before the signature line on the last page of the informed consent document, and provide yes/no options at each decision point.

4. State that a copy of the informed consent document shall be given to the study participant.

5. Reference to study approval by the IRB, NCI, CTEP, or Cooperative Group may be misleading to the patient.

Consult the NCI web site, [http://www.cancer.gov/clinicaltrials/understanding/simplification-of-informed-consent-docs/page1](http://www.cancer.gov/clinicaltrials/understanding/simplification-of-informed-consent-docs/page1), to access the complete document titled Simplification of Informed Consent Documents to find additional information and recommendations regarding writing informed consent documents and about the informed consent process.
Appendix VI

CTEP Glossary

**ACTIVATION**: The decision by Group/Institution to open a study for patient entry (which occurs only after CTEP approval).

**ACTIVATION AMENDMENT**: Any protocol change that occurs after CTEP approval and prior to local activation. Examples: CTEP approves the study with recommendations that are incorporated prior to activation; the investigator must list these changes and submit them to CTEP as an activation amendment.


**AE**: Adverse Event - Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medical treatment or procedure regardless of whether it is considered related to the medical treatment or procedure.

**AGREEMENT COORDINATION GROUP**: a group within the Regulatory Affairs Branch which is responsible for collaborative agreements between NCI and pharmaceutical companies and between NCI and academic institutions.

**AMENDMENT**: Any protocol change that occurs after activation.

**APPROVAL**: CTEP approves the protocol in writing when the science and informed consent are acceptable, the IRB documentation is on file (not applicable to Groups), and the agents to be supplied are specified by the Pharmaceutical Management Branch. If recommendations are specified, CTEP expects an "Activation Amendment" to indicate any changes to the approved document.

**APPROVAL ON HOLD**: The protocol document is approved by CTEP but outstanding issues prevent study activation i.e. IRB approval or drug supply.

**BLA**: *Biologics License Application* - The formal process by which the FDA makes a biological product generally available to patients and physicians for specific indications.

**BRB**: Biometric Research Branch, [http://dctd.cancer.gov/ProgramPages/brb/default.htm](http://dctd.cancer.gov/ProgramPages/brb/default.htm), DCTD, NCI.

**CANCER CENTER**: An institution designated by the NCI as a comprehensive or clinical cancer center and eligible to conduct IND investigational agent studies.

**CANCER CLINICAL TRIALS SEARCH**: a website to search for information on cancer clinical trials [http://www.cancer.gov/search/SearchClinicalTrials.aspx](http://www.cancer.gov/search/SearchClinicalTrials.aspx)

**CCOP**: Community Clinical Oncology Program - A cooperative agreement supported program that provides support to community-based oncologists to participate in clinical trials sponsored by clinical cooperative groups and/or cancer centers. Each CCOP is expected to enter a minimum of 50 patients annually on NCI approved research protocols. [http://prevention.cancer.gov/programs-resources/programs/ccop](http://prevention.cancer.gov/programs-resources/programs/ccop)

**CIB**: Clinical Investigations Branch, [http://ctep.info.nih.gov/branches/cib/default.htm](http://ctep.info.nih.gov/branches/cib/default.htm), CTEP, DCTD, NCI.


**CLINICAL COOPERATIVE GROUPS**: Cancer clinical cooperative groups are composed of investigators who join together to develop and implement common protocols. The characteristic of cooperative groups is the central operations and statistical offices which support the administrative requirements of the research and perform central data collection and analysis.
CLINICAL SITE: An institution, cooperative group, Cancer Center or Consortia that assumes a broad range of responsibilities and functions for the support of clinical trials conducted under its name. It supports the investigator in developing, organizing, implementing, and analyzing clinical trials. It assumes responsibility for the quality of the research, both in concept and execution, and has an important role in assuring patient safety.

CLINICALTRIALS.GOV: offers up-to-date information for locating federally and privately supported clinical trials for a wide range of diseases and conditions http://clinicaltrials.gov/

CLINICAL TRAIL MONITORING SERVICE: An organization that receives, reviews, and performs data management tasks on individual patient case report forms for phase 1 and some phase 2 NCI investigational agent studies.

CLOSED A: (Protocol Status) Study is closed to accrual.

CLOSED B: (Protocol Status) Study is closed to accrual and treatment.

COMPLETE: (Protocol Status) The study is closed and no patients are being treated or followed for data collection. At this time a final report or summary of study results has been submitted to CTEP.

COOPERATIVE ONCOLOGY GROUP ASSURANCE: An agreement for the protection of human research subjects filed with the Office for Human Research Protections (OHRP), http://www.hhs.gov/ohrp/, by an institution participating in cooperative group trials.


DCTD: Division of Cancer Treatment and Diagnosis, NCI, http://dctd.cancer.gov/


Drug Regulatory Group, Regulatory Affairs Branch (RAB), CTEP, DCTD, NCI. Involved in IND and FDA related activities.
http://ctep.cancer.gov/branches/rab/default.htm


FDA: Food and Drug Administration, http://www.fda.gov/, DHHS.

FDA 1572: Also referred to as a "Statement of Investigator;" it is a requirement of Section 505(I) of the Food, Drug and Cosmetic Act and 312.1 of Title 21 CFR, that an investigator complete this form as a condition for receiving and conducting clinical studies involving investigational agent(s). It includes the investigator's training and experience and provides for legal certifications, http://ctep.cancer.gov/forms/index.html.

FEDERAL WIDE ASSURANCE: Under an FWA, an institution commits to HHS that it will comply with the requirements set forth in 45 CFR part 46, as well as the Terms of Assurance, http://www.hhs.gov/ohrp/assurances/assurances_index.html


IND: Investigational New Drug Application - The legal mechanism under which experimental agent research is performed in the United States. An IND is submitted to the Food and Drug Administration in order to receive an exception from premarketing approval requirements so that experimental clinical trials may be conducted.

INVESTIGATOR: Any physician who assumes full responsibility for the treatment and evaluation of patients on research protocols as well as the integrity of the research data.

INVESTIGATOR’S BROCHURE: A document containing all relevant information about the agent, including animal screening, preclinical toxicology, and detailed pharmaceutical data. Also included, if available, is a summary of current knowledge about pharmacology and mechanism of action and a full description of the clinical toxicities.

INVESTIGATIONAL AGENT: in accordance with 21 C.F.R. § 50.3(j), any drug (including a biological product), medical device, food additive, color additive, electronic product, or any other article subject to regulation under the Federal Food, Drug, and Cosmetic Act that is intended for administration to humans or animals.

LOI (CLINICAL PROTOCOL): Letter of Intent - An investigator’s declaration of interest in conducting a phase 1, 2, or pilot trial with a specific investigational agent in a particular disease. Approval of the LOI by CTEP commits an investigator to submit a protocol within a specified time frame.


MULTIPLE PROJECT ASSURANCE (MPA): A formal written agreement with the Office of Human Research Protection, http://ohrp.osophs.dhhs.gov/index.html, (on behalf of the Secretary of DHHS) and an institution which conducts or supports a large amount of DHHS-sponsored research involving human subjects. The MPA specifies how the institution will implement the DHHS regulations 45 CFR 46.

NCI: National Cancer Institute, http://www.cancer.gov/, NIH, DHHS.

NDA: New Drug Application - The formal process by which the FDA makes the agent generally available to patients and physicians for specific indications.

NEW DRUG STUDIES GROUP: Highly qualified clinical researchers at an institution specifically approved by IDB to participate in NCI’s agent development program.


OHRP: Office of Human Research Protection,

PIO: The Protocol and Information Office is within the Operations and Information Branch, CTEP, DCTD, NCI. PIO manages the protocol and amendment review process, LOIs, and Concepts and maintains the official record of all NCI-sponsored protocols.

http://ctep.cancer.gov/branches/pio/default.htm

PMB: Pharmaceutical Management Branch,

http://ctep.cancer.gov/branches/pmb/default.htm, CTEP, DCTD, NCI.

PRB: Pharmaceutical Resources Branch, DTP, DCTD, NCI.

PRC: The CTEP Protocol Review Committee reviews and approves all studies involving CTEP-supported study agents

PRINCIPAL INVESTIGATOR (PI): Name of physician who has organizational and fiscal responsibility for the use of federal funds to conduct a clinical study.

PROTOCOL CHAIR: The scientific coordinator of the study who is responsible for developing and monitoring the clinical study as well as analyzing, reporting, and publishing its results.

QACS: Quality Assurance and Compliance Section, Clinical Trials Monitoring Branch (CTMB), http://ctep.cancer.gov/branches/ctmb/default.htm, CTEP, DCTD, NCI.

QUALITY ASSURANCE: The monitoring of a clinical trial to assure the quality of the data that supports scientific conclusions.

REVISIONS: Any protocol change that occurs between initial submission and CTEP approval and official filing.

SENIOR CLINICAL INVESTIGATOR: A physician in the IDB who is assigned to an IND agent to coordinate its clinical development. Each investigational agent has a Senior Clinical Investigator assigned to it.

SINGLE PROJECT ASSURANCE (SPA): A formal written agreement with the Office of Human Research Protection (OHRP), (on behalf of the Secretary of DHHS) and an institution which does not have Multiple Project Assurance and conducts a DHHS-sponsored research project. The SPA specifies how the institution will implement the DHHS regulations at 45 CFR 46. [http://www.hhs.gov/ohrp/humansubjects/assurance/asur.htm](http://www.hhs.gov/ohrp/humansubjects/assurance/asur.htm)

SPONSOR: An organization or individual who assumes legal responsibility for supervising or overseeing clinical trials with investigational agents.

TEMPORARILY CLOSED: (Protocol Status) The decision by a Group, Institution, or NCI to stop patient entry pending study evaluation.
Appendix VII

National Study Commission on Cytotoxic Exposure: Recommendations for Handling Cytotoxic Agents

Many cytotoxic agents’ mutagenic, teratogenic, carcinogenic, and local irritant properties are well established and pose a possible health hazard to occupationally exposed individuals. These potential hazards necessitate special attention to the procedures used in their handling, preparation and administration, and proper disposal of residues and wastes. These recommendations are intended to provide information for the protection of personnel participating in the clinical process of chemotherapy. It is the responsibility of institutional and private health care providers to adopt and use appropriate procedures for protection and safety.

See also: http://dohs.ors.od.nih.gov/

Environmental Protection
- Preparation of cytotoxic agents should be performed in a Class II biological safety cabinet located in an area with minimal traffic and air turbulence. Class II Type A cabinets are the minimal requirement. Class II cabinets which are exhausted to the outside are preferred.
- The biological safety cabinet must be certified by qualified personnel at least annually or any time the cabinet is physically moved.

Operator Protection
- Disposable surgical latex gloves are recommended for all procedures involving cytotoxic agents.
- Gloves should routinely be changed approximately every 30 minutes when working steadily with cytotoxic agents. Gloves should be removed immediately after overt contamination.
- Protective barrier garments should be worn for all procedures involving the preparation and disposal of cytotoxic agents. These garments should have a closed front, long sleeves and closed cuff (either elastic or knit).
- Protective garments must not be worn outside the work area.

Techniques and precautions for use in the class II Biological Safety Cabinet
- Special techniques and precautions must be utilized because of the vertical (downward) laminar airflow.
- Clean surfaces of the cabinet using 70% alcohol and a disposable towel before and after preparation. Discard towel into a hazardous chemical waste container.
- Prepare the work surface of the biological safety cabinet by covering it with a plastic-backed absorbent pad. This pad should be changed when the cabinet is cleaned or after a spill.
- The biological safety cabinet should be operated with the blower on, 24 hours per day - seven days a week. Where the biological safety cabinet is utilized infrequently (e.g. 1 or 2 times weekly) it may be turned off after thoroughly cleaning all interior surfaces. Turn on the blower 15 minutes before beginning work in the cabinet.
Agent preparations must be performed only with the view screen at the recommended access opening. Professionally accepted practices concerning the aseptic preparation of injectable products should be followed.

All materials needed to complete the procedure should be placed into the biological safety cabinet before beginning work to avoid interruptions of cabinet airflow. Allow a two to three minute period before beginning work for the unit to purge itself of airborne contaminants.

The proper procedures for use in the biological safety cabinet differ from those used in the horizontal laminar hood because of the nature of the airflow pattern. Clean air descends through the work zone from the top of the cabinet toward the work surface. As it descends, the air is split, with some leaving through the rear perforation and some leaving through the front perforation.

The least efficient area of the cabinet in terms of product and personnel protection is within three inches of the sides near the front opening, and work should not be performed in these areas.

Entry into and exit from the cabinet should be in a direct manner perpendicular to the face of the cabinet. Rapid movements of the hands in the cabinet and laterally through the protective air barrier should be avoided.

**Compounding Procedures and Techniques**

- Hands must be washed thoroughly before gloving and after gloves are removed.
- Care must be taken to avoid puncturing of gloves and possible self-inoculation.
- Syringes and I.V sets with Luer-lock fittings should be used whenever possible to avoid spills due to disconnection.
- To minimize aerosolization, vials containing cytotoxic agents should be vented with a hydrophobic filter to equalize internal pressure, or utilize negative pressure technique.
- Before opening ampules, care should be taken to insure that no liquid remains in the tip of the ampule A sterile disposable sponge should be wrapped around the neck of the ampule to reduce aerosolization. Ampules should be broken in a direction away from the body.
- For sealed vials, final agent measurement should be performed prior to removing the needle from the stopper of the vial and after the pressure has been equalized.
- A closed collection vessel should be available in the biological safety cabinet or the original vial may be used to hold discarded excess agents solutions.
- Cytotoxic agents should be properly labeled to identify the need for caution in handling (e.g., "Chemotherapy: Dispose of properly)
- The final prepared dosage form should be protected from leakage or breakage by being sealed in a transparent plastic container labeled "Do Not Open if Contents Appear to be Broken."

**Precautions for Administration**

- Disposable surgical latex gloves should be worn during administration of cytotoxic agents. Hands must be washed thoroughly before gloving and after gloves are removed.
- Protective barrier garments may be worn. Such garments should have a closed front, long sleeves and closed cuffs (either elastic or knit)
- Syringes and I.V sets with Luer-lock fittings should be used whenever possible.
• Special care must be taken in priming I.V. sets. The distal tip or needle cover must be removed before priming. Priming can be performed into a sterile, alcohol-dampened gauze sponge. Other acceptable methods of priming such as closed receptacles (e.g., evacuated containers) or back-filling of I.V. sets may be utilized. Do not prime sets or syringes into the sink or any open receptacle.

**Disposal Procedures**

• Place contaminated materials in a leak proof, puncture-proof container appropriately marked as hazardous chemical waste. These containers should be suitable to collect bottles, vials, gloves, disposable gowns and other materials used in the preparation and administration of cytotoxic agents.
• Contaminated needles, syringes, sets and tubing should be disposed of intact. In order to prevent aerosolization, needles and syringes should not be clipped.
• Cytotoxic agent waste should be transported according to the institutional procedures for hazardous material.
• There is insufficient information to recommend any preferred method for disposal of cytotoxic agent waste.
  • One acceptable method for disposal of hazardous waste is by incineration in an Environmental Protection Agency (EPA) permitted hazardous waste incinerator.
  • Another acceptable method of disposal is by burial at an EPA permitted hazardous waste site.
  • A licensed hazardous waste disposal company may be consulted for information concerning available methods of disposal in the local area.

**Personal Policy Recommendations**

• Personnel involved in any aspect of the handling of cytotoxic agents must receive an orientation to the agents, including their known risks, and special training in safe handling procedures.
• Access to the compounding area must be limited to authorized personnel.
• Personnel working with these agents should be supervised regularly to insure compliance with procedures.
• Acute exposures must be documented, and the employee referred for medical examination.
• Personnel should refrain from applying cosmetics in the work area. Cosmetics may provide a source of prolonged exposure if contaminated.
• Eating, drinking, chewing gum, smoking or storing food in areas where cytotoxic agents are handled is prohibited. Each of these can be a source of ingestion if they are accidentally contaminated.

**Monitoring Procedures**

• Policies and procedures to monitor the equipment and operating techniques of personnel handling cytotoxic agents should be implemented and performed on a regular basis with appropriate documentation. Specific methods of monitoring should be developed to meet the complexities of the function.
• It is recommended that personnel involved in the preparation of cytotoxic agents be given periodic health examinations in accordance with institutional policy.
**Procedure for Acute Exposure or Spills**

**Acute Exposure**
- Overtly contaminated gloves or outer garments should be removed immediately.
- Hands must be washed after removing gloves. Some cytotoxic agents have been documented to penetrate gloves.
- In case of skin contact with a cytotoxic agent, the affected area should be washed thoroughly with soap and water. Refer for medical attention as soon as possible.
- For eye exposure, flush affected eye with copious amounts of water, and refer for medical attention immediately.

**Spills**
- All personnel involved in the clean-up of a spill should wear protective barrier garments (e.g. gloves, gowns, etc.). These garments and other material used in the process should be disposed of properly.
- Double gloving is recommended for cleaning up spills.

**Position Statement**

**Handling of cytotoxic agents by women who are pregnant, attempting to conceive, or breast feeding.**

There are substantial data regarding the mutagenic, teratogenic and abortifacient properties of certain cytotoxic agents both in animals and humans who have received therapeutic doses of these agents. Additionally, the scientific literature suggests a possible association of occupational exposure to certain cytotoxic agents during the first trimester of pregnancy with fetal loss, or malformation. These data suggest the need for caution when women who are pregnant, or attempting to conceive, handle cytotoxic agents. Incidentally there is no evidence relating male exposure to cytotoxic agents with adverse fetal outcome.

There are no studies which address the possible risk associated with the occupational exposure to cytotoxic agents and the passage of these agents into breast milk. Nevertheless, it is prudent that women who are breast feeding should exercise caution in handling cytotoxic agents.

If all procedures for safe handling, such as those recommended by the Commission are complied with, the potential for exposure will be minimized.

Personnel should be provided with information to make an individual decision. This information should be provided in written form and it is advisable that a statement of understanding be signed.

It is essential to refer to individual state right-to-know laws to insure compliance.

**National Study Commission on Cytotoxic Exposure**

**Chairman**

| Louis P. Jeffrey, Sc.D. |
| Director of Pharmacy Services, Rhode Island Hospital |
| Providence, Rhode Island 02902 |
## Commissioners

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roger W. Anderson, M.S.</td>
<td>Director of Pharmacy, University of Texas System Cancer Center, M.D.</td>
<td>Anderson Hospital and Tumor Institute</td>
</tr>
<tr>
<td>Thomas H. Connor, Ph.D.</td>
<td>Assistant Professor of Environmental Sciences, Houston School of Public Health, University of Texas Health Sciences Center at Houston</td>
<td></td>
</tr>
<tr>
<td>William E. Evans, Pharm.D.</td>
<td>Director, Pharmaceutical Division, St. Jude Children's Research Hospital</td>
<td></td>
</tr>
<tr>
<td>Clarence L. Fortner, M.S.</td>
<td>Head, Drug Management and Authorization Section, IDB,CTEP Division of Cancer Treatment, National Cancer Institute</td>
<td></td>
</tr>
<tr>
<td>Joseph E. Gallelli, Ph.D.</td>
<td>Chief, Pharmacy Department, The Clinical Center, National Institutes of Health</td>
<td></td>
</tr>
<tr>
<td>Joseph N. Gallina, Pharm.D.</td>
<td>Director of Pharmacy Services, University of Maryland, Medical System Hospital</td>
<td></td>
</tr>
<tr>
<td>Dennis M. Hoffman, Pharm.D.</td>
<td>Director of Pharmacy Services, University of New York at Stony Brook</td>
<td></td>
</tr>
<tr>
<td>Louis A. Leone, M.D.</td>
<td>Director of Medical Oncology, Rhode Island Hospital</td>
<td></td>
</tr>
<tr>
<td>Suzanne A. Miller, R.N.</td>
<td>Oncology Nurse Consultant</td>
<td></td>
</tr>
<tr>
<td>Robert M. O’Bryan, M.D.</td>
<td>Division Head, Medical Oncology, Henry Ford Hospital</td>
<td></td>
</tr>
</tbody>
</table>

### For additional information contact:
Louis P. Jeffrey, Sc.D., Chairman
National Study Commission on Cytotoxic Exposure
Massachusetts College of Pharmacy and Allied Health Sciences
179 Longwood Avenue Boston, Massachusetts 02115
Appendix VIII

National Cancer Institute Procedure of Investigational Agents Acquired for Compassionate (Special Exception) Treatment of Individual Patients

Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) policy require the following steps to be completed as indicated:

1) Investigator Registration:
A physician must be registered with the National Cancer Institute as an investigator by having completed a "Statement of Investigator" FDA Form 1572, Supplemental Investigator Data Form (SIDF), Financial Disclosure Form (FDF), and a CV. Forms are available at: http://ctep.cancer.gov/investigatorResources/investigator_registration.htm
If you are NOT currently registered, a Form 1572, SIDF, and FDF are enclosed, with the understanding you will complete and return these registration forms within 10 working days of their receipt.

2) Protocol:
A brief protocol must be submitted for each patient that describes the treatment plan, toxicity, activity, and monitoring procedures. For your convenience we have devised a standard protocol form which is included and must be completed. The original must be returned to the Pharmaceutical Management Branch, 6130 Executive Boulevard, Room 7149, Bethesda, MD, 20892, within 10 working days. Please retain a copy for your records.

3) Institutional Review Board Approval:
You must obtain Institutional Review Board Approval before treating the patient and retain documentation of this approval in the patient’s medical record.

4) Informed Consent:
You must obtain a written informed consent which must be signed by the patient or their guardian before treatment. The informed consent must be retained in the patient's medical record. The informed consent should include a reasonable statement about the potential side effects of the agent. The informed consent must address each of the eight elements required under FDA regulations, as detailed on the accompanying sheet.

5) Final Patient Report:
Upon completion of therapy you must provide NCI a report of the treatment experience that describes toxicity and activity. We have enclosed the form, “The Report of the Independent Investigator.” Please return this form to the Pharmaceutical Management Branch, 6130 Executive Boulevard, Room 7149, Bethesda, MD, 20892.
6) Adverse Events:
Reporting of adverse events is required for all NCI Special Exception protocols. The following is a summary of the procedures. For more detailed instructions, computer based training, and the tools used below please see the CTEP home page at: http://ctep.cancer.gov/protocolDevelopment/default.htm#adverse_events_adeers.
Reporting requirements vary according the investigational agent. Please contact PMB for guidance on which AE reporting chart to use in the Compassionate Use/Special Exception protocol. All reports should be submitted via AdEERS.

Definitions

Adverse Event - Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medical treatment or procedure regardless of whether it is considered related to the medical treatment or procedure.

Attribution – The determination of whether an adverse event is related to a medical treatment or procedure. Attribution categories include Definite, Probable, Possible, Unlikely and Unrelated.

When reporting in AdEERS use the patient’s first name and last initial for the patient ID in the patient information section.

Procedure
1. Identify the event using the most current version of the Common Terminology Criteria for Adverse Events (CTCAE) (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm).
2. Determine the grade or severity of the event by using the CTCAE criteria. The severity is graded between 1 – 5
3. Determine Attribution of the event (Definite, Probable, Possible, Unlikely or Unrelated).
Determine how the event should be reported according to the AE chart embedded in the protocol.
7) **Investigational Drug Accountability:**
Investigational drug accountability records (Drug Accountability Record Form: [http://ctep.cancer.gov/forms/index.html](http://ctep.cancer.gov/forms/index.html)) must be maintained and retained in your records. These records may be inspected upon request by an authorized representative of the FDA, NCI or agent collaborator.

8) **Failure to comply with any of the above procedures may result in suspension of investigator status and prevent further agent shipments.**

9) **Agent Reorders:**
Additional agent may be requested by completing a Clinical Drug Request Form NIH-986 ([http://ctep.cancer.gov/forms/index.html](http://ctep.cancer.gov/forms/index.html)). You may only order more agent for the patient specifically named on this protocol. The patient's first name and initial of last name should be indicated on the Clinical Drug Request. A blank request form is enclosed in each agent shipment. Telephone orders will not be accepted.
Appendix IX

Guidelines for Treatment Regimen Expression and Nomenclature

INTRODUCTION

The Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), are reviews all protocols it sponsors for safety and scientific integrity. Cancer Therapy Evaluation Program (CTEP) staff has developed *Guidelines for Treatment Regimen Expression and Nomenclature* to express chemotherapy regimens in a uniform, clear and consistent manner. The intention is to minimize undue risks to patients on DCTD sponsored investigational clinical trials. CTEP screens all protocol-related documents (e.g. Letters of Intent, Concept Reviews, protocols, protocol amendments, protocol related publications and correspondence) to assure compliance with the treatment regimen guidelines since we cannot approve protocols unless they comply.

Clear, consistent chemotherapy dosage schedules and treatment regimens are important public health issues. Recent events have heightened awareness and concern about the potential for adverse and fatal outcomes as a consequence of medication errors with oncology agents. The American Society of Health-System Pharmacists (ASHP), the American Medical Association (AMA), and the American Nursing Association (ANA) have recommended systematic standardized approaches to reducing medication errors. Their recommendations include educating health care providers and patients regarding appropriate agent therapy, improving collaboration between health care providers, establishing dosage limits, and standardizing a prescribing vocabulary. The *Guidelines for Treatment Regimen Expression and Nomenclature* supplement and reinforce the AMA, ANA, and ASHP recommendations with specific examples illustrating how the guidelines can be applied during protocol development.

CTEP solicited comments and recommendations for the treatment regimen guidelines from clinical pharmacists from comprehensive cancer centers, home infusion services, industry and the Cooperative Group pharmacy chair. Guidelines for expressing dose regimens in treatment plans, agent orders, physician notes and product labeling have also been developed. Investigators should refer to *Standardized Guidelines for Treatment Regimens Expression and Nomenclature*, ASHP 1997, for additional information on this topic.

**POLICY**

- Instructions for dose regimens should be complete, clear, and simple to follow.
- Treatment regimens should be expressed accurately, completely and consistently throughout a protocol document.

**GENERAL GUIDELINES**

- Do not abbreviate agent names or treatment schedules. Abbreviations can be misinterpreted.
- Use complete approved generic agent names. Brand names and abbreviations are not acceptable (e.g., specify 'carboplatin' instead of CBDCA, 'cisplatin' instead of CDDP).
• Write treatment instructions clearly and explicitly. No detail (no matter how minor) should be omitted; however, avoid unnecessary redundancy.

• Delete extraneous information that may confuse readers (e.g., protocols that use only injectable agents products should not include information for a tablet formulation).

• Use consistent notation in expressing quantifiable units, (ex. either; 1mcg or 1mg; qid or Q6h; kg or m²; either arms or groups)

• Do not use abbreviations that appear on The Joint Commission/Institute of Medicine “do not use” list. In particular, do not use trailing zeroes or the Greek letter µ.

• Insist that prescribers spell out the word, "units" out to avoid confusion; a letter "U" can be easily mistaken for a zero and may result in a 10-fold overdose.

• Decimal Points -
  • Never trail a whole number with a decimal point followed by a zero (i.e., "5 mg" not "5.0 mg"). The decimal point may not be seen, resulting in a 10-fold overdose.
  • In expressing units that are less than the whole number one, the dosage should be written with a decimal point preceded by a zero (i.e., "0.125 mg" not ".125 mg"). Without the 'zero' prefix, the decimal point may be missed resulting in a dosing error.

• Body weight - Agent dosages may be expressed as a function of body surface area, body weight, or may be calculated to produce a pharmacokinetically-targeted endpoint (e.g., serum or plasma concentration or area under the curve [AUC]).
  • Specify whether clinicians should use absolute (i.e., actual), ideal, or lean body weight to calculate agent dosage as a function of body weight in the treatment plan section.
  • Include the equation describing how clinicians should calculate ideal or lean body weight if you use either.
  • If agent dosage is a function of a calculated pharmacokinetic endpoint, include the equation(s) describing how that value is calculated in the treatment plan.

• Contiguous treatment days - Specify the total number of days the agent is administered and the cycle day that treatment commences in the treatment plan. Include parenthetically the cycle days on which treatment occurs.

• Non-contiguous days - Specify the cycle days on which each dose should be given in the treatment plan.

• Cycle (or Course) duration – Specify the treatment cycle duration (or length). When a treatment regimen is 21 days in duration, the regimen will be repeated on the twenty-second, forty-third, sixty-fourth..., etc. days following treatment initiation.

• Duration of administration:
  • Indicate administration duration clearly. If an agent is to be administered on more than one day per cycle, explicitly identify each cycle day.
  • "Day One" typically describes the day on which treatment commences when treatment day enumeration is arbitrary. Avoid using 'day 0 (zero)' when describing treatment schedules unless it is necessary (e.g., when describing the day on which hematopoietic progenitor cells are
administered after a cytotoxic conditioning regimen in transplantation protocols).

- **Clarify total dose planned per treatment course** - In all treatment plans (protocols) and agent orders, identify and append parenthetically the total dose (as a function of body weight or surface area) that patients are to receive during a treatment course (or cycle).

- **Administration Dates and Times** - When appropriate include specific starting days and times. Be very clear (spell out) in directions for the twelve o'clock hour "12:00 noon" and "12:00 midnight." Expressing time by 24-hour clock notation (‘military time’) likewise precludes errors due to ambiguous 'a.m.' and 'p.m.' time notations.

- **Treatment information should contain the following elements:**

<table>
<thead>
<tr>
<th>Agent Name</th>
<th>Dosage</th>
<th>Administration vehicle name and volume</th>
<th>Administration route</th>
<th>Administration Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Example 1</td>
<td>ABC 200 mg/m²</td>
<td>0.9% sodium chloride injection 500 ml</td>
<td>Intravenously</td>
<td>Over 1 hour</td>
</tr>
<tr>
<td>Example 2</td>
<td>XYZ 50 mg/m²</td>
<td>NA</td>
<td>Orally</td>
<td>With food</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Administration Schedule</th>
<th>Number of doses to administer, treatment duration, or date when treatment should be discontinued</th>
<th>Starting dates (and times when appropriate)</th>
<th>Total amount of agent administered per course (expressed parenthetically)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Example 1</td>
<td>Every 12 hours</td>
<td>For 6 doses</td>
<td>Start on Day 1</td>
</tr>
<tr>
<td>Example 2</td>
<td>Every morning</td>
<td>For 14 days</td>
<td>Start on Day 1</td>
</tr>
</tbody>
</table>

**PARENTERAL ADMINISTRATION**

- Prepare agent products within documented stability and sterility guidelines in accordance with practitioners' local clinical and institutional policies and procedures. Change agent containers at least daily unless extended stability and sterility data are available.

- In protocol descriptions and orders for treatment, express agent dosage as the total amount of agent that will be administered from a single agent container, *i.e.*, the total amount of agent per syringe, bag, or other container that will be dispensed.

  - Exception to this rule: Agent products with extended stability, where an agent is administered from a single container for longer than 24 hours. In such cases, treatment plans and prescribers’ orders should specify the amount of agent that is administered during each 24-hour interval. Product container labels should always identify the amount of agent within the container.
• For agent admixtures that can be prepared in more than one way, institute reasonable, standard and consistent methods governing how each agent will be prepared and administered.
• Include specific fluid volumes and types when possible.

EXAMPLES

**Bolus infusion (administration duration < 24 hours):**
• Express the amount of agent per container.
• Include the rate of administration, the infusion duration, and days on which the agent is to be administered.

**example**
"XYZ" 15 mg/m² diluted in 50 mL 0.9% sodium chloride injection, infuse intravenously over 15 minutes for one dose on day 1 (total dose/cycle = 15 mg/m²)

**Agent products stable for > 24 hours - (Containers are prepared daily):**
• Express the dose per container.
• Include the total dose (as a function of BSA, weight, etc., when appropriate) in parentheses.
• State that the agent must be prepared daily.

**example**
"XYZ" 8 mg/m² per day diluted in 50 mL 0.9% sodium chloride injection, administer by continuous intravenous infusion over 24 hours, daily for three days starting on day 1 (days 1, 2, and 3; total dose/cycle = 24 mg/m² over 72 hours). A new IV bag should be prepared daily for 3 days.

**Agent products stable for > 24 hours - (Containers are prepared for multiple days):**
• Express the dose as the amount of agent administered per day and indicate the number of days for which it is administered.
• Include the total dose (as a function of BSA, weight, etc., when appropriate) in parentheses.
• State that this is a multi-day preparation and for how long the preparation should be infused.

**example**
"XYZ" 8 mg/m² per day diluted in 50 mL 0.9% sodium chloride injection, by continuous intravenous infusion for three days starting on day 1 (total dose = 24 mg/m² over 72 hours). This is a multi-day infusion to be infused over 72 hours.

**Continuous infusions that require multiple agent product containers:**
• Express the dose per container.
• Include the total dose (as a function of BSA, weight..., etc., when appropriate) in parentheses.
• Include the total number of containers used per day.

**example**
"XYZ" 1 mg/m² diluted in 50 mL 0.9% sodium chloride injection, administer by continuous intravenous infusion over three hours, every three hours for three days, starting on day 1 (8 bags/day, total dose = 24 mg/m² over 3 days)

**ORAL ADMINISTRATION**
• Describe agent dosages and schedules as the amount of agent that will be given (or taken) each time the agent is administered, not as a total daily dose that will be given (or taken) in divided doses, (e.g. 20 mg orally every 6 hours for 5 days vs. 80 mg per day, given in four divided doses for 5 days
• Include guidelines regarding 'rounding-off' doses to the nearest capsule or tablet size.
• Whenever possible, indicate whether agents should be administered (or taken) with food and explain dietary restrictions.

CONCOMITANT (ANCILLARY) MEDICATIONS
• Clearly identified supportive care and essential ancillary medications required by a treatment regimen.
• State complete instructions including appropriate indication, dosage, administration route, schedule, restrictions to use, and any other relevant data explicitly.

TREATMENT MODIFICATIONS
• Define the maximum number of allowable dose reductions before treatment must stop
• Include consistent descriptions of modifications among a study’s treatment arms for the same agent
• Use consistent terminology for the same meaning (i.e., < grade 3 or < grade 2)
• Describe exactly how a toxicity must resolve before treatment can be resumed or doses re-escalated
• Explain exactly how modifications are to be handled during a cycle or at the start of the next cycle
• Specify how modifying or stopping therapy of one agent impacts the rest of the treatment regimen
• Describe dose modifications as actual doses, e.g. X mg/m2, and not as a percent of the previous dose
• Use values for CTCAE grades consistent with the actual definition

For dose escalation studies (particularly for patients treated at the initial dose levels), the maximum number of allowable dose level reductions in the dose modification section must be less than or equal to the number of available dose levels defined in the treatment section.